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General introduction and outline of the thesis
Quoting Professor Patrick W Serruys, promoter of this thesis, the history of interventional 
cardiology has undergone four revolutions1. As in many other aspects of life, each revolu-
tion arose to solve a specific problem, but it often generated new problems itself, or left 
some aspects insufficiently solved, so the stimulus to keep on improving the results has been 
always present to date.
the problem: coronary heart DIsease 
the 1st revolution: balloon angioplasty
Ischemic heart disease is still today the first cause of mortality in the world, especially in the 
developed countries2-4. The vast majority of cases are due to atherosclerosis, a complex sys-
temic degenerative process resulting in cholesterol accumulation in the extra-cellular space 
of the arterial intima, with inflammation, foam-cells formation, and necrosis5-8. The clinical 
manifestations of coronary atherosclerosis comprise from stable angina, due to flow-limiting 
stenosis of the artery, to acute myocardial infarction or sudden death, when the atheroma 
gets complicated by thrombotic phenomena9.
The first revolution in the treatment of this disease came in 1977, when Andreas Grüntzig 
performed the first coronary balloon angioplasty10-12. The inflation of a balloon in a narrowed 
coronary vessel resulted in smash of the atheroma plaque and enlargement of the lumen, 
thus solving the flow limitation imposed by the stenosis. The success of this therapy was how-
ever mitigated by the risk of acute coronary occlusion due to extensive dissection requiring 
emergency bypass surgery13-16 and also by high restenosis rates at follow-up (about 30-50% 
after 1 year)15, 17-23. The mechanism of restenosis had at least two differentiated components: 
constrictive remodelling of the vessel, defined as reduction in the area of the elastic external 
lamina (accounting for 73% of the lumen reduction) and neointimal hyperplasia (accounting 
for 27% of the lumen reduction)24-26.
the problem: restenosIs Due to arterIal remoDellIng 
the 2nd revolution: coronary stenting
The advent of bare metal coronary stents solved the main drawbacks of balloon angioplasty: 
acute vessel occlusion and restenosis. This technology was able to tackle eventual dissections 
occurring during the balloon inflation and to prevent the subsequent arterial recoil, thus 
reducing the rates of acute and subacute coronary occlusion to 2.6%27. The radial strength 
of the metallic scaffold could counterbalance effectively that of elastic recoil and prevent 
constrictive remodelling at the external elastic lamina, acknowledged as the main mecha-
nism of restenosis24-26. Two landmark randomised trials, BENESTENT and STRESS, published 
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simultaneously in the same issue of the same journal, compared the performance of coronary 
stenting vs. balloon angioplasty, demonstrating the safety and superior performance of bare 
metal stents in terms of higher angiographic and clinical success during the procedure, lower 
need for emergency coronary bypass surgery and lower restenosis rates at follow-up (22-
32% at seven months)28, 29. These results represented a crucial leap forward for percutaneous 
coronary interventions, thus starting to become autonomous from surgery and to claim for 
their own niche in the therapeutic panoply against coronary heart disease. Stenting became 
the second revolution.
Nonetheless, the restenosis rates were still high (22-32% in the pivotal trials28,  29). The 
second mechanism of restenosis, neointimal hyperplasia, although it only contributed to 
27% of the lumen reduction after balloon angioplasty24-26, was still present and unaffected by 
stenting, leading to failure of the intervention in up to 20.0 – 50.3% of unselected cases30, 31.
Moreover, this new technique left a foreign metallic body inside the coronary vessel per-
manently. It is known that the metallic surface of the stent in contact with the circulating 
blood exerts a pro-thrombotic effect through different mechanisms. The electromechani-
cal conductance of the metal promotes the adsorption of plasma proteins, most of them 
negatively charged at human blood pH32-38. Most of the adsorbed proteins are fibrinogen and 
albumin32, 35, 36, 39-42, but also fibronectin, vitronectin and von Willebrand factor43. The negative 
charge of the platelets membrane enhances in vitro their adhesion to the metallic surface 
and subsequent activation33, 34, 44-46, but in vivo the platelets do not interact directly with the 
metallic surface, but rather with the adsorbed protein coat32, 35, 36, 39-43, 47, more precisely with the 
fibrinogen through the GP IIb/IIIa receptor35, 36, 48-51. The ratio of fibrinogen / albumin adsorbed 
is directly proportional to the platelet adhesion and activation32, 35, 42, 47, i.e. preferential ad-
sorption of albumin results in passivation of the surface35, 36. The hydrophilicity of the surface 
material seems to favour higher fibrinogen / albumin ratios in the adsorption, and therefore 
higher platelet adhesion and activation35. As additional mechanisms, the coagulation factor 
XII adsorbs preferentially to negatively-charged metallic surfaces, resulting in activation of 
the intrinsic pathway of the coagulation cascade52-56. Finally, the metallic surface activates 
the complement system by the alternative pathway; the factor sC5b-9 induces activation of 
platelets and leukocytes and expression of p-selectin in the platelet membrane, contributing 
to create a prothrombotic milieu57-59. In summary, bare metal stents tended to get thrombosed 
in contact with the circulating blood, thus requiring specific anti-thrombotic treatment after 
implantation. Initially this therapy included aspirin, dipyridamole and warfarin28, 29, 60, 61, but 
in the following years the combination of aspirin with a thienopyridine demonstrated to be 
more effective in the prevention of stent thrombosis and to have a better safety profile62-66.
The second revolution in interventional cardiology, the bare metal stent (BMS), was 
tarnished by neointimal hyperplasia, resulting in restenosis in 20.0 – 50.3% of real-world 
cases30, 31 and created a new problem, stent thrombosis, requiring specific attention.
13
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the problem: restenosIs Due to neoIntImal hyperplasIa 
the 3rd revolution: drug-eluting stents
The third revolution in interventional cardiology came with the concept of using metallic 
stents with enough radial force to prevent constrictive remodelling and also able to inhibit 
neointimal hyperplasia through the sustained elution of an antiproliferative agent. These 
break-through devices were named drug-eluting stents (DES) and exerted specific actions 
against the main mechanisms involved in restenosis24-26. Intravascular ultrasound (IVUS) 
studies proved the concept of an efficient suppression of neointimal proliferation achieved 
by the elution of sirolimus67,  68. In pioneer large scale trials, RAVEL, SIRIUS and TAXUS-IV, 
drug-eluting stents reduced the restenosis rates to 7.9 - 8.9 % at 9 months69-71. After these 
results interventional cardiology started to rival by-pass surgery as best therapeutic option 
for revascularization of coronary heart disease: a true revolution.
However the Congress of the European Society of Cardiology held in Barcelona in 2006 un-
dermined this initial enthusiasm: the results of several registries and meta-analysis coincided 
to report higher rates of late and very late stent thrombosis in DES than in BMS72-75. Moreover, 
DES seemed to increase cardiac73, non-cardiac74 and overall mortality75 with respect to BMS 
as well. The news had a tremendous impact on the cardiology community: the recommenda-
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Pathophysiology of thrombogenicity on metallic surfaces.
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tions of dual anti-platelet therapy were extended up to 12 months and the interest for evi-
dence about long-term safety of DES grew enormously. Registries of all-comers treated with 
DES showed stent thrombosis rates of 0.53% per year, with a continued increase to 3% over 
four years76, 77. In patients with complex multivessel disease (ARTS II), the rate of combined 
definite, probable and possible stent thrombosis was as high as 9.4% at five years, accounting 
for 32% of MACE events78.
Pathology and imaging studies played an instrumental role in elucidating the mechanism 
of late and very late stent thrombosis. Since the BMS era, pathology had described the pres-
ence of uncovered struts in fatal cases of stent thrombosis79, 80. As for late stent thrombosis 
(>30 days, ≤365 days after stent implantation), several angioscopy studies reported signs 
of delayed healing in DES, with still considerable amounts of uncovered struts after the 6th 
month, when dual anti-platelet therapy was normally interrupted81-84. As for very late stent 
thrombosis (>365 days after stent implantation), pathology described also delayed neointi-
mal healing and incomplete endothelialization in experimental studies or autopsies of fatal 
cases85-88, but the mechanism for this incomplete neointimal coverage seemed to go beyond 
the failure to restore the endothelial continuity because of the antiproliferative potency of 
the drug and to involve also an inflammatory reaction88-92. The implantation of these devices 
elicited an inflammatory reaction in the vessel wall91,  93, presumably due to the polymeric 
coating93 and inducing some positive (expansive) remodelling91. Hydrophobic polymeric 
coatings induced an inflammatory reaction more intense than hydrophilic polymers94,  95. 
Moreover, the presence of intense eosinophilic infiltrates in the vessel wall88 and in the 
thrombus harvested from patients with an episode of very late stent thrombosis90 suggested 
an additional inflammatory mechanism, mediated by a delayed type IVb hypersensitivity 
reaction, recruiting preferentially eosinophils. This hypersensitivity reaction was supposed to 
be triggered by the polymer rather than by other components of the device, given the timing 
of onset (later than 90 days, when the drug is no longer detectable in the vessel wall) and the 
presence of polymer fragments surrounded by giant cells88, 91.
Intense investigational efforts were then undertaken to improve the haemocompatibility 
(reduced thrombogenicity) and biocompatibility (reduced inflammation) of the DES, preserv-
ing their efficacy in preventing restenosis. Several approaches were then tested, with variable 
outcomes: thinner struts67, 68, 96; hydrophobic fluoropolymers with improved haemocompat-
ibility profiles97-101 and eventually inducing fluoropassivation102-104; hydrophilic polymers with 
improved biocompatibility profile105-111; polymer-free corrugated abluminal surfaces112-118; 
non-polymeric mineral carriers (hydroxyapatite)119-121; elution from reservoirs122-130; non-stent-
based local delivery systems, comprising intrapericardial administration131, double-balloon 
catheter132, porous balloon133 and drug-coated balloons (DCB)134-146; biodegradable polymers 
in solely abluminal coating, engineered to provide sustained kinetics of release for the antipro-
liferative drug, coupled with the hydrolysis and degradation of the polymer up to its complete 
resorption and disappearance115, 147-166; or endothelial-progenitor-cells-capturing stents167-170.
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the problem: stent thrombosIs
looking for a solution: evaluation of the neointimal healing after stenting
This PhD thesis took shape in this context of deep concern about DES thrombosis in paral-
lel with an unprecedented momentum of technological innovation intended to promote 
optimal neointimal healing after DES implantation. Aristotle defined virtue as an intermedi-
ate state between the opposed vices of excess and deficiency171. Thus “optimal” neointimal 
healing could be defined in Aristotelian terms as an intermediate degree of neointimal pro-
liferation between the vice for excess (neointimal hyperplasia, resulting in stent restenosis) 
and the vice for deficiency (incomplete neointimal coverage, augmenting the risk of stent 
thrombosis). Furthermore, this intermediate degree could be delimited more precisely as 
the minimal neointimal proliferation that warrants coverage of the whole metallic surface 
of the stent without flow-compromising re-narrowing of the vessel. The scope of this thesis 
is the qualitative and quantitative evaluation in vivo of the neointimal healing process after 
EEL
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figure 2:
Case of definite very late stent thrombosis associated to late-acquired malapposition, illustrated by matched OCT and IVUS studies (left panels). 
Intraluminal thrombus (asterisks) can be clearly seen in the OCT longitudinal view (left upper panel), within the region of interest delimited 
by two vertical white bars. The matched IVUS longitudinal view (left lower panel) shows positive remodelling of the external elastic lamina 
together with enlargement of the internal elastic lamina and massive malapposition of the stent. The thrombus harvested from the coronary 
artery (right panel A) presented intense eosinophilic infiltration in the histological analysis (right panel, B and C). These findings suggest a 
delayed hypersensitivity mechanism with intense inflammatory reaction, resulting in weakening of the vessel wall, late-acquired malapposition 
and stent thrombosis.
Images courtesy of Dr. Lorenz Räber, Inselspital, Bern, CH.
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stenting, which determines the clinical outcome of the intervention at a great extent. The 
neointimal healing response can be evaluated in vivo by invasive imaging techniques: coro-
nary angiography, IVUS, angioscopy and optical coherence tomography.
coronary angiography – quantitative coronary angiography (Qca)
Coronary angiography is still today the workhorse invasive imaging technique for diagnostic 
and interventional procedures. The simple injection of a radiopaque contrast medium into the 
coronary arteries provides clear real-time luminograms, that translate into accurate and highly 
reproducible measurements for clinical decision-making and for research applications172, 173. In the 
BMS era restenosis (the vice for excess in the neointimal reaction) could be efficiently assessed by 
quantitative coronary angiography (QCA) through percent diameter stenosis (% DS), a parameter 
derived from the minimal lumen diameter (MLD) in the segment of interest with respect to the in-
terpolated reference vessel diameter at that point. Thus, restenosis was defined on a binary basis 
as a % DS equal to or greater than an arbitrary threshold of 50%21, 61, 174-176. Although angiographic 
restenosis had poor clinical predictive value for the need of revascularization on individual sub-
jects177, the restenosis rates in clinical trials were well correlated with the rates of revasculariza-
tion, thus fitting the principle of angiographic surrogate endpoints178-180. With the advent of DES, 
however, the restenosis rates were reduced below 10%69-71, so the sample sizes and the costs 
required to find relevant differences in comparative trials using binary restenosis as primary 
endpoint increased considerably. Late lumen loss (LLL) became then the parameter of choice to 
evaluate neointimal hyperplasia and the trend to restenosis. Contrary to binary restenosis, LLL is 
a continuous variable, very sensitive to subtle differences between devices, well correlated with 
the propensity to binary restenosis, following a curvilinear and monotonic relation, independent 
from the type of stent type and from the reference vessel diameter, that permits to increase the 
power and to reduce the sample sizes required to find significant differences in clinical trials180-183. 
Thus, although QCA can evaluate restenosis efficiently, it loses accuracy in presence of overlap-
ping vessels, foreshortening or calcium in the vessel wall. It gives scarce and often unreliable 
information about the mechanical settlement of the stent (sizing, expansion, apposition) and no 
information at all about the completeness or incompleteness of neointimal coverage (the vice for 
defect). Furthermore, the methodology developed to quantify restenosis by QCA relies solely on 
the point of MLD, disregarding the regional distribution of the lumen re-narrowing.
Intravascular ultrasound (Ivus)
IVUS can improve the accuracy of the coronary luminogram in cases of overlapping, fore-
shortened or calcified vessels, because it is not affected by these limitations. IVUS provides 
also detailed information about the mechanical aspects of the stent and can accurately quan-
tify neointimal hyperplasia along the whole stented segment at conventional longitudinal 
17
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intervals of 1mm, reporting minimal and also mean diameters, areas and volumes. Unlike 
QCA, IVUS can image also the vessel wall extracting information about the plaque burden, 
plaque morphology or calcium distribution. Like QCA, IVUS can reliably discern whether the 
neointimal response is exaggerated or not. Indeed trials comparing DES vs. BMS used IVUS 
to confirm that DES reduced the extent of neointimal proliferation184-188. However, its axial 
resolution (100 μm) still results insufficient to assess the completeness of coverage, because 
the thin neointimal layer covering DES struts is often below this resolution.
coronary angioscopy
After several investigators reported higher rates of late / very late stent thrombosis and higher 
late mortality rates in DES than in BMS in the Congress of the European Society of Cardiology 
in Barcelona in 200672-75, the interest to study the neointimal reaction after stenting shifted 
from the quantification of restenosis to the opposite pole of the spectrum: the evaluation of 
the completeness of neointimal healing. At that point, the only imaging technique able to 
detect uncovered struts and ready for immediate in vivo clinical application was coronary 
angioscopy. The availability of the technique was limited to a few frontline centers in Japan 
and Asia. The performance of the study was cumbersome for the patient and for the opera-
tor, since it required occlusion of the coronary vessel and removal of the blood in order to 
obtain good quality images. Finally, unlike the accurate objective quantification provided by 
QCA or IVUS, angioscopy had limited quantitative abilities, relying on a rather qualitative and 
subjective evaluation of the images obtained often from a manual and irregular pullback. In 
spite of all these drawbacks, angioscopy was the first technique to evaluate systematically 
in vivo the completeness of coverage, making an instrumental contribution to our current 
understanding of the mechanisms underlying the phenomenon of late DES thrombosis81-84. 
A semi-quantitative approach was used to grade the neointimal coverage, based on a clas-
sification with 4 ordered categories82, 84:
•	 Grade 0 - stent struts exposed.
•	 Grade 1 - struts covered but bulging into the lumen.
•	 Grade 2 - struts embedded but visible translucently.
•	 Grade 3 - struts fully embedded and invisible.
Minimum, maximum and predominant grades of coverage observed within the stented 
segment were normally reported.
It must be noticed that this semi-quantitative grading used in angioscopy follows the “win-
ter coat principle: everything covered, and the thicker the better”. Thick neointimal responses 
obtain higher scores, no matter if they are functionally maladaptive or the consequence of 
inefficient neointimal suppression. Likewise, once the neointimal healing proliferation has 
been completed, subsequent processes of intima maturation resulting in thickening of the 
layer will translate into an increase in the angioscopy grades, especially the maximum82, 189.
18
optical coherence tomography
The interest to assess the completeness of coverage boosted the development of Optical 
Coherence Tomography (OCT) for coronary applications. OCT uses near-infrared light (NIR) 
to generate cross-sectional images of the coronary arteries. NIR has shorter wavelength and 
higher frequency than ultrasound, therefore OCT images have 10-fold higher resolution 
than IVUS images, at the expense of lower penetration into the tissue190, 191. OCT provides an 
axial resolution of 10-15 µm, thus enabling accurate evaluation of the tissue coverage after 
stenting. OCT-derived tissue coverage correlates well with histological neointimal healing 
and endothelialization after stenting in animal models192-196, thus constituting a valid in-vivo 
surrogate to assess the completeness of coverage, with superior diagnostic performance to 
that of IVUS192. The high resolution of OCT enables the visualization and objective measure-
ment of details that had remained elusive for the other imaging techniques hitherto. With the 
first time-domain systems, occlusion of the coronary artery and blood removal was required, 
similarly to angioscopy190, 197, 198. However, since NIR radiation has very high signal-to-noise 
ratio that enables very fast pullback speeds, acquisition is also feasible with non-occlusive 
techniques, taking advantage of the viscosity and the transparency of ordinary angiographic 
contrast media to remove transiently the blood from the coronary artery for the short time 
needed to complete the pullback199, 200. The newest Fourier-Domain systems of interferom-
etry enable even faster pullbacks190, 201, so currently the non-occlusive technique prevails and 
the acquisition of OCT images is extremely simplified. This technology is becoming rapidly 
available worldwide.
OCT can analyse the whole stented segment at conventional longitudinal intervals of 1mm 
or even shorter. Neointimal hyperplasia and restenosis can be assessed using minimal and 
mean diameters, areas and volumes, like in IVUS studies, but OCT can go further and per-
form a detailed analysis strut by strut. Per strut analysis usually reports coverage as a binary 
outcome and the thickness of coverage as a continuous outcome. Binary coverage has been 
the primary endpoint in most OCT trials and studies hitherto111,  159,  202-207. It is considered a 
figure 3:
Grading of the neointimal coverage assessed by coronary angioscopy.
Modified from Awata et al. J Am Coll Cardiol 2008; 52(9): 787–92.
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surrogate for the completeness of neointimal healing, which is believed to be protective 
against stent thrombosis. An important caveat is the inability of OCT to detect thin layers of 
neointima below its axial resolution (10-20 µm, limited sensitivity), and to discern between 
neointima and other material like fibrin or thrombus (limited specificity). The latter becomes 
an issue at very early phases after stenting, when the prevalence of struts covered by fibrin 
is high. Endothelial cells can be found on the metallic surface of the stent as early as day 
5 after implantation in a swine model, but these endothelial cells restore the endothelial 
continuity very seldom, and areas devoid of endothelium appear covered by granulation 
tissue or fibrin208. Thus, DES are completely covered with fibrin (not with neointima) 1-3 days 
after implantation, but the low discriminative power of OCT results in false coverage rates 
of 45-76%196. The analysis of optical density might overcome this limitation in the future 
and discern between neointima and fibrin196. Since the greatest interest is to assess intimal 
coverage at later phases, months or years after stent implantation, when the prevalence of 
fibrin-covered struts is low, the practical impact of this limitation is minimal195.
In contrast with angioscopy, it must be noticed that the evaluation of neointimal coverage 
in OCT follows the “bikini principle: everything covered, but the less the better”. Binary coverage 
will be exactly the same, irrespective of the neointimal rim thickness, and will not augment 
after processes of intima maturation and thickening. Thick neointimal responses are reflected 
in high values of the thickness of coverage per strut and considered the consequence of 
inefficient neointimal suppression. OCT is the imaging technique that best accommodates 
the definition of optimal neointimal healing as “the minimal neointimal proliferation that 
warrants coverage of the whole metallic surface of the stent without flow-compromising re-
narrowing of the vessel”. Thus, the optimal neointimal healing is considered to be that with 
high binary coverage rates but with low thickness of coverage.
Most of the studies compiled in this PhD thesis will use OCT for the evaluation of the neo-
intimal response after stenting, taking advantage of its ease of acquisition, the high resolu-
tion of the images, the accuracy and reproducibility of the measurements and the unlimited 
analytical capabilities
the problem: the cage 
the 4th revolution: bioresorbable vascular scaffolds (bvs)
Although DES had efficiently reduced the restenosis rates to 7.9 - 8.9 %69-71, this technology 
had several flaws that remained incompletely solved: late and very late stent thrombosis 
rates were high after implantation of 1st generation devices; the polymer and the metal were 
foreign bodies exerting chronically a pro-inflammatory action on the vessel wall91, 93 and pos-
ing the risk for catastrophic delayed hypersensitivity reactions88-90; finally the metallic stent 
caged the artery, interfering with normal vascular physiology (abnormal vasoconstriction 
20
was observed distal to the stent in vasomotion tests after infusion of acetylcholine, probably 
as consequence of structural or functional defects in the endothelium209) and preventing an 
eventual late luminal gain.
Among all the scientific and technological approaches implemented to address DES limita-
tions, one must be highlighted and deserves specific mention: the bioresorbable vascular 
scaffolds (BVS). These devices constitute a genuine breakthrough in the treatment of coronary 
heart disease and have been heralded as the fourth revolution in interventional cardiology1, 
since they can potentially yield the same efficacy as DES in terms of restenosis prevention, 
A B
C D
figure 4:
Assessment of coverage by OCT as a binary outcome (A and B): struts are classified as covered if a rim of tissue can be seen over the whole 
reflecting surface of the strut (white arrows) or as uncovered if the reflecting surface of the strut is totally or partially exposed to the lumen 
of the vessel (red arrows). The lower panel presents matched cross-sections corresponding to an overlapping region of two undersized nitinol 
self-expandable stents immediately post-stent implantation (C) and at 6 month follow-up (D): notice the neointimal bridges trying to cover the 
grossly malapposed areas.
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overcoming all their aforementioned limitations. Currently there exist several bioresorbable 
devices available for treatment of coronary stenosis210-215, but the Abbott Vascular BVS was 
pioneer in the development for clinical use, so we will focus on it as paradigm.
The BVS (Abbott Vascular, Santa Clara, CA, USA) consists of a semicrystalline poly(L-lactide) 
(PLLA) backbone and conformal coating of amorphous poly(D,L-lactide) (PDLLA) containing 
the antiproliferative agent, everolimus. The molecular weight of the BVS polymers is degraded 
primarily through hydrolysis of the ester bonds present in each monomer subunit. Crystalline 
residues with characteristic dimension less than 2 µm are phagocytosed by macrophages. 
Ultimately, PLLA and PDLLA degrade to lactate, which is metabolised via the Krebs’ cycle 
and other metabolic pathways216. Hydrolysis is a slow process evolving in three phases: 1) In 
the revascularization phase (0-3 months) the hydrolysis erodes the surface of the structure, 
degrading the PDDLA coating and thus releasing the everolimus. The oriented crystallites 
that comprise the load-bearing structural elements lose molecular weight because of 
surface hydrolysis, but they preserve their structural organization, so the radial strength of 
the device remains intact. These features of the design are of capital importance to prevent 
recoil, constrictive remodelling and neointimal hyperplasia. 2) In the restoration phase (3-6 
months), the hydrolysis starts to affect the tie chains that connect oriented crystallite do-
mains so the structural organization slowly disintegrates and the device loses progressively 
radial strength. After the 3rd month neither recoil nor remodelling play a relevant role, so 
the radial strength is no longer necessary, and the neointimal healing reaction is stopped. 
Chromatography studies show very low molecular weight in the scaffold, but relatively small 
loss in total mass, suggesting the scission of the polymers in smaller domains, losing their 
structural integrity. At the end of the restoration phase, a natural vasomotor response has 
been restored in the vessel. The device remains there, but as a totally passive implant that 
does not interfere with the normal physiology of the vessel. 3) Finally, in the resorption phase 
(6-24 months) the polymer remnants are slowly hydrolysed and substituted by a matrix of 
proteoglycans and finally by functional smooth muscle cells. Complete polymer resorption 
occurs approximately two years after implantation217, 218. BVS has delivered acceptable and 
durable clinical and angiographic results up to 4 years follow-up218-223, with low MACE rates of 
3.4-7.1%, depending on the series221, 223. The revision 1.1 has reduced restenosis rates to 2.4% 
at 6 month222, with lumen late loss as low as 0.27mm at 12 month223.
Based on these initial results, the BVS promises to solve all the limitations of DES without 
compromise of their anti-restenotic efficacy: no single case of spontaneous thrombosis of the 
scaffold has been reported up to 4 years follow-up in the revision 1.0 (hence, after complete 
resorption of the device)218-221 and up to 1 year follow-up in the revision 1.1222, 223, vasomotion 
is restored 12 months after implantation218, 223, and in some series late lumen enlargement has 
been reported218. These encouraging outcomes stem from relatively small series of selected 
patients and require confirmation in larger studies. Furthermore, the relative fragility of 
the PLLA polymer as compared with the metallic alloys, might become an insurmountable 
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limitation in the treatment of heavily calcified lesions, thus precluding the use of BVS in some 
patients.
BVS is not only revolutionizing the treatment of coronary heart disease, but also the 
conventional imaging approach used in the study of intracoronary devices. In contrast to 
metallic stents, BVS is translucent to optical radiation and totally radiolucent to gamma 
radiation, with the only exception of the radiopaque platinum markers at the edges. The 
translucency of the processed polylactide used in the BVS makes it particularly suitable for 
optical coherence tomography (OCT) imaging. The optical radiation can penetrate the trans-
lucent polymer with significant backscattering occurring only at the borders of struts where 
the refractive index of the medium changes. Alternatively, the strut core has been character-
ized as a “black box”218, 219, 222, signifying the absence of refractive index changes within the 
material. Thus, the abluminal side of an implanted intracoronary device becomes accessible 
for an invasive imaging technique for the first time. The study of the BVS by OCT demands 
a specific methodology, differentiated from that applied with metallic stents, affecting the 
assessment of apposition or coverage. The assessment of neointimal coverage on the BVS 
is particularly challenging due to the convolution of the signals generated by the polymer 
and the neointimal rim. Both signals have very similar optical impedance and become indis-
cernible in a standard OCT analysis using log-transformed images. This thesis would not be 
complete without a special chapter dedicated to the evaluation of the neointimal healing 
after implantation of the BVS, indeed one of the most challenging, inspiring and interesting 
parts of this compilation. The opportunity of getting involved in the scientific development 
of this fascinating technology has been a truly privilege that secures my eternal gratitude to 
Erasmus Medical Center, to Cardialysis BV and to Professor Patrick W Serruys.
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General introduction and outline of the thesis
aIms of the thesIs
The aim of this thesis is to evaluate in vivo the neointimal healing response elicited by differ-
ent interventional approaches and specific device designs aimed to optimize the restoration 
of the endothelial continuity after stent implantation. For that purpose, most of the hereby 
presented studies will take advantage of the accuracy, resolution and versatility offered by 
OCT, although other invasive imaging techniques are also applied when required.
A
B
figure 5:
Bioresorbable vascular scaffold (left) imaged by OCT immediately post-implantation (right A) and at 6 month follow-up (right B). Notice the 
translucency of the polymer allows detailed visualization of the abluminal side of the struts and of the underlying tissue.
24
reference lIst
 1. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in 
interventional cardiology and the ultimate “rosy” prophecy. EuroIntervention 2009 December 15;5 
Suppl F:F7-F8.
 2. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease 
Study. Lancet 1997 May 3;349(9061):1269-76.
 3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: 
Global Burden of Disease Study. Lancet 1997 May 24;349(9064):1498-504.
 4. Mathers CD, Boerma T, Ma FD. Global and regional causes of death. Br Med Bull 2009;92:7-32.
 5. Stary HC, Blankenhorn DH, Chandler AB et al. A definition of the intima of human arteries and of 
its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council 
on Arteriosclerosis, American Heart Association. Circulation 1992 January;85(1):391-405.
 6. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions 
of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arterioscle-
rosis, American Heart Association. Circulation 1994 May;89(5):2462-78.
 7. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions 
and a histological classification of atherosclerosis. A report from the Committee on Vascular Le-
sions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995 September 
1;92(5):1355-74.
 8. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: 
a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler 
Thromb Vasc Biol 2000 May;20(5):1262-75.
 9. Schaar JA, Muller JE, Falk E et al. Terminology for high-risk and vulnerable coronary artery plaques. 
Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 
2004 June;25(12):1077-82.
 10. Gruntzig A, Schneider HJ. [The percutaneous dilatation of chronic coronary stenoses—experi-
ments and morphology]. Schweiz Med Wochenschr 1977 November 5;107(44):1588.
 11. Gruntzig A, Hirzel H, Goebel N et al. [Percutaneous transluminal dilatation of chronic coronary 
stenoses. First experiences]. Schweiz Med Wochenschr 1978 November 4;108(44):1721-3.
 12. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978 February 
4;1(8058):263.
 13. Bredlau CE, Roubin GS, Leimgruber PP, Douglas JS, Jr., King SB, III, Gruentzig AR. In-hospital 
morbidity and mortality in patients undergoing elective coronary angioplasty. Circulation 1985 
November;72(5):1044-52.
 14. Detre K, Holubkov R, Kelsey S et al. Percutaneous transluminal coronary angioplasty in 1985-1986 
and 1977-1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988 Febru-
ary 4;318(5):265-70.
 15. Detre KM, Holmes DR, Jr., Holubkov R et al. Incidence and consequences of periprocedural oc-
clusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal 
Coronary Angioplasty Registry. Circulation 1990 September;82(3):739-50.
 16. Gaul G, Hollman J, Simpfendorfer C, Franco I. Acute occlusion in multiple lesion coronary angio-
plasty: frequency and management. J Am Coll Cardiol 1989 February;13(2):283-8.
 17. Fleck E, Dirschinger J, Rudolph W. [Quantitative coronary angiography before and after PTCA. 
Rate of restenosis, analysis of modifying factors]. Herz 1985 December;10(6):313-20.
25
General introduction and outline of the thesis
 18. DePuey EG, Leatherman LL, Leachman RD et al. Restenosis after transluminal coronary angio-
plasty detected with exercise-gated radionuclide ventriculography. J Am Coll Cardiol 1984 
December;4(6):1103-13.
 19. Holmes DR, Jr., Vlietstra RE, Smith HC et al. Restenosis after percutaneous transluminal coronary 
angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood 
Institute. Am J Cardiol 1984 June 15;53(12):77C-81C.
 20. Leimgruber PP, Roubin GS, Hollman J et al. Restenosis after successful coronary angioplasty in 
patients with single-vessel disease. Circulation 1986 April;73(4):710-7.
 21. Serruys PW, Luijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: 
a time- related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 
2, 3, and 4 months. Circulation 1988 February 1;77(2):361-71.
 22. Nobuyoshi M, Kimura T, Nosaka H et al. Restenosis after successful percutaneous transluminal 
coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988 Sep-
tember;12(3):616-23.
 23. Gruentzig AR, King SB, III, Schlumpf M, Siegenthaler W. Long-term follow-up after percutane-
ous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med 1987 April 
30;316(18):1127-32.
 24. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal 
hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the 
hypercholesterolemic Yucatan micropig. Circulation 1994 June;89(6):2816-21.
 25. Mintz GS, Popma JJ, Pichard AD et al. Arterial remodeling after coronary angioplasty: a serial 
intravascular ultrasound study. Circulation 1996 July 1;94(1):35-43.
 26. Mintz GS, Popma JJ, Hong MK et al. Intravascular ultrasound to discern device-specific effects and 
mechanisms of restenosis. Am J Cardiol 1996 August 14;78(3A):18-22.
 27. Betriu A, Masotti M, Serra A et al. Randomized comparison of coronary stent implantation and 
balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year 
follow-up. J Am Coll Cardiol 1999 November 1;34(5):1498-506.
 28. Serruys PW, de JP, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with 
balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 
1994 August 25;331(8):489-95.
 29. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement 
and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study 
Investigators. N Engl J Med 1994 August 25;331(8):496-501.
 30. Kastrati A, Mehilli J, Dirschinger J et al. Restenosis after coronary placement of various stent types. 
Am J Cardiol 2001 January 1;87(1):34-9.
 31. Garg S, Serruys PW. Coronary Stents: Current Status. J Am Coll Cardiol 2010 August 31;56(10, 
Supplement 1):S1-S42.
 32. Roohk HV, Pick J, Hill R, Hung E, Bartlett RH. Kinetics of fibrinogen and platelet adherence to 
biomaterials. Trans Am Soc Artif Intern Organs 1976;22:1-8.
 33. Zitter H, Plenk H, Jr. The electrochemical behavior of metallic implant materials as an indicator of 
their biocompatibility. J Biomed Mater Res 1987 July;21(7):881-96.
 34. Bertrand OF, Sipehia R, Mongrain R et al. Biocompatibility aspects of new stent technology. J Am 
Coll Cardiol 1998 September;32(3):562-71.
 35. Jones MI, McColl IR, Grant DM, Parker KG, Parker TL. Protein adsorption and platelet attachment 
and activation, on TiN, TiC, and DLC coatings on titanium for cardiovascular applications. J Biomed 
Mater Res 2000 November;52(2):413-21.
26
 36. Mikhalovska LI, Santin M, Denyer SP et al. Fibrinogen adsorption and platelet adhesion to metal 
and carbon coatings. Thromb Haemost 2004 November;92(5):1032-9.
 37. Yu Y, Jin G. Influence of electrostatic interaction on fibrinogen adsorption on gold studied by 
imaging ellipsometry combined with electrochemical methods. J Colloid Interface Sci 2005 March 
15;283(2):477-81.
 38. Yun YH, Turitto VT, Daigle KP, Kovacs P, Davidson JA, Slack SM. Initial hemocompatibility studies of 
titanium and zirconium alloys: prekallikrein activation, fibrinogen adsorption, and their correla-
tion with surface electrochemical properties. J Biomed Mater Res 1996 September;32(1):77-85.
 39. Hong J, Nilsson EK, Reynolds H, Larsson R, Nilsson B. A new in vitro model to study interaction 
between whole blood and biomaterials. Studies of platelet and coagulation activation and the 
effect of aspirin. Biomaterials 1999 April;20(7):603-11.
 40. Hong J, Larsson A, Ekdahl KN, Elgue G, Larsson R, Nilsson B. Contact between a polymer and 
whole blood: sequence of events leading to thrombin generation. J Lab Clin Med 2001 Au-
gust;138(2):139-45.
 41. Nygren H, Tengvall P, Lundstrom I. The initial reactions of TiO2 with blood. J Biomed Mater Res 
1997 March 15;34(4):487-92.
 42. Salzman EW, Lindon J, McManama G, Ware JA. Role of fibrinogen in activation of platelets by 
artificial surfaces. Ann N Y Acad Sci 1987;516:184-95.
 43. Grunkemeier JM, Tsai WB, McFarland CD, Horbett TA. The effect of adsorbed fibrinogen, fibro-
nectin, von Willebrand factor and vitronectin on the procoagulant state of adherent platelets. 
Biomaterials 2000 November;21(22):2243-52.
 44. Whicher SJ, Brash JL. Platelet-foreign surface interactions: release of granule constituents from 
adherent platelets. J Biomed Mater Res 1978 March;12(2):181-201.
 45. Salzman EW. Influence of antiplatelet drugs on platelet-surface interactions. Adv Exp Med Biol 
1978;102:265-83.
 46. Salzman EW, Brier-Russell D, Lindon J, Merrill EW. Platelets and artificial surfaces: the effects of 
drugs. Philos Trans R Soc Lond B Biol Sci 1981 August 18;294(1072):389-98.
 47. Nygren H, Eriksson C, Lausmaa J. Adhesion and activation of platelets and polymorphonuclear 
granulocyte cells at TiO2 surfaces. J Lab Clin Med 1997 January;129(1):35-46.
 48. Gemmell CH. Platelet adhesion onto artificial surfaces: inhibition by benzamidine, pentamidine, 
and pyridoxal-5-phosphate as demonstrated by flow cytometric quantification of platelet adhe-
sion to microspheres. J Lab Clin Med 1998 January;131(1):84-92.
 49. Sivaraman B, Latour RA. Delineating the roles of the GPIIb/IIIa and GP-Ib-IX-V platelet receptors 
in mediating platelet adhesion to adsorbed fibrinogen and albumin. Biomaterials 2011 Au-
gust;32(23):5365-70.
 50. Broberg M, Eriksson C, Nygren H. GpIIb/IIIa is the main receptor for initial platelet adhesion to 
glass and titanium surfaces in contact with whole blood. J Lab Clin Med 2002 March;139(3):163-72.
 51. Riederer MA, Ginsberg MH, Steiner B. Blockade of platelet GPIIB-IIIA (Integrin alphaII(b)beta(3)) 
in flowing human blood leads to passivation of prothrombotic surfaces. Thromb Haemost 2002 
November;88(5):858-64.
 52. Courtney JM, Forbes CD. Thrombosis on foreign surfaces. Br Med Bull 1994 October;50(4):966-81.
 53. Hunt BJ, Parratt R, Cable M, Finch D, Yacoub M. Activation of coagulation and platelets is affected 
by the hydrophobicity of artificial surfaces. Blood Coagul Fibrinolysis 1997 June;8(4):223-31.
 54. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, pro-
fibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997 November 15;90(10):3819-
43.
27
General introduction and outline of the thesis
 55. Grunkemeier JM, Tsai WB, Horbett TA. Hemocompatibility of treated polystyrene substrates: 
contact activation, platelet adhesion, and procoagulant activity of adherent platelets. J Biomed 
Mater Res 1998 September 15;41(4):657-70.
 56. Walivaara B, Aronsson BO, Rodahl M, Lausmaa J, Tengvall P. Titanium with different oxides: in vitro 
studies of protein adsorption and contact activation. Biomaterials 1994 August;15(10):827-34.
 57. Sims PJ, Wiedmer T. The response of human platelets to activated components of the comple-
ment system. Immunol Today 1991 September;12(9):338-42.
 58. Sims PJ, Wiedmer T. Induction of cellular procoagulant activity by the membrane attack complex 
of complement. Semin Cell Biol 1995 October;6(5):275-82.
 59. Rinder CS, Rinder HM, Smith BR et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and 
platelet activation during extracorporeal circulation. J Clin Invest 1995 September;96(3):1564-72.
 60. Schatz RA, Baim DS, Leon M et al. Clinical experience with the Palmaz-Schatz coronary stent. 
Initial results of a multicenter study. Circulation 1991 January;83(1):148-61.
 61. Serruys PW, Strauss BH, Beatt KJ et al. Angiographic follow-up after placement of a self-expanding 
coronary-artery stent. N Engl J Med 1991 January 3;324(1):13-7.
 62. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and an-
ticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996 April 
25;334(17):1084-9.
 63. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens 
after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 
1998 December 3;339(23):1665-71.
 64. Moussa I, Oetgen M, Roubin G et al. Effectiveness of clopidogrel and aspirin versus ticlopidine 
and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999 
May 11;99(18):2364-6.
 65. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspi-
rin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000 
February 15;101(6):590-3.
 66. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopido-
grel with and without a loading dose in combination with aspirin compared with ticlopidine in 
combination with aspirin after coronary stenting : the clopidogrel aspirin stent international 
cooperative study (CLASSICS). Circulation 2000 August 8;102(6):624-9.
 67. Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of 
sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and 
three-dimensional intravascular ultrasound study. Circulation 2001 January 16;103(2):192-5.
 68. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by 
sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circula-
tion 2001 October 23;104(17):2007-11.
 69. Morice MC, Serruys PW, Sousa JE et al. A Randomized Comparison of a Sirolimus-Eluting Stent 
with a Standard Stent for Coronary Revascularization. N Engl J Med 2002 June 6;346(23):1773-80.
 70. Moses JW, Leon MB, Popma JJ et al. Sirolimus-Eluting Stents versus Standard Stents in Patients 
with Stenosis in a Native Coronary Artery. N Engl J Med 2003 October 2;349(14):1315-23.
 71. Stone GW, Ellis SG, Cox DA et al. A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coro-
nary Artery Disease. N Engl J Med 2004 January 15;350(3):221-31.
 72. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent 
thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005 June 21;45(12):2088-
92.
28
 73. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinu-
ation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus 
bare-metal stents. J Am Coll Cardiol 2006 December 19;48(12):2584-91.
 74. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-
eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006 Decem-
ber;27(23):2784-814.
 75. Lagerqvist B, James SK, Stenestrand U et al. Long-Term Outcomes with Drug-Eluting Stents versus 
Bare-Metal Stents in Sweden. N Engl J Med 2007 March 8;356(10):1009-19.
 76. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-
eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional 
cohort study. The Lancet 2007 February 24;369(9562):667-78.
 77. Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent throm-
bosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll 
Cardiol 2008 September 30;52(14):1134-40.
 78. Serruys PW, Onuma Y, Garg S et al. 5-year clinical outcomes of the ARTS II (Arterial Revasculariza-
tion Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel 
de novo coronary artery lesions. J Am Coll Cardiol 2010 March 16;55(11):1093-101.
 79. Farb AM, Sangiorgi GM, Carter AJD et al. Pathology of Acute and Chronic Coronary Stenting in 
Humans. Circulation 1999 January 5;99(1):44-52.
 80. Farb AM, Burke APM, Kolodgie FDP, Virmani RM. Pathological Mechanisms of Fatal Late Coronary 
Stent Thrombosis in Humans. Circulation 2003 October 7;108(14):1701-6.
 81. Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K. Angioscopic differences in neointimal 
coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents 
after a 6-month implantation. Eur Heart J 2006 September 2;27(18):2189-95.
 82. Awata M, Kotani Ji, Uematsu M et al. Serial Angioscopic Evidence of Incomplete Neointimal Cov-
erage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents. Circulation 
2007 August 21;116(8):910-6.
 83. Awata M, Nanto S, Uematsu M et al. Angioscopic Comparison of Neointimal Coverage Between 
Zotarolimus- and Sirolimus-Eluting Stents. J Am Coll Cardiol 2008 August 26;52(9):789-90.
 84. Kotani Ji, Awata M, Nanto S et al. Incomplete Neointimal Coverage of Sirolimus-Eluting Stents: 
Angioscopic Findings. J Am Coll Cardiol 2006 May 16;47(10):2108-11.
 85. Farb A, Heller PF, Shroff S et al. Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-
Coated Stent. Circulation 2001 July 24;104(4):473-9.
 86. Joner M, Finn AV, Farb A et al. Pathology of Drug-Eluting Stents in Humans: Delayed Healing and 
Late Thrombotic Risk. J Am Coll Cardiol 2006 July 4;48(1):193-202.
 87. Finn AV, Joner M, Nakazawa G et al. Pathological Correlates of Late Drug-Eluting Stent Thrombo-
sis: Strut Coverage as a Marker of Endothelialization. Circulation 2007 May 8;115(18):2435-41.
 88. Virmani R, Guagliumi G, Farb A et al. Localized Hypersensitivity and Late Coronary Thrombosis 
Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? Circulation 2004 February 
17;109(6):701-5.
 89. Cook S, Wenaweser P, Togni M et al. Incomplete Stent Apposition and Very Late Stent Thrombosis 
After Drug-Eluting Stent Implantation. Circulation 2007 May 8;115(18):2426-34.
 90. Cook S, Ladich E, Nakazawa G et al. Correlation of Intravascular Ultrasound Findings With His-
topathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent 
Thrombosis. Circulation 2009 August 4;120(5):391-9.
29
General introduction and outline of the thesis
 91. Wilson GJ, Nakazawa G, Schwartz RS et al. Comparison of Inflammatory Response After Implanta-
tion of Sirolimus- and Paclitaxel-Eluting Stents in Porcine Coronary Arteries. Circulation 2009 July 
14;120(2):141-9.
 92. Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of 
delayed healing. Arterioscler Thromb Vasc Biol 2007 July;27(7):1500-10.
 93. van der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation 
of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996 
October 1;94(7):1690-7.
 94. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyper-
plasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol 1996 Octo-
ber;16(10):1312-8.
 95. Hezi-Yamit A, Sullivan C, Wong J et al. Impact of polymer hydrophilicity on biocompatibility: 
implication for DES polymer design. J Biomed Mater Res A 2009 July;90(1):133-41.
 96. Simon C, Palmaz JC, Sprague EA. Influence of topography on endothelialization of stents: clues 
for new designs. J Long Term Eff Med Implants 2000;10(1-2):143-51.
 97. Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer Everolimus-
eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005 
May;1(1):58-65.
 98. Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting 
coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention 2006 
November;2(3):286-94.
 99. Ruygrok PN, Desaga M, Van Den BF et al. One year clinical follow-up of the XIENCE V Everolimus-
eluting stent system in the treatment of patients with de novo native coronary artery lesions: the 
SPIRIT II study. EuroIntervention 2007 November;3(3):315-20.
 100. Stone GW, Midei M, Newman W et al. Comparison of an Everolimus-Eluting Stent and a Paclitaxel-
Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial. JAMA 2008 April 
23;299(16):1903-13.
 101. Stone GW, Midei M, Newman W et al. Randomized Comparison of Everolimus-Eluting and 
Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience 
V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native 
Coronary Artery Lesions (SPIRIT) III Trial. Circulation 2009 February 10;119(5):680-6.
 102. Guidoin R, Marois Y, Zhang Z et al. The benefits of fluoropassivation of polyester arterial prosthe-
ses as observed in a canine model. ASAIO J 1994 July;40(3):M870-M879.
 103. Xie X, Guidoin R, Nutley M, Zhang Z. Fluoropassivation and gelatin sealing of polyester arterial 
prostheses to skip preclotting and constrain the chronic inflammatory response. J Biomed Mater 
Res B Appl Biomater 2010 May;93(2):497-509.
 104. Kolandaivelu K, Swaminathan R, Gibson WJ et al. Stent thrombogenicity early in high-risk inter-
ventional settings is driven by stent design and deployment and protected by polymer-drug 
coatings. Circulation 2011 April 5;123(13):1400-9.
 105. Udipi K, Melder RJ, Chen M et al. The next generation Endeavor Resolute Stent: role of the BioLinx 
Polymer System. EuroIntervention 2007 May;3(1):137-9.
 106. Udipi K, Chen M, Cheng P et al. Development of a novel biocompatible polymer system for 
extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 2008 June 
15;85(4):1064-71.
30
 107. Meredith IT, Worthley S, Whitbourn R et al. The next-generation Endeavor Resolute stent: 4-month 
clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention 
2007 May;3(1):50-3.
 108. Meredith IT, Worthley S, Whitbourn R et al. Clinical and angiographic results with the next-
generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc 
Interv 2009 October;2(10):977-85.
 109. Meredith IT, Worthley S, Whitbourn R et al. Long-term clinical outcomes with the next-generation 
Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. Euro-
Intervention 2010;5:692-7.
 110. Serruys PW, Silber S, Garg S et al. Comparison of Zotarolimus-Eluting and Everolimus-Eluting 
Coronary Stents. New Engl J Med 2010 June 16;363(2):136-46.
 111. Gutierrez-Chico JL, van Geuns RJ, Regar E et al. Tissue coverage of a hydrophilic polymer-coated 
zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month 
follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur 
Heart J 2011 June 9;32:2454-63.
 112. Wessely R, Hausleiter J, Michaelis C et al. Inhibition of neointima formation by a novel drug-elut-
ing stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler 
Thromb Vasc Biol 2005 April;25(4):748-53.
 113. Hausleiter J, Kastrati A, Wessely R et al. Prevention of restenosis by a novel drug-eluting stent 
system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005 Au-
gust;26(15):1475-81.
 114. Mehilli J, Kastrati A, Wessely R et al. Randomized trial of a nonpolymer-based rapamycin-eluting 
stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circula-
tion 2006 January 17;113(2):273-9.
 115. Mehilli J, Byrne RA, Wieczorek A et al. Randomized trial of three rapamycin-eluting stents 
with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008 Au-
gust;29(16):1975-82.
 116. Adriaenssens T, Mehilli J, Wessely R et al. Does addition of estradiol improve the efficacy of a 
rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol 2007 
March 27;49(12):1265-71.
 117. Byrne RA, Mehilli J, Iijima R et al. A polymer-free dual drug-eluting stent in patients with coro-
nary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009 
April;30(8):923-31.
 118. Byrne RA, Kastrati A, Tiroch K et al. 2-year clinical and angiographic outcomes from a randomized 
trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [cor-
rected] drug-eluting stents. J Am Coll Cardiol 2010 June 8;55(23):2536-43.
 119. Costa JR, Jr., Abizaid A, Costa R et al. Preliminary results of the hydroxyapatite nonpolymer-based 
sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human 
analysis of a third-generation drug-eluting stent system. JACC Cardiovasc Interv 2008 Octo-
ber;1(5):545-51.
 120. Costa JR, Jr., Abizaid A, Costa R et al. 1-year results of the hydroxyapatite polymer-free sirolimus-
eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC 
Cardiovasc Interv 2009 May;2(5):422-7.
 121. van der Giessen WJ, Sorop O, Serruys PW, Peters-Krabbendam I, van Beusekom HM. Lowering the 
dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces 
signs of delayed healing. JACC Cardiovasc Interv 2009 April;2(4):284-90.
31
General introduction and outline of the thesis
 122. Finkelstein A, McClean D, Kar S et al. Local drug delivery via a coronary stent with programmable 
release pharmacokinetics. Circulation 2003 February 11;107(5):777-84.
 123. Serruys PW, Sianos G, Abizaid A et al. The Effect of Variable Dose and Release Kinetics on 
Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform: The Paclitaxel In-Stent 
Controlled Elution Study (PISCES). J Am Coll Cardiol 2005 July 19;46(2):253-60.
 124. Dawkins KD, Verheye S, Schuhlen H et al. The European cobalt STent with Antiproliferative for 
Restenosis trial (EuroSTAR): 12 month results. EuroIntervention 2007 May;3(1):82-8.
 125. Wang TY, Hasselblad V, Peterson JL et al. The Cobalt chromium STent with Antiproliferative for 
Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-
generation drug-eluting stents. Am Heart J 2007 May;153(5):743-8.
 126. Krucoff MW, Kereiakes DJ, Petersen JL et al. A novel bioresorbable polymer paclitaxel-eluting 
stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR 
(Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008 April 
22;51(16):1543-52.
 127. Silber S, Gutiérrez-Chico JL, Behrens S et al. Effect of paclitaxel elution from reservoirs with 
bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment 
of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. EuroIntervention 2011 
May;7(1):64-73.
 128. Ormiston JA, Abizaid A, Spertus J et al. Six-Month Results of the NEVO RES-ELUTION I (NEVO RES-
I) Trial: A Randomized, Multicenter Comparison of the NEVO Sirolimus-Eluting Coronary Stent 
With the TAXUS Liberte Paclitaxel-Eluting Stent in De Novo Native Coronary Artery Lesions. Circ 
Cardiovasc Interv 2010 November 9.
 129. Otake H, Honda Y, Courtney BK et al. Intravascular ultrasound results from the NEVO ResElution-I 
trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting 
TAXUS Liberte stents in de novo native coronary artery lesions. Circ Cardiovasc Interv 2011 April 
1;4(2):146-54.
 130. Verheye S, Agostoni P, Dawkins KD et al. The GENESIS (Randomized, Multicenter Study of the 
Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients 
with De Novo Lesions of the Native Coronary Arteries) trial. JACC Cardiovasc Interv 2009 
March;2(3):205-14.
 131. Hou D, Rogers PI, Toleikis PM, Hunter W, March KL. Intrapericardial Paclitaxel Delivery Inhibits 
Neointimal Proliferation and Promotes Arterial Enlargement After Porcine Coronary Overstretch. 
Circulation 2000 September 26;102(13):1575-81.
 132. Herdeg C, Oberhoff M, Baumbach A et al. Local paclitaxel delivery for the prevention of restenosis: 
biological effects and efficacy in vivo. J Am Coll Cardiol 2000 June;35(7):1969-76.
 133. Axel DI, Kunert W, Goggelmann C et al. Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation 
and Migration In Vitro and In Vivo Using Local Drug Delivery. Circulation 1997 July 15;96(2):636-
45.
 134. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media pre-
vents restenosis after coronary stent implantation. J Am Coll Cardiol 2003 October 15;42(8):1415-
20.
 135. Scheller B, Speck U, Romeike B et al. Contrast media as carriers for local drug delivery. Success-
ful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003 
August;24(15):1462-7.
32
 136. Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of restenosis in 
stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest 
Radiol 2004 March;39(3):182-6.
 137. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a 
novel method for prevention and therapy of restenosis. Circulation 2004 August 17;110(7):810-4.
 138. Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-
coated balloon catheter. N Engl J Med 2006 November 16;355(20):2113-24.
 139. Scheller B, Kuhler M, Cremers B, Mahnkopf D, Bohm M, Boxberger M. Short- and long-term effects 
of a novel paclitaxel coated stent in the porcine coronary model. Clin Res Cardiol 2008 Febru-
ary;97(2):118-23.
 140. Posa A, Hemetsberger R, Petnehazy O et al. Attainment of local drug delivery with paclitaxel-
eluting balloon in porcine coronary arteries. Coron Artery Dis 2008 June;19(4):243-7.
 141. Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus 
paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009 June 
16;119(23):2986-94.
 142. Speck U, Scheller B, Abramjuk C et al. Neointima inhibition: comparison of effectiveness of non-
stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 
2006 August;240(2):411-8.
 143. Gutiérrez-Chico JL, Regar E, van Geuns RJ et al. Moxy(R) drug-coated balloon: a novel device for 
the treatment of coronary and peripheral vascular disease. EuroIntervention 2011 June;7(2):274-7.
 144. Gutiérrez-Chico JL, van Geuns RJ, Koch K et al. Paclitaxel-coated balloon in combination with bare 
metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-
human randomized trial balloon-first vs. stent first. EuroIntervention 2011 October 30;7(6):711-22.
 145. Gutiérrez-Chico JL, Serruys PW. Drug-coated balloons. Controversies and Consensus in Imaging 
and Intervention 2011 August 9;Available at: URL: http://mail.c2i2.org/web11-01/drug-coated-
balloons.asp.
 146. Scheller B, Clever YP, Kelsch B et al. Long-term follow-up after treatment of coronary in-stent re-
stenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv 2012 March;5(3):323-30.
 147. Grube E, Hauptmann KE, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study 
to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coat-
ing. EuroIntervention 2005 May;1(1):53-7.
 148. Grube E, Buellesfeld L. BioMatrix-« Biolimus A9-«-eluting coronary stent: a next-generation 
drug-eluting stent for coronary artery disease. Expert Review of Medical Devices 2006 November 
1;3(6):731-41.
 149. Chevalier B, Serruys PW, Silber S et al. Randomised comparison of Nobori, biolimus A9-eluting 
coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in na-
tive coronary arteries: the Nobori 1 trial. EuroIntervention 2007 February;2(4):426-34.
 150. Chevalier B, Silber S, Park SJ et al. Randomized Comparison of the Nobori Biolimus A9-Eluting 
Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Steno-
sis in Native Coronary Arteries: The NOBORI 1 Trial—Phase 2. Circ Cardiovasc Interv 2009 June 
1;2(3):188-95.
 151. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer 
versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a 
randomised non-inferiority trial. Lancet 2008 September 27;372(9644):1163-73.
 152. Wykrzykowska JJ, Serruys PW, Onuma Y et al. Impact of vessel size on angiographic and clinical 
outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and 
33
General introduction and outline of the thesis
sirolimus-eluting stent with durable polymer the LEADERS trial substudy. JACC Cardiovasc Interv 
2009 September;2(9):861-70.
 153. Wykrzykowska JJ, Raber L, de VT et al. Biolimus-eluting biodegradable polymer versus sirolimus-
eluting permanent polymer stent performance in long lesions: results from the LEADERS multi-
centre trial substudy. EuroIntervention 2009 August;5(3):310-7.
 154. Wykrzykowska JJ, Garg S, Girasis C et al. Value of the SYNTAX score for risk assessment in the 
all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable 
versus ERodable Stent coating) trial. J Am Coll Cardiol 2010 July 20;56(4):272-7.
 155. Wykrzykowska JJ, Garg S, Onuma Y et al. Value of age, creatinine, and ejection fraction (ACEF 
score) in assessing risk in patients undergoing percutaneous coronary interventions in the ‘All-
Comers’ LEADERS trial. Circ Cardiovasc Interv 2011 February 1;4(1):47-56.
 156. Wykrzykowska JJ, Garg S, Onuma Y et al. Implantation of the biodegradable polymer biolimus-
eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality 
compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the 
“all-comers” LEADERS trial. EuroIntervention 2011 September;7(5):605-13.
 157. Sarno G, Garg S, Onuma Y et al. The impact of body mass index on the one year outcomes of 
patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting 
stents (from the LEADERS Trial). Am J Cardiol 2010 February 15;105(4):475-9.
 158. Garg S, Sarno G, Serruys PW et al. The twelve-month outcomes of a biolimus eluting stent with a 
biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIn-
tervention 2010 June;6(2):233-9.
 159. Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a biodegradable vs. 
durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010 Janu-
ary;31(2):165-76.
 160. Gutiérrez-Chico JL, Jüni P, García-García HM et al. Long term tissue coverage of a biodegradable 
polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with 
optical coherence tomography until complete resorption of the polymer. Am Heart J 2011 No-
vember 21;162(5):922-31.
 161. Klauss V, Serruys PW, Pilgrim T et al. 2-Year Clinical Follow-Up From the Randomized Comparison 
of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Du-
rable Polymer in Routine Clinical Practice. J Am Coll Cardiol Intv 2011 August 1;4(8):887-95.
 162. Wykrzykowska J, Serruys P, Buszman P et al. The three year follow-up of the randomised “all-
comers” trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer 
sirolimus-eluting stent (LEADERS). EuroIntervention 2011 November;7(7):789-95.
 163. Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer 
biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary 
artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011 
December 3;378(9807):1940-8.
 164. Stefanini GG, Byrne RA, Serruys PW et al. Biodegradable polymer drug-eluting stents reduce the 
risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: 
a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS 
randomized trials. Eur Heart J 2012 May;33(10):1214-22.
 165. Byrne RA, Kastrati A, Massberg S et al. Biodegradable polymer versus permanent polymer drug-
eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery 
disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011 September 
20;58(13):1325-31.
34
 166. Han Y, Jing Q, Xu B et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting 
stents in “real-world” practice: 18-month clinical and 9-month angiographic outcomes. JACC 
Cardiovasc Interv 2009 April;2(4):303-9.
 167. Aoki J, Serruys PW, van BH et al. Endothelial progenitor cell capture by stents coated with anti-
body against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal 
Growth-First In Man) Registry. J Am Coll Cardiol 2005 May 17;45(10):1574-9.
 168. Duckers HJ, Silber S, de WR et al. Circulating endothelial progenitor cells predict angiographic 
and intravascular ultrasound outcome following percutaneous coronary interventions in the 
HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 
2007 May;3(1):67-75.
 169. Duckers HJ, Soullie T, den HP et al. Accelerated vascular repair following percutaneous coronary 
intervention by capture of endothelial progenitor cells promotes regression of neointimal 
growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor 
cell capturing stent (Genous R stent). EuroIntervention 2007 November;3(3):350-8.
 170. Garg S, Duckers HJ, Serruys PW. Endothelial progenitor cell capture stents: will this technology 
find its niche in contemporary practice? Eur Heart J 2010 May;31(9):1032-5.
 171. Aristotle. Nicomachean Ethics, book II, chapter 6. 350 B.C.
 172. Spears JR, Sandor T, Als AV et al. Computerized image analysis for quantitative measurement of 
vessel diameter from cineangiograms. Circulation 1983 August;68(2):453-61.
 173. Reiber JH, Serruys PW, Kooijman CJ et al. Assessment of short-, medium-, and long-term varia-
tions in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. 
Circulation 1985 February;71(2):280-8.
 174. Lesperance J, Bourassa MG, Schwartz L et al. Definition and measurement of restenosis after 
successful coronary angioplasty: implications for clinical trials. Am Heart J 1993 May;125(5 Pt 
1):1394-408.
 175. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and 
late angiographic outcome after successful balloon angioplasty. Circulation 1994 Septem-
ber;90(3):1239-51.
 176. Beatt KJ, Serruys PW, Hugenholtz PG. Restenosis after coronary angioplasty: new standards for 
clinical studies. J Am Coll Cardiol 1990 February;15(2):491-8.
 177. Gordon PC, Friedrich SP, Piana RN et al. Is 40% to 70% diameter narrowing at the site of previ-
ous stenting or directional coronary atherectomy clinically significant? Am J Cardiol 1994 July 
1;74(1):26-32.
 178. Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: perspectives 
from multicenter clinical trials. J Am Coll Cardiol 2002 December 18;40(12):2082-9.
 179. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary 
angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: 
results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II 
Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol 
1999 October;34(4):1067-74.
 180. Pocock SJ, Lansky AJ, Mehran R et al. Angiographic surrogate end points in drug-eluting stent 
trials: a systematic evaluation based on individual patient data from 11 randomized, controlled 
trials. J Am Coll Cardiol 2008 January 1;51(1):23-32.
 181. Mauri L, Orav EJ, O’Malley AJ et al. Relationship of late loss in lumen diameter to coronary reste-
nosis in sirolimus-eluting stents. Circulation 2005 January 25;111(3):321-7.
35
General introduction and outline of the thesis
 182. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting 
stent comparison. Circulation 2005 June 28;111(25):3435-42.
 183. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating 
drug-eluting stents across variable observational and randomized trials. Circulation 2005 Novem-
ber 1;112(18):2833-9.
 184. Serruys PW, Degertekin M, Tanabe K et al. Intravascular ultrasound findings in the multicenter, 
randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-
expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. 
Circulation 2002 August 13;106(7):798-803.
 185. Degertekin M, Serruys PW, Foley DP et al. Persistent inhibition of neointimal hyperplasia after 
sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intra-
vascular ultrasound follow-up. Circulation 2002 September 24;106(13):1610-3.
 186. Park SJ, Shim WH, Ho DS et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. 
N Engl J Med 2003 April 17;348(16):1537-45.
 187. Sonoda S, Morino Y, Ako J et al. Impact of final stent dimensions on long-term results following 
sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. 
J Am Coll Cardiol 2004 June 2;43(11):1959-63.
 188. Weissman NJ, Koglin J, Cox DA et al. Polymer-based paclitaxel-eluting stents reduce in-stent 
neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the 
TAXUS-IV trial. J Am Coll Cardiol 2005 April 19;45(8):1201-5.
 189. Takano M, Yamamoto M, Xie Y et al. Serial long-term evaluation of neointimal stent coverage and 
thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart 2007 
December;93(12):1533-6.
 190. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence 
tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv 
2009 November;2(11):1035-46.
 191. Gutierrez-Chico JL, Alegria-Barrero E, Teijeiro-Mestre R et al. Optical coherence tomography: from 
research to practice. Eur Heart J Cardiovasc Imaging 2012 May;13(5):370-84.
 192. Suzuki Y, Ikeno F, Koizumi T et al. In vivo comparison between optical coherence tomography and 
intravascular ultrasound for detecting small degrees of in-stent neointima after stent implanta-
tion. JACC Cardiovasc Interv 2008 April;1(2):168-73.
 193. Deuse T, Erben RG, Ikeno F et al. Introducing the first polymer-free leflunomide eluting stent. 
Atherosclerosis 2008 September;200(1):126-34.
 194. Prati F, Zimarino M, Stabile E et al. Does optical coherence tomography identify arterial healing 
after stenting? An in vivo comparison with histology, in a rabbit carotid model. Heart 2008 Febru-
ary 1;94(2):217-21.
 195. Murata A, Wallace-Bradley D, Tellez A et al. Accuracy of optical coherence tomography in the 
evaluation of neointimal coverage after stent implantation. JACC Cardiovasc Imaging 2010 Janu-
ary;3(1):76-84.
 196. Templin C, Meyer M, Muller MF et al. Coronary optical frequency domain imaging (OFDI) for in 
vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 2010 
July;31(14):1792-801.
 197. Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging 
to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008 August 
1;72(2):237-47.
36
 198. Prati F, Regar E, Mintz GS et al. Expert review document on methodology, terminology, and clini-
cal applications of optical coherence tomography: physical principles, methodology of image 
acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur 
Heart J 2010 February;31(4):401-15.
 199. Prati F, Cera M, Ramazzotti V, Imola F, Giudice R, Albertucci M. Safety and feasibility of a new non-
occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisi-
tion in various clinical and anatomical scenarios. EuroIntervention 2007 November;3(3):365-70.
 200. Prati F, Cera M, Ramazzotti V et al. From bench to bedside: a novel technique of acquiring OCT 
images. Circ J 2008 May;72(5):839-43.
 201. Prati F, Guagliumi G, Mintz GS et al. Expert review document part 2: methodology, terminology 
and clinical applications of optical coherence tomography for the assessment of interventional 
procedures. Eur Heart J 2012 May 31.
 202. Moore P, Barlis P, Spiro J et al. A randomized optical coherence tomography study of coronary 
stent strut coverage and luminal protrusion with rapamycin-eluting stents. JACC Cardiovasc Interv 
2009 May;2(5):437-44.
 203. Guagliumi G, Musumeci G, Sirbu V et al. Optical coherence tomography assessment of in vivo 
vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC 
Cardiovasc Interv 2010 May;3(5):531-9.
 204. Guagliumi G, Sirbu V, Musumeci G et al. Strut coverage and vessel wall response to a new-
generation paclitaxel-eluting stent with an ultrathin biodegradable abluminal polymer: Optical 
Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI). Circ Cardiovasc Interv 2010 
August;3(4):367-75.
 205. Guagliumi G, Sirbu V, Bezerra H et al. Strut coverage and vessel wall response to zotarolimus-
eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial 
infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. 
JACC Cardiovasc Interv 2010 June;3(6):680-7.
 206. Guagliumi G, Ikejima H, Sirbu V et al. Impact of Drug Release Kinetics on Vascular Response to 
Different Zotarolimus-Eluting Stents Implanted in Patients With Long Coronary Stenoses The 
LongOCT Study (Optical Coherence Tomography in Long Lesions). JACC Cardiovasc Interv 2011 
July;4(7):778-85.
 207. Guagliumi G, Costa MA, Sirbu V et al. Strut Coverage and Late Malapposition With Paclitaxel-
Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction: Optical Coher-
ence Tomography Substudy of the Harmonizing Outcomes With Revascularization and Stents in 
Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 2011 January 25;123(3):274-81.
 208. van Beusekom HM, Sorop O, van den HM et al. Endothelial function rather than endothelial 
restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting 
stents. EuroIntervention 2010 May;6(1):117-25.
 209. Hofma SH, van der Giessen WJ, van Dalen BM et al. Indication of long-term endothelial dysfunc-
tion after sirolimus-eluting stent implantation. Eur Heart J 2006 January;27(2):166-70.
 210. Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coro-
nary stents in humans. Circulation 2000 July 25;102(4):399-404.
 211. Waksman R, Pakala R, Kuchulakanti PK et al. Safety and efficacy of bioabsorbable magnesium 
alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006 October;68(4):607-17.
 212. Erbel R, Di MC, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorb-
able magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007 June 
2;369(9576):1869-75.
37
General introduction and outline of the thesis
 213. Slottow TL, Pakala R, Okabe T et al. Optical coherence tomography and intravascular ultrasound 
imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. Cardiovasc 
Revasc Med 2008 October;9(4):248-54.
 214. Ghimire G, Spiro J, Kharbanda R et al. Initial evidence for the return of coronary vasoreactivity 
following the absorption of bioabsorbable magnesium alloy coronary stents. EuroIntervention 
2009 January;4(4):481-4.
 215. Waksman R, Erbel R, Di MC et al. Early- and long-term intravascular ultrasound and angiographic 
findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC 
Cardiovasc Interv 2009 April;2(4):312-20.
 216. Oberhauser JP, Hossainy S, Rapoza RJ. Design principles and performance of bioresorbable poly-
meric vascular scaffolds. EuroIntervention Supplement 2009 December;5(Supplement F):F15-F22.
 217. Onuma Y, Serruys PW, Perkins LE et al. Intracoronary Optical Coherence Tomography and Histology 
at 1 Month and 2, 3, and 4 Years After Implantation of Everolimus-Eluting Bioresorbable Vascular 
Scaffolds in a Porcine Coronary Artery Model. An Attempt to Decipher the Human Optical Coher-
ence Tomography Images in the ABSORB Trial. Circulation 2010 November 30;122(22):2288-300.
 218. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent sys-
tem (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009 March 
14;373(9667):897-910.
 219. Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system 
for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. 
Lancet 2008 March 15;371(9616):899-907.
 220. Onuma Y, Serruys PW, Ormiston JA et al. Three-year results of clinical follow-up after a bioresorb-
able everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB 
trial. EuroIntervention 2010 September;6(4):447-53.
 221. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical 
follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de 
novo coronary artery disease: the ABSORB trial. EuroIntervention 2012 January;7(9):1060-1.
 222. Serruys PW, Onuma Y, Ormiston JA et al. Evaluation of the second generation of a bioresorbable 
everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: 
6-month clinical and imaging outcomes. Circulation 2010 November 30;122(22):2301-12.
 223. Serruys PW, Onuma Y, Dudek D et al. Evaluation of the Second Generation of a Bioresorbable 
Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 
12-Month Clinical and Imaging Outcomes. J Am Coll Cardiol 2011 October 4;58(15):1578-88.
“Was man von der Minute ausgeschlagen,
 
gibt keine Ewigkeit zurück”.
 
(What one refuses in one minute, 
no eternity will return)
 
Resignation
Friedrich Schiller 
Part 1
druG-coated balloons

chaPter 1
Rationale for the use of drug-coated balloons
Drug-coated balloons.
Gutiérrez-Chico JL, Serruys PW.
Controversies and Consensus in Imaging and Interventions, 2011.
http://c2i2.digithalamus.com/web11-01/drug-coated-balloons.asp
42
leaD author bIography
Juan Luis Gutiérrez-Chico studied Medicine in Valladolid University (Spain). He completed 
his first PhD in the Department of Cardiovascular Imaging of “Clínico San Carlos” Hospital 
(Madrid) under the direction of Drs. Zamorano and Macaya (2007). Master degree in Statis-
tics by Barcelona University (2008). He worked in Benjamin Franklin Hospital (Berlin) and 
Inselspital (Bern) before becoming interventional cardiologist. Currently he works in the 
Erasmus MC (Rotterdam, NL) on invasive evaluation of intracoronary devices, under Dr. Ser-
ruys’ supervision. His main areas of expertise are optical coherence tomography, healing after 
stenting, biocompatible and bioresorbable polymers, drug-coated balloons, bifurcations and 
biomechanics.
abstract
Drug-coated balloons (DCB) have the potential advantages with respect to drug-eluting 
stents (DES) of being polymer-free and enabling an even transfer of the drug along the vessel 
wall, instead of creating a peri-strut drug gradient. This scenario seems more favourable for 
a complete reendothelialization, without compromising an efficient inhibition of neointimal 
hyperplasia.
Paclitaxel is the antiproliferative drug of all currently available DCB, at a concentration of 
2-3 μg/mm2 of balloon surface. Paclitaxel is markedly hydrophobic and cannot be transferred 
onto the vessel wall unless it is bound to a hydrophilic carrier. The role of this carrier is of 
capital importance to determine the clinical efficacy of the DCB.
DCB with hydrophilic carriers have proven to be clinically and angiographically superior to 
plain-balloon angioplasty and to paclitaxel-eluting stents for the treatment of coronary in-
stent restenosis. The same type of DCB has proven to be superior to plain balloon angioplasty 
for the treatment of de novo femoropopliteal stenosis. The combination of DCB with a bare 
metal stent might represent an alternative to DES for the treatment of de novo coronary 
lesions in selected cases. The role of DCB in bifurcations or small coronary vessels is still has 
to be determined.
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IntroDuctIon
Aristotle wrote that virtue is always between two vices that fall short of and exceed, respec-
tively, what is right. For Interventional Cardiology keeping the neointimal response after 
stenting within a “virtuous” range is still a challenge. In the bare metal stent (BMS) era the 
main concern was the vice for excess of neointimal hyperplasia, namely restenosis, that oc-
curred in 20.0 – 50.3% of the cases 6 months after implantation1. Drug-eluting stents (DES) 
inhibit neointimal proliferation and have efficiently reduced the restenosis rates to 7.9 - 8.9% 
at 9 months1. However, these encouraging results have been tempered by some reports sug-
gesting higher incidence of late and very late stent thrombosis in DES2-5, due to incomplete 
neointimal healing6 with incomplete endothelialization of the metallic struts7 (the vice for 
defect). In the DES the antiproliferative drug is paradoxically eluted from the same metallic 
struts that should be ideally endothelialized, creating a drug gradient that plays against the 
healing of the metallic scaffold. Moreover, other mechanisms have been also implicated in 
DES thrombosis, like inflammation. The polymer containing and releasing the drug might 
induce inflammation of the vascular layers8, trigger a delayed hypersensitivity reaction9,10 and 
stent thrombosis9,10.
The need for drug-coated balloons (DCB) can be understood as an attempt to overcome 
the limitations of DES. They represent the most advanced step in a group of therapies named 
“non-stent-based local delivery of antiproliferative drugs”, comprising different experimental 
techniques, like double balloon catheter11, porous balloon12 or intrapericardial administra-
tion of paclitaxel13. DCB have been tested clinically in several indications and are ready to be 
part of the routine armamentarium of the modern cathlab. The appealing principles of DCB 
mechanism of action are 1) the drug transferred from the DCB onto the vessel wall inhibits 
neointimal hyperplasia efficiently and prevents restenosis (prevents the vice for excess), 2) 
the drug is transferred evenly along the vessel wall, instead of creating a peri-strut gradi-
ent, what seems a more favourable scenario for complete endothelialization of the struts 
(prevents the vice for defect). Furhtermore, the absence of polymer permits to circumvent 
the pro-inflammatory and pro-thrombotic phenomena that this component might elicit.
the Development of Dcb: a pharmacokInetIc DIlemma
The concept of DCB has been long time confronted to a question that seemed impossible to 
be answered satisfactorily: “how could a brief local application of an antiproliferative drug 
for a few seconds have a biological effect on a process prolonged up to 3 months?” Actually 
the question entails two major challenges: 1) the transfer time is very short compared to 
the sustained elution of DES; 2) the marked hydrophobicity of the antiproliferative drugs 
hinders their diffusion in hydrophilic milieus like the vessel wall. The physicochemical and 
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pharmacokinetic dilemma does not have an easy solution: hydrophobic drugs could bind 
tightly to fixed tissue components and have a prolonged effect, but their diffusion into the 
hydrophilic vessel wall is problematic (they form micelles that prevent an adequate contact 
with the vessel wall and an efficient uptake); conversely, hydrophilic drugs permeate eas-
ily the vessel layers, but they are also easily washed out, thus being unlikely to exert the 
expected biological effect. Scepticism seems more than justified.
Paclitaxel is a markedly hydrophobic molecule, hence its transfer onto the arterial wall dur-
ing the time of a balloon inflation is minimal. However, an interesting observation opened 
new perspectives: addition of paclitaxel to the contrast media iopromide (used for coronary 
angiography) during percutaneous coronary stenting resulted in a therapeutic effect inhibit-
ing neointimal hyperplasia, in spite of the limited contact time14-16. The viscosity of the contrast 
media could prolong the contact time at some extent, but not to explain a therapeutic effect. 
The key mechanism seems to be the affinity of the hydrophilic iopromide for the hydropho-
bic paclitaxel: the former facilitates the tissular uptake of the latter up to the adventitia17. 
Once in the target tissue, paclitaxel would bind to fixed hydrophobic components, becoming 
resistant to clearance and exerting a prolonged biological effect. This finding represents the 
pharmacokinetic basics for the development of DCB: combining a hydrophobic active drug 
(that remains) with a hydrophilic carrier (that diffuses), both with mutual affinity.
components of a Dcb
Most of the commercially available DCB to date have three components: the balloon catheter, 
the active drug and the carrier. The most compelling evidence about efficacy of DCB stems 
from devices with this kind of design. Actually, some companies that started manufacturing 
paclitaxel-coated balloons without carrier have recently revised their product and incorpo-
rated a hydrophilic carrier.
the balloon catheter
The balloon is usually a compliant or semi-compliant rapid-exchange balloon catheter. The 
balloon exerts the same mechanical action than any conventional angioplasty balloon, dilat-
ing the target lesion and enlarging the lumen to restore a normal coronary flow. However the 
balloon catheter of a DCB has a second function at least as important as the first one: it puts 
the drug in contact with the vessel wall to enable its diffusion. The conformability of a balloon 
to the lumen shape and consequently the contact surface and the transfer of the drug might 
be better at low-pressure inflation. In this regard a systematic preparation of the coronary 
lesions, using predilatation, atherectomy or cutting-balloon as required might be advisable, 
to allow a final DCB balloon inflation as smooth as possible, to optimize the drug transfer.
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the active antiproliferative drug
Paclitaxel is hitherto the drug of choice in all the commercially available DCB, due to their 
aforementioned pharmacokinetic properties for local delivery17, at a dose of 2-3 μg/mm2 of 
balloon surface area. Paclitaxel binds to the β subunit of tubulin and hyper-stabilizes the 
microtubules of the cell, thus inhibiting the mitosis. Other hydrophobic agents could be also 
tested for this application in the next future.
the carrier
The carrier plays a capital role in the efficacy of the DCB, since it determines the amount of 
drug lost in the transit, and its transference to the vessel wall. A balloon coated just with pa-
clitaxel (without carrier) will suffer negligible loss of the hydrophobic drug during the transit, 
but the paclitaxel transference to the vessel wall will be also very low during balloon inflation. 
Manufacturers of this kind of devices recommended repeat balloon inflations, in an attempt 
to increase the contact time without provoking ischemia. The association of paclitaxel to a 
hydrophilic carrier (iopromide, e.g.) will result in considerable loss of paclitaxel load during 
transit, but also in a high transference rate of the drug into the vessel wall17-19. Manufacturers 
of these devices recommend a single prolonged inflation. The hydrophilic carrier could partly 
explain the efficacy of some DCB18,20-22, compared to the poor performance of other DCB us-
ing carriers of a different type or no carrier18,23.
In presence of a hydrophilic carrier, the longer the transit time, the lower the paclitaxel 
dose reaching the target. In order to minimize the transit time, systematic pre-dilatation of 
the target lesion should be performed before the DCB applications.
The formulation employed will determine the pharmacokinetic properties and the diffusion 
of the active agent. Some animal studies suggest that paclitaxel diffuses not only in a radial 
direction from the balloon surface, but also distally and proximally following the longitudi-
nal axis of the vessel19. This finding is at variance with the evidence from paclitaxel-eluting 
stents using reservoirs technology: in the first experimental designs neointimal hyperplasia 
was maximal at the bridge sites, where no wells for paclitaxel reservoirs had been initially 
implemented24. It is unknown if the alleged longitudinal diffusion is effective to prevent edge 
restenosis, and actually some clinical studies with DCB suggest that geographical mismatch 
(no drug delivery to a stented or injured vessel segment) is associated with restenosis and 
target lesion revascularization (TLR)25. Until more solid evidence is available in this regard, 
it is recommended to extend the balloon applications some mm beyond the stent edges or 
target segment to avoid geographical miss.
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the fourth element: the stent
Some companies have assembled pre-mounted BMS on DCB for the treatment of de novo le-
sions. These combinations are aimed to be an alternative to DES with interesting advantages: 
polymer-free, limited exposure to the antiproliferative drug and homogeneous distribution 
of the drug along the vessel wall. Animal studies also suggest that the loss of paclitaxel dur-
ing vascular transit is lower in folded DCB with a crimped stent than in plain DCB18.
currently avaIlable DevIces
paclitaxel-coated balloons with hydrophilic carrier
paccocath (Bayer Schering Pharma AG, Berlin, Germany) and seQuent please (B Braun Mel-
sungen AG, Vascular Systems, Berlin, Germany) use a hydrophilic iopromide-derived carrier. 
The concentration of paclitaxel is 3 μg/mm2 of balloon surface. 16% of the total paclitaxel 
load is transferred to the vessel wall during a single 30’’ balloon inflation, and this amount 
exerts an efficient neointimal inhibition18. This technology has been the pioneer in develop-
ing the concept of DCB, and has generated the most solid clinical evidence.
Dior (Eurocor GmbH, Bonn, Germany) has also a paclitaxel concentration of 3 μg/mm2 of 
balloon surface, but it followed initially a carrier-free design: paclitaxel coated a microporous 
balloon surface, being the balloon three-folded to minimize the transit loss. However, the 
poor clinical performance of the first Dior generation forced the company to incorporate a 
hydrophilic Shellac carrier. Shellac is a hydrophilic natural resin. The 2nd Dior generation has 
a Paclitaxel-Shellac (1:1) coating in layers, obtained through micropipetting. The layered and 
non-crystalline nature of the coating might make it very robust and resistant to scratching.
The In.pact falcon DCB (Invatec, Italy) has a paclitaxel concentration of 3 μg/mm2 and a 
proprietary hydrophilic FreePac carrier. The moxy DCB (Lutonix, Mapple Grove, MN, USA) has 
a paclitaxel concentration of 2 μg/mm2 and a proprietary hydrophilic non-disclosed carrier. 
No more specific information can be provided about these two devices.
paclitaxel-coated balloons with a pre-mounted bms
coroflex-Deblue is the combination of a Coroflex Blue BMS with the Sequent Please DCB (B 
Braun Melsungen AG, Vascular Systems, Berlin, Germany). The magical system is a CoCr BMS 
pre-mounted on a Dior balloon (Eurocor, Bonn, Germany).
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porous balloons for paclitaxel delivery
genIe (Acrostak, Winterthur, Switzerland), is a liquid drug delivery catheter available in vari-
ous diameters and shaft lengths. After determining the vessel diameter and lesion length, 
the balloons are inflated with diluted paclitaxel.
evIDence about Dcb
DCB have been tested in different clinical coronary scenarios, like in-stent restenosis (ISR), de 
novo coronary lesions, small vessels non-amenable for stenting or bifurcations, but also in 
peripheral femoropopliteal stenosis.
In-stent restenosis
Treatment of ISR is currently a favoured indication for DCB, because the optimal therapeutic 
approach to ISR is still a matter of debate. Re-stenting with DES has proven to be superior to 
brachytherapy and to plain balloon angioplasty26,27, but it cannot be considered an optimal 
solution, because double stent layers have been associated to delayed neointimal healing28 
and suboptimal clinical outcomes29.
DCB have proven to be superior to plain-balloon angioplasty for the treatment of ISR in 
randomized trials. Paccocath DCB has less incidence of major adverse cardiovascular events 
(MACE), mainly due to a significant reduction in TLR, lower in-segment late lumen loss and 
lower rates of binary restenosis30,31. Compared to paclitaxel-eluting stents (PES), the SeQuent 
Please DCB has proven lower in-segment late loss and a statistically non-significant trend to 
lower binary restenosis and MACE, the latter mainly driven by the larger need for TLR with PES32. 
In the scope of these results, DCB has emerged as the best currently available therapy for ISR.
De novo coronary lesions
The combination of a BMS premounted on a DCB resulted in larger inhibition of neointimal 
hyperplasia than sirolimus-eluting stent (SES) in animal coronary overstretch models33. How-
ever, this combination failed to prove non-inferiority vs. SES for the treatment of human de 
novo coronary lesions in the PEPCAD-III trial34. The recently presented “De Novo” trial compared 
the OCT neointimal volume obstruction of the Moxy DCB used in combination with a non-
premounted BMS depending on the sequence of application (DCB first vs. BMS first). No signifi-
cant difference in efficacy endpoints were found between both sequences of application35, and 
the reported endpoints are similar to those historically reported for paclitaxel-eluting stents. 
These OCT results constitute an additional evidence of the biological effect of DCB (figure 1).
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small coronary vessels
PEPCAD I was a multi-centric registry of the Sequent-Please DCB for treatment of small ves-
sels (2.25 - 2.8mm). Cross-over to stenting or plain balloon angioplasty occurred in 30% of the 
cases. At 6 months follow-up in-segment late loss and binary restenosis were 0.28±0.53mm 
and 19,0%, respectively; TLR 14% and MACE 18%. Only 10% of the cases suffered acute elastic 
recoil requiring bailout intervention36.
The randomized PICOLETTO trial compared the carrier-free Dior vs. PES for treatment of 
small coronary vessels (≤ 2.75 mm diameter) in 57 patient with stable or unstable angina. The 
DCB failed to prove non-inferiority; indeed percent diameter stenosis (the primary endpoint), 
binary restenosis and minimal lumen diameter were significantly worse in those treated with 
DCB at 6 months follow-up. Although clinical outcomes were comparable in terms of death 
and MI, there was still a trend towards higher TLR with the DCB23.
The role of DCB in treatment of small coronary vessels is still to define. The inability to 
counteract acute recoil and late remodelling will be probably a severe limitation precluding 
good results in the future.
bifurcations
The DEBIUT registry enrolled 20 patients with bifurcation lesions, who sequentially had the 
main branch and then the side branch treated with the Dior DCB, followed by provisional 
stenting of only the main branch using a BMS. In no case stenting of the side branch was 
required. At 4-month follow-up there were no MACE events; however no angiographic data 
were reported37.
BMS DCB + BMS DES
figure 1: Examples of typical neointimal hyperplasia reaction 6-9 months after bare metal stent (BMS), after the combination of a drug-
coated balloon (DCB) with a BMS and after a drug-eluting stent (DES), as observed with optical coherence tomography. Notice how the thin 
layer covering the stent struts in the combination DCB-BMS is closer to the one observed after DES than to the typical thick layer after BMS, 
suggesting a clear biological effect of the paclitaxel transferred during the balloon inflation.
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More recently the PEPCAD V study enrolled 28 patients with bifurcation lesions, the major-
ity of them class 011 or 111 of Medina. Both branches were treated with the SeQuent Please 
DCB, followed by provisional stenting of the main branch with a BMS; 14% of side branches 
eventually received a stent. At 9-month follow-up, whilst there were significant reductions in 
both main-branch and side-branch late lumen loss, and only 1 TLR, of concern were the two 
late stent thrombosis events in patients receiving DCB and BMS in the main branch38.
DCB have currently no clear indication and no clear advantage for the treatment of coro-
nary bifurcations.
peripheral artery disease
DCB with iopromide-based additive have proven to be superior to plain balloon angio-
plasty39,40 and to balloon angioplasty with paclitaxel dissolved in the contrast media39 for the 
treatment of de novo femoropopliteal stenosis, in terms of late loss at 6 months39 and TLR 
rates at 3 years follow-up40.
key learnIng poInts
1) Currently there is compelling evidence that DCB efficiently inhibit neointimal hyperplasia, 
stemming from clinical and imaging studies.
2) The hydrophilic carrier plays a capital role in the transfer of the drug onto the vessel wall 
and determines the efficacy of the device, or the lack of it.
3) DCB have proven superiority with respect to the hitherto predicate treatments for ISR and 
femoropopliteal stenosis.
4) DCB in combination with BMS might be an alternative for the treatment of de novo 
coronary lesions in selected cases.
5) The role of DCB for the treatment of bifurcations or small coronary vessels is still to define.
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DescrIptIon
The Moxy Drug-Coated PTCA/PTA Balloon is a paclitaxel-coated balloon with a hydrophilic 
carrier to optimize the drug release onto the vessel wall. It represents an interesting alterna-
tive to drug-eluting stent (DES) for the percutaneous treatment of in-stent restenosis, de 
novo-coronary lesions or peripheral artery disease.
hIstory
Adoption of DES has reduced coronary restenosis rates to 7.9 - 8.9% at 9 months1-3, but this 
benefit is compromised by a higher incidence of late and very late stent thrombosis4-8. The 
polymer component of DES may contribute to inflammation of the vascular layers9, eventu-
ally resulting in thrombosis10-12, and the antiproliferative drug is eluted from the same metallic 
struts that should ideally be endothelialized, creating a drug-gradient that prevents proper 
neointimal healing. In this perspective, drug-coated balloons (DCB) represent an interesting 
alternative, since they don’t utilize polymers and the drug is distributed along the vessel wall 
without creating a peri-strut gradient.
DCB have three components: the balloon, the drug and the carrier, which is a critical 
component. The balloon is usually compliant or semi-compliant. The antiproliferative drug 
is paclitaxel at a dose of 2-3 μg/mm2 in all the currently available devices. Paclitaxel is mark-
edly hydrophobic, therefore alone it has very limited transfer onto the vessel wall during the 
short time of a balloon inflation. However, once delivered to tissue it diffuses through the 
vessel wall and binds to fixed hydrophobic components of the tissue, becoming resistant 
to wash out and exerting a prolonged biological effect13. The carrier is the substance that 
enables the transfer of the hydrophobic paclitaxel onto the tissues of the vessel wall through 
a hydrophilic milieu. It plays a critical role in the pharmacokinetics and in the efficacy of the 
different devices tested. The carrier also determines the amount of drug lost in transit. Thus 
a carrier-free balloon will suffer negligible loss of paclitaxel (hydrophobic) during transit, but 
the drug transference to the vessel wall will also be minimal. The hydrophilic carrier (e.g., 
iopromide) increases transference rate of the drug onto the vessel wall13-15 but also loss of 
paclitaxel during transit.
Lutonix (Maple Grove, MN) has developed a DCB with a proprietary hydrophilic carrier for 
coronary and peripheral applications.
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Description of the moxy Dcb
The Moxy DCB is a standard angioplasty catheter with a highly specialized drug coating on 
the balloon portion. The device consists of a dual lumen shaft in two separate designs: Rapid 
Exchange (Rx) and Over-the-Wire (OTW), for coronary and peripheral applications, respectively. 
The coronary Rx system is compatible with 0.014” guidewire and 5 Fr guide catheters. The pe-
ripheral OTW system is compatible with 0.018” guidewire, 7 Fr guide catheters and 6 Fr sheaths.
The Moxy DCB is semi-compliant with a low-profile tapered tip (Figure 1).  The balloon is 
made from a polyamide material capable of achieving high inflation pressures (>16atm for 
Rx and >12atm for OTW). Two radiopaque marker bands are located at the proximal and 
distal ends of the balloon to facilitate fluoroscopic visualization of the DCB during delivery 
and placement. The proximal portion of the DCB catheter includes a female luer lock hub 
connected to the inflation lumen used to inflate and deflate the balloon. Each product has a 
balloon protector and stainless steel stylet to protect the balloon prior to use.
Description of the lutonix Drug coating
The Lutonix drug coating is a non-polymer based formulation consisting of the anti-prolifer-
ative agent Paclitaxel and a proprietary hydrophilic carrier that is designed to minimize the 
loss of drug during transit and to optimize the drug uptake by target vessel tissue during an-
gioplasty. Paclitaxel is evenly distributed along the working length of the balloon at a surface 
concentration of 2µg/mm2 (33% lower than other DCBs)..The proprietary carrier was selected 
among more than 200 substances tested as the one providing the best coating uniformity, 
pharmacokinetic profile and transfer efficiency.
figure 1: Moxy drug-coated semi-compliant balloon in folded and inflated positions.
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InDIcatIons for use
coronary in-stent restenosis (Isr)
Treatment of ISR is currently a favoured indication for DCB, because the optimal therapeutic 
approach to ISR is still a matter of debate. Re-stenting with DES has proven to be superior 
to brachytherapy16,17 and to plain balloon angioplasty18,19, but it cannot be considered an 
optimal solution, because double stent layers have been associated to delayed neointimal 
healing20 and suboptimal clinical outcomes21.
Other DCB with paclitaxel at a dose of 3µg/mm2 and hydrophilic carrier have proven to be 
superior to plain-balloon angioplasty for the treatment of ISR in randomized trials. DCB have 
less incidence of major adverse cardiovascular events (MACE), mainly due to a significant 
reduction in target lesion revascularization (TLR), lower in-segment late lumen loss and lower 
rates of binary restenosis22,23. Compared to paclitaxel-eluting stents (PES), DCB have proven 
lower in-segment late loss and a statistically non-significant trend to lower binary restenosis 
and MACE, the latter mainly driven by the larger need for TLR with PES24. In the scope of these 
results, DCB has emerged as the best currently available therapy for ISR.
The Moxy DCB is currently being tested for the treatment of coronary ISR in an observa-
tional registry titled PERVIDEO I (ClinicalTrials.gov Identifier: NCT00916279).
De novo coronary lesions
The combination of DCB (paclitaxel-coated at 3µg/mm2, hydrophilic carrier) with BMS results 
in larger inhibition of neointimal hyperplasia than sirolimus-eluting stent (SES) in animal 
coronary overstretch models25. However, this combination failed to prove non-inferiority vs. 
SES for the treatment of human de novo coronary lesions26.
The ongoing De Novo Pilot Study (NCT00934752) is a multicenter study assessing perfor-
mance of the Moxy DCB in combination with a BMS (Multilink Vision, Abbot Vascular, Santa 
Clara, CA, USA) for treatment of de novo coronary lesions. This study incorporates a random-
ized, single-blind, open-label design to better understand outcomes based on the sequence 
of application (DCB first vs. BMS first) with OCT-derived neointimal volume as the primary 
endpoint.
small coronary vessels
A randomized clinical trial comparing a carrier-free DCB vs. PES for treatment of small coro-
nary vessels (≤ 2.75 mm diameter) was prematurely stopped due to disappointing results of 
the DCB in an interim analysis27. Vessel recoil and the absence of a carrier to facilitate drug 
transfer might explain these results.
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The PEPCAD I registry used a DCB with hydrophilic carrier for treatment of lesions in vessels 
with 2.25 – 2.80 mm of diameter. Cross-over to stenting or plain balloon angioplasty occurred 
in 30% of the cases. At 6 months follow-up in-segment late loss and binary restenosis were 
0.28±0.53mm and 19,0%, TLR 14% and MACE 18%. Only 10% of the cases suffered acute 
elastic recoil requiring bailout intervention28.
DCB might be an alternative for treatment of small coronary vessels, but their role for this 
indication still requires further clarification. Moxy DCB is not being clinically tested for this 
indication to date.
coronary bifurcations
The feasibility of treating sequentially both branches of a bifurcation with DCB, followed by 
provisional stenting of the main vessel with BMS, has been tested in small series of patients29,30. 
There are no comparative data vs. other strategies and the report of 2 stent thrombosis has 
raised some concerns31. The role of DCB for the treatment of bifurcations is still unclear. Moxy 
DCB is not being clinically tested for this indication to date.
peripheral artery disease
DCB are superior to plain balloon angioplasty32,33 for the treatment of de novo femoropopli-
teal stenosis. Treatment with another DCB (paclitaxel-coated at 3µg/mm2, hydrophilic carrier) 
resulted in significantly lower late loss at 6 months34 and lower TLR rates at 2 years follow-up35.
Further evidence of DCB efficacy is being investigated in the LEVANT I multicenter, single 
blind, randomized, controlled trial (NCT00930813) which compares the Moxy OTW peripheral 
balloon vs. plain balloon angioplasty for the treatment of de novo femoropopliteal stenosis.
tIps anD trIcks for use
The following comments about tips and tricks for use of the Moxy DCB are based on current 
evidence but also in the personal experience of the main operators involved in the different 
clinical studies.
In order to minimize the transit time and hence the loss of paclitaxel, systematic predilation 
is recommended. This also minimizes potential disruption of the drug coating from the me-
chanical stress during difficult lesion crossing. For the treatment of ISR, where the neointimal 
tissue is usually fibrotic and “slippery” for hydrophilic balloons, predilation is recommended 
and may require the use of non-compliant devices or cutting balloons. The aggressiveness 
of pre-dilatation may depend on the lesion characteristics (e.g. calcification) and indication 
(e.g. ISR vs. de novo lesions).
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Although some studies suggest that paclitaxel diffuses into the vessel wall not only in a ra-
dial direction, but also distal and proximally following the longitudinal axis of the vessel36, it is 
somewhat unknown if this longitudinal diffusion is effective to prevent stent edge restenosis. 
Some clinical studies suggest that geographical mismatch (no drug delivery to a stented or 
injured vessel segment) is associated with restenosis and TLR37. Until more solid evidence is 
available in this regard, if the DCB is used in combination with a BMS for treatment of de novo 
coronary lesions, it is recommended to extend the balloon applications beyond the stent 
edges (2-5 mm).
The conformability of a balloon to the lumen shape of the vessel is better at low-pressure 
inflation, suggesting the possibility that transfer of paclitaxel may be optimal at lower atmo-
spheres.
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abstract
aims: To test the efficacy of sequential application of drug-coated balloon (DCB) and bare 
metal stent (BMS) for treatment of de novo coronary lesions, comparing the sequence of 
application (DCB first vs. BMS first).
methods and results: In a multicenter pilot trial, 26 patients with de novo coronary lesions 
were randomized to receive a paclitaxel-coated balloon application followed by BMS im-
plantation (DCB first) or viceversa (BMS first). Quantitative coronary angiography (QCA) and 
optical coherence tomography (OCT) were performed post-procedure and at 6 months, with 
OCT % neointimal volume obstruction as primary endpoint. Longitudinal geographical miss 
was only observed in DCB first (23.1 vs. 0.0%, p=0.220). Implantation of BMS first resulted in 
fewer malapposed struts (p=0.013) but similar coverage at 6 months. No significant differ-
ence was found regarding the primary endpoint (25.5 vs. 24.9%, p=0.922), mean thickness 
of coverage (261 vs. 225μm, p=0.763), late loss (0.53 vs. 0.45mm, p=0.833), binary restenosis 
(27.3 vs. 16.7% in-segment, p=0.640) or clinical endpoints.
conclusion: Sequential application of DCB and not-premounted BMS for treatment of de 
novo coronary lesions results in efficient inhibition of neointimal hyperplasia. The sequence 
of application (DCB first vs. BMS first) does not seem to influence the outcome, except for 
better apposition in BMS first.
key words: Coronary vessels; coronary stenosis; angioplasty, transluminal percutaneous 
coronary; angioplasty, balloon; paclitaxel; stents.
conDenseD abstract
In a multicentre trial, 26 patients with de novo coronary lesions were randomized to receive a 
novel paclitaxel-coated balloon application followed by bare metal stent implantation (DCB 
first) or viceversa (BMS first). Longitudinal geographical miss was only observed in DCB first 
(23.1 vs. 0.0%, p=0.220). BMS first resulted in fewer malapposed struts (p=0.013) but similar 
coverage at 6 months by optical coherence tomography (OCT). No significant difference 
was found regarding OCT percent neointimal volume obstruction (25.5 vs. 24.9%, p=0.922, 
primary endpoint), mean thickness of coverage (261 vs. 225μm, p=0.763), angiographic late 
loss (0.53 vs. 0.45mm, p=0.833) or clinical endpoints.
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lIst of abbrevIatIons
bms: Bare-metal stent
Dcb: Drug-coated balloon
Des: Drug-eluting stent
Isa: Incomplete stent apposition
mace: Major acute cardiovascular event
mla: Minimal lumen area
mlD: Minimal lumen diameter
nasb: Non-apposed side-branch struts
nIh: Neointimal hyperplasia
oct: Optical coherence tomography
pcI: Percutaneous coronary intervention
pes: Paclitaxel-eluting stent
Qca: Quantitative coronary angiography
rvD: Reference vessel diameter
ses: Sirolimus-eluting stent
tlr: Target lesion revascularization
tvr: Target vessel revascularization
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IntroDuctIon
Drug-eluting stents (DES) have efficiently reduced the restenosis rates to 7.9 - 8.9 % at 9 
months1, due to the sustained elution of an antiproliferative agent that inhibits neointimal 
hyperplasia. However some reports have suggested an eventually higher incidence of late 
stent thrombosis2-5. In all these cases, the common pathological finding was an incomplete 
neointimal healing6 with incomplete endothelialization of the metallic struts7. In DES the an-
tiproliferative drug is eluted from the struts, creating a peri-strut gradient that plays against 
a proper healing. Likewise, the polymer containing and releasing the drug might induce 
inflammation and thrombosis8-10.
Drug-coated balloons (DCB) represent an alternative to DES for inhibiting neointimal hyper-
plasia. DCB transfer the drug evenly along the vessel wall, instead of creating a peri-strut 
gradient, what seems a more favourable scenario for complete endothelialization of the 
struts. However this technology must circumvent two limitations: first, the marked hydro-
phobicity of the antiproliferative drugs hinders their diffusion in a hydrophilic milieu like 
the vessel wall; second, the transfer time is very short, compared to the sustained elution of 
DES. A hydrophilic carrier with affinity for the drug facilitates its transfer onto the vessel wall. 
This mechanism would explain why the combination of paclitaxel with the contrast media 
iopromide during injection for coronary angiography results in a therapeutic effect inhibiting 
neointimal hyperplasia11-13, even though the contact time with the vessel wall is limited to a 
few seconds: the hydrophilic iopromide would act as carrier for the hydrophobic paclitaxel, 
facilitating its transfer into the tissue up to the adventitia14. Once in the tissue, paclitaxel 
would bind to fixed lipophilic compounds, becoming resistant to wash-out and exerting a 
prolonged effect14.
In swine coronary overstretch models, DCB combining paclitaxel with a hydrophilic iopro-
mide-based carrier have proven dose-dependant reduction of the neointimal area, with 
complete endothelialization of all the struts and reduction of inflammatory markers15. In the 
clinical setting the same device was superior to plain balloon angioplasty16,17 and to paclitax-
el-eluting stent (PES)18 for the treatment of in-stent restenosis. For de novo coronary lesions, 
the combination of DCB with BMS results in larger inhibition of neointimal hyperplasia than 
a sirolimus-eluting stent (SES) in porcine coronary overstretch models19. These studies used 
a DCB with a hydrophilic iopromide-based carrier, and BMS premounted on the DCB. There 
is scarce information about the efficacy of this combination in the clinical setting. Moreover, 
the effect of sequential application of DCB and BMS for treatment of de novo coronary le-
sions, and the impact of the sequence (DCB first vs. BMS first) are unknown. Hypothetically, 
sequential application might increase the risk of “geographical miss” (mismatching between 
the DCB-treated and the stented segments) compared to premounted devices, especially if 
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DCB is applied first. On the other hand, application of DCB first might enhance the diffusion 
of the drug onto the vessel wall, with better contact than in the presence of an interposed 
stent.
methoDs
The De Novo Pilot Study (NCT00934752) was a multicenter, prospective, single-blind, open-
label randomized trial assessing the performance of the Moxy DCB (Lutonix Inc, Maple Grove, 
MN, USA) in combination with an independent not-premounted BMS for treatment of de 
novo coronary lesions, comparing the effect of the sequence of application (DCB first vs. BMS 
first) on the extent of neointimal hyperplasia (NIH) at 6 months.
study population and allocation to treatment
The study enrolled patients with stable/unstable angina or with documented silent ischemia, 
and one de novo coronary stenosis ≥50% and <100%, ≤18mm length, with a reference vessel 
diameter (RVD) ≥2.5 and ≤3.25mm and amenable for percutaneous coronary intervention 
(PCI). Exclusion criteria included: 1) Myocardial infarction or thrombolysis in previous 72 
hours, 2) History of stroke within the past 6 months, 3) Intervention required in >2 coronary 
lesions, or in one additional lesion lying in the same vessel as the study lesion 4) Coronary 
intervention within 60 days before the index procedure or planned after it, 5) Any previous 
intervention on the target coronary vessel, 6) Left ventricular ejection fraction < 25%, 7) Tar-
get lesion located in the left main coronary artery, or involving bifurcation of vessels ≥2.5mm, 
8) Planned use of adjunctive coronary devices (e.g. cutting-balloon, atherectomy).
Patients were screened for eligibility before entering the procedure. All potentially eligible 
patients provided informed signed consent for enrolment. Final inclusion was done after 
verifying the eventual successful treatment of the non-study lesion and after the guidewire 
had crossed the target lesion without complications. Patients were randomly allocated on a 
1:1 basis to receive treatment with Moxy DCB before BMS (DCB first) or after BMS (BMS first) 
using computer generated-sequences, in blocks stratified by centre.
The study was conducted in accordance with Good Clinical Practice, Declaration of Helsinki 
and local regulations, and protocol was approved by the Ethical Committees of the centres 
involved in the trial: Erasmus MC, Rotterdam; Academic MC, Amsterdam and Catharina Ziek-
enhuis, Eindhoven, NL.
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study endpoints and sample size calculation
The primary endpoint of the trial was the in-stent percent neointimal volume obstruction at 
6 months assessed by optical coherence tomography (OCT). No evidence about the expected 
magnitude of the effect was available when the trial was designed, and therefore no formal 
sample size calculation based on the primary endpoint could be done. Based on unpublished 
data from other ongoing OCT trials, a minimum number of 10 patients per treatment arm was 
considered necessary to provide reliable and non-trivial results, and to detect a significant 
deviation in any of the arms from the results obtained with DES.
Secondary endpoints of the study included OCT endpoints (apposition at baseline and at 
6 months; coverage at 6 months), quantitative coronary angiography (QCA) endpoints (late 
lumen loss, percent diameter stenosis, binary restenosis defined as diameter stenosis ≥50%) 
and clinical endpoints (composite of cardiac death, myocardial infarction [MI] and clinically-
driven target lesion revascularizatio [TLR]; stent thrombosis; major/minor bleeding).
study devices
The DCB used in this study was the Moxy catheter (Lutonix, Maple Grove, MN, USA), model 
9001. It is a standard rapid exchange semi-compliant balloon, coated by paclitaxel at a sur-
face concentration of 2 μg/mm2, and by a proprietary hydrophilic non-polymeric carrier. The 
device was available at 2.5 and 3.0mm diameter, and at 18 and 30mm length for this study. 
All patients were stented with the Multi-link Vision/MiniVision stent (Abbott Vascular, Santa 
Clara, CA, USA). It is a cobalt-chromium BMS with a strut thickness of 81μm, available at 2.5, 
2.75 and 3.0mm diameter, and at 15, 18 and 23mm length for this study.
Description of the intervention
Before the intervention all subjects received aspirin 100-325mg and clopidogrel 75mg daily 
for 3 days or in a loading dose of 300mg. Use of glycoprotein IIb/IIIa inhibitors was left at the 
operator’s discretion. Intravenous heparin or other thrombin inhibitor was administered to 
maintain an activated clotting time ≥250 seconds (or ≥200 seconds if a glycoprotein IIb/IIIa 
inhibitor was being administered) during the procedure. The interventions were performed 
with a ≥6F guiding catheter. Systematic predilatation of the target lesion was mandatory 
regardless the allocation to treatment. The implanted BMS had to cover the whole target 
lesion length. The DCB should extend at least 2mm beyond the distal and proximal margins 
of the stent and of the segment exposed to predilatation, A single DCB inflation ≥ 30 seconds 
was mandatory. If necessary, post-dilatation could be performed with the DCB catheter or 
with other shorter compliant or non-compliant balloon. After optimization of the result, 
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intracoronary nitroglycerin was administered and final angiography and OCT pullback were 
recorded. Optimization of the result based on OCT images was strongly discouraged.
follow-up
Subjects with a single study-lesion were kept on dual anti-platelet therapy with aspirin and 
clopidogrel for 3 months. In case a non-study lesion had been also treated during the same 
procedure, duration of anti-platelet therapy could be extended to meet the requirements of 
the devices employed.
Clinical follow-up visits were scheduled at 30 days, 6, 12 and 24 months. Angiographic and 
OCT follow-up were performed at 6 months.
Qca analysis
QCA analysis was performed with the CAAS II system20 (Pie Medical BV, Maastricht, The 
Netherlands) in a core-lab setting (Cardialysis BV, Rotterdam, NL). An in-DCB region of inter-
est was defined as that coronary segment between the two radiopaque markers of the DCB 
during inflation. In-segment region comprised the in-DCB segment plus 5mm proximal and 
5mm distal. MLD was automatically detected by the software. RVD at the point of MLD was 
calculated by the software by interpolation. Percent diameter stenosis was calculated as: 
(1-[MLD/RVD])*100
oct study and analysis
OCT pullbacks were obtained post-procedure and at 6 months follow-up with a Fourier-
domain C7 system, using a Dragonfly catheter (Lightlab Imaging, Westford, MS, USA) at a 
rotation speed of 100 frames/sec using non-occlusive technique21. After infusion of intra-
coronary nitroglycerine, the optical catheter was withdrawn by a motorized pullback at a 
constant speed of 20 mm/second, while Iodixanol 320 contrast (VisipaqueTM, GE Health Care, 
Cork, Ireland) was infused through the guiding catheter at a continuous rate of 2-6 ml/sec.
OCT pullbacks were analysed offline in a core-laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) by independent investigators blinded to the allocation and to clinical and 
procedural characteristics of the patients, using proprietary software (Lightlab Imaging, 
Westford, Massachusetts, USA). Cross-sections at 1mm intervals within the stented segment 
and 5mm proximal and distal to the stent edges were analyzed. Lumen and stent areas were 
calculated in each analysed cross-section. A metallic strut typically appears as a bright signal-
intense structure with dorsal shadowing. Apposition was assessed strut by strut at baseline 
and follow-up by measuring the distance between the strut marker and the lumen contour22. 
The marker of each strut was placed at the endoluminal leading edge, in the mid-point of its 
74
long-axis, and the distance was measured following a straight line connecting this marker 
with the gravitational centre of the vessel. Struts located at the ostium of side branches, with 
no vessel wall behind, were labelled as non-apposed side-branch (NASB) struts and excluded 
from the analysis of apposition. Struts were classified as malapposed (ISA, incomplete stent 
apposition) during the statistical analysis if their distance to lumen contour was ≥100μm, 
threshold resulting from rounding up the sum of the strut thickness (81μm) plus the axial 
resolution of OCT (14μm). Tissue coverage thickness was measured only at follow-up from 
the marker of each visible strut to the endoluminal edge of the tissue coverage, following a 
straight line connecting the strut marker with the gravitational centre of the vessel. A strut 
was considered non-covered when the thickness of coverage was 0μm. If the thickness of 
figure 1:
Examples of cross-sections in the optical coherence tomography studies 6 months after treatment with the combination of Moxy DCB and BMS 
(upper panel): neointimal hyperplasia (NIH) area is calculated as [stent area – lumen area] (lower panel).
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coverage was ≥60μm for any of the struts in the cross-section, neointimal hyperplasia (NIH) 
area was calculated (Figure 1). From lumen, stent and NIH areas and stent length, the corre-
sponding volumes were calculated. In-stent percent neointimal volume obstruction (primary 
endpoint) was calculated as: (NIH volume / Stent volume) * 100
To summarize the spatial distribution of the non-covered struts along the stents, “spread-
out vessel graphics” were created by correlating the longitudinal distance from the distal 
edge of the stent to the strut (abscises) with the angle where the struts were located in the 
circular cross-section section with respect to the gravitational centre of the vessel (ordinates), 
taking as reference 0º the position at three o’clock. The resultant graphic represented the 
stented vessel, as if it had been cut longitudinally along the reference angle 0º and spread 
out on a flat surface.
assessment of longitudinal and axial mismatch (geographical miss)
Longitudinal geographical miss, defined as presence of ballooned or stented segments not 
covered in their whole length by the DCB application, was assessed by angiography in both 
treatment groups, using the stent and the edge markers of the corresponding balloons as 
references.
Axial geographical miss, defined as inability of the inflated DCB to contact the vessel wall at 
some regions of the stented segment, was exploratorily assessed in the group B (stent first), 
by means of graphics comparing the final stent area with the nominal area of the inflated 
DCB per cross-section. Thus, in those portions where stent area was bigger than the nominal 
inflated DCB area, axial geographical miss would be more likely to occur. This graphics were 
contrasted vs. the NIH area distribution along the stent, to explore a potential association 
between axial geographical miss and the extent of NIH.
statistical analysis
Results are reported as mean±standard deviation for continuous variables, and as count (per-
cent) for nominal variables. Continuous variables were compared with U-Mann-Whittney’s 
test. Nominal variables were compared with Pearson’s chi-square, or Fisher’s exact test if the 
expected frequency was <5 in any cell.
In the OCT per strut analysis, the proportions of uncovered and ISA struts were analyzed 
using multi-level logistic regression models with random effects at 3 different levels: 1) treat-
ment arm, 2) patient, 3) stent. Mean thickness of coverage was analyzed using a multi-level 
linear regression model with random effects at the same 3 levels, after logarithmic transform. 
Overlap segments were considered as separate units of clustering.
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Clinical endpoints followed a hierarchical events model. Backward step logistic regres-
sion and proportional hazards Cox regression were used for 30 days and 6 months results, 
respectively.
All statistical analyses were performed according to the intention-to-treat principle, using 
the SAS v8.2 package (SAS Institute Inc., Cary, North Carolina, USA).
results
Figure 2 shows the flow chart of the study. Between the 24th of June and the 15th of December 
2009, 26 patients were enrolled and randomized. Two patients, both in the DCB-first group, 
withdrew consent after randomization, one of them before the 30 days visit, the other one 
between 30 days and 6 months. One of the angiographies and OCT studies in the BMS-first 
group were lost. One OCT study in each group was considered of insufficient quality to be 
analyzed. One patient in BMS-first underwent implantation of other type of stent than the 
one established per protocol (Skylor, Invatec S.p.a., Roncadelle, Brescia, Italy). Considering 
26 patients (26 lesions) randomized
n=26
Baseline information
13 DCB first 13 BMS first
11 QCA 10 OCT
n=25
13 DCB first 13 BMS first
30-Day Follow-Up
n=24
11 DCB before 13 DCB after
6-Month Follow-Up
12 QCA 11 OCT
1 pt withdrew consent
1 pt withdrew consent
1 lost 1 lost
1 non-analyzable
1 non-analyzable
figure 2:
Flow chart of the study patients, with allocation to treatment and loss at follow-up.
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the similar characteristics of both types of stent, the steering committee decided not to ex-
clude the patient from the analysis. Tables 1 and 2 show the baseline clinical and procedural 
characteristics of the patients, with no significant imbalance. Longitudinal geographical miss 
was only found in DCB first, although the difference did not reach statistical significance.
Table 3 presents the results of the QCA analysis. In spite of randomization, patients allo-
cated to BMS-first had significantly smaller vessels than patients in DCB-first (RVD: 2.41 vs. 
2.81mm, p=0.026, respectively). Late loss was non-significantly different between the groups 
(0.45 vs. 0.53 mm in-DCB, p=0.833).
Table 4 presents the OCT in-stent areas and volumetric analysis. Lumen and stent areas 
parallel the QCA findings of smaller vessels in BMS-first. There was no significant difference 
in in-stent % NIH volume obstruction (primary endpoint of the trial) between DCB-first and 
table 1: Baseline clinical characteristics of the groups.
Dcb before bms
n=13
bms before Dcb
n=13
p-value all
n=26
Age (years) 57.4 ± 10.9 58.2 ± 11.0 0.724 57.8 ± 10.7
Male 10 (76.9%) 9 (69.2%) 1.000* 19 (73.1%)
BMI (kg/m2) 28.2 ± 4.6 26.8 ± 3.2 0.614 27.5 ± 3.9
Hypertension 7 (53.8%) 7 (53.8%) 1.000 12 (46.2%)
Hypercholesterolemia 9 (69.2%) 10 (76.9%) 1.000* 7 (26.9%)
Diabetes mellitus 3 (23.1%) 2 (15.4%) 1.000* 5 (19.2%)
Insulin 1 (7.7%) 0 (0.0%) 1.000* 1 (3.8%)
Oral antidiabetics 2 (15.4%) 2 (15.4%) 1.000* 4 (15.4%)
Smoking 9 (69.2%) 6 (46.2%) 0.234 11 (57.7%)
Ex-smoker 6 (46.2%) 4 (30.8%) 0.420 10 (38.5%)
Current smoker 3 (23.1%) 2 (15.4%) 1.000* 5 (19.2%)
Family history 9 (69.2%) 6 (46.2%) 0.226* 15 (57.7%)
Renal insufficiency 1 (7.7%) 0 (0.0%) 1.000* 1 (3.8%)
Stroke/TIA 1 (7.7%) 0 (0.0%) 1.000* 1 (3.8%)
CHF 0 (0.0%) 0 (0.0%) NA 0 (0.0%)
Previous MI 4 (30.8%) 4 (30.8%) 1.000* 8 (30.8%)
Previous PCI 2 (15.4%) 1 (7.7%) 1.000* 3 (11.5%)
Previous CABG 0 (0.0%) 0 (0.0%) NA 0 (0.0%)
clinical indication
Unstable angina 5 (38.5%) 6 (46.2%) 0.691 11 (42.3%)
Stable angina 8 (61.5%) 6 (46.2%) 0.431 14 (53.8%)
Silent ischemia 0 (0.0%) 1 (7.7%) 1.000* 1 (3.8%)
*Fisher’s exact test.
BMI: Body mass index; BMS: Bare metal stent; BP: Blood pressure; CABG: Coronary artery by-pass graft; CHF: Cardiac heart failure; DCB: Drug-
coated balloon; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; TIA: Transient ischemic attack.
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table 2: Procedural characteristics of the groups.
Dcb before bms
n=13
bms before Dcb
n=13
p-value all
n=26
Diseased vessels RCA 5 (38.5%) 6 (46.2%) 0.691 11 (42.3%)
LAD 7 (53.8%) 6 (46.2%) 0.695 13 (50.0%)
LCX 3 (23.1%) 7 (53.8%) 0.107 10 (38.5%)
Treatment vessel RCA 5 (38.5%) 2 (15.4%) 0.378* 7 (26.9%)
LAD 5 (38.5%) 6 (46.2%) 0.691 11 (42.3%)
LCX 3 (23.1%) 5 (38.5%) 0.673* 8 (30.8%)
Moderate/heavy calcification 2 (15.4%) 1 (7.7%) 1.000* 3 (11.5%)
Bifurcation involved 1 (7.7%) 3 (23.1%) 0.593* 4 (15.4%)
DCB Transit time (sec) 65.3 ± 33.2 68.7 ± 34.0 0.649 66.9 ± 32.8
Time inflation (sec) 56.0 ± 21.6 61.2 ± 20.7 0.413 58.5 ± 20.9
Max inflation press (atm) 9.0 ± 2.9 8.5 ± 2.9 0.880 8.8 ± 2.8
Need for a 2nd DCB 1 (7.7%) 2 (15.4%) 1.000* 3 (11.5%)
BMS Nr stents implanted 1.2 ± 0.4 1.1 ± 0.3 0.511 1.2 ± 0.4
Need for additional stents 3 (23.1%) 1 (7.7%) 0.593* 4 (15.4%)
Residual stenosis 1 (7.7%) 0 (0.0%) 1.000* 1 (3.8%)
Lesion not covered by BMS 1 (7.7%) 0 (0.0%) 1.000* 1 (3.8%)
Dissection 2 (15.4%) 1 (7.7%) 1.000* 3 (11.5%)
Device success 13 (100.0%) 13 (100.0%) NA 26 (100.0%)
Post-dilatation 7 (53.8%) 5 (38.5%) 0.431 12 (46.2%)
Longitudinal geographical miss 3 (23.1%) 0 (0.0%) 0.220* 3 (11.5%)
angiographic complications
Coronary dissection not repaired 1 (7.7%) 0 (0.0%) 1.000* 1 (3.8%)
*Fisher’s exact test.
BMS: Bare metal stent; DCB: Drug-coated balloon; LAD: Left anterior descending; LCX: Left circumflex; RCA: Right coronary artery.
table 3: Quantitative coronary angiography (QCA) results.
Dcb before bms bms before Dcb p-value all
lesion length (mm) 10.7 ± 4.9 11.2 ± 5.1 0.960 10.9 ± 4.9
rvD (mm) 2.81 ± 0.45 2.41 ± 0.37 0.026 2.61 ± 0.45
mlD (mm) 1.07 ± 0.28 0.91 ± 0.23 0.204 0.99 ± 0.26
% diam stenosis 61.8 ± 9.4 61.9 ± 8.1 0.920 61.8 ± 8.6
In-Dcb
Acute gain (mm) 1.42 ± 0.45 1.09 ± 0.42 0.087 1.26 ± 0.46
Late loss (mm) 0.53 ± 0.52 0.45 ± 0.57 0.833 0.49 ± 0.54
Binary restenosis 1 (9.1%) 2 (16.7%) 1.000* 3 (13.0%)
In-segment
Acute gain (mm) 1.20 ± 0.40 0.90 ± 0.41 0.098 1.06 ± 0.43
Late loss (mm) 0.52 ± 0.65 0.31 ± 0.41 0.651 0.41 ± 0.54
Binary restenosis 3 (27.3%) 2 (16.7%) 0.640* 5 (21.7%)
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BMS-first groups (25.5 vs. 24.9%, p=0.922, respectively). No correction for stent volume 
was required for the primary endpoint, because % NIH volume obstruction is by definition 
corrected for stent size. Table 5 presents the OCT areas and volumetric analysis of the stent 
edges. The exploratory assessment of axial geographical miss in BMS-first (figure 3) did not 
show any clear association between axial DCB-BMS mismatch and the extent of local NIH. 
In the per-strut analysis, apposition immediately post-implantation tended to be worse in 
DCB first compared to BMS first (table 6). Although the absolute proportion of ISA struts was 
substantially reduced in both groups at 6 months, the difference became then significant 
(0.1 vs. 2.3%, p<0.0001). Also the proportion of uncovered struts tended to be higher in 
DCB-first than in BMS-first (9.1% vs. 5.3%, p=0.237, respectively), without significant differ-
ences in thickness of coverage (p=0.575). After correction for vessel size (mean stent area), 
the difference in proportion of ISA struts still remained significant at 6 months (p=0.013). 
The spread-out vessel charts summarize the spatial distribution and clustering of uncovered 
struts (figure 4). Uncovered struts cluster in some subjects, in some regions within a stent, or 
around the overlap segment.
Table 7 summarizes the clinical and safety secondary endpoints at 30 days and 6 months 
follow-up. Median follow-up time was 181 days (IQ range: 171 – 186.25): 176 days in group A 
(IQ range: 162.5 – 185), 181 days in group B (IQ range: 175 – 188).
table 4: Optical coherence tomography (OCT) areas and volumes: in-stent analysis.
Dcb before bms
10 pt, 11 stents
bms before Dcb
12 pt, 12 stents
p-value all
22 pt, 23 stents
po
st
-im
pl
an
t
stent length (mm) 14.91 ± 6.47 17.48 ± 3.77 0.151 16.25 ± 5.28
min stent area (mm²) 7.77 ± 2.36 5.30 ± 1.46 0.013 6.49 ± 2.28
mean stent area (mm²) 9.11 ± 2.38 6.50 ± 1.79 0.013 7.75 ± 2.44
stent volume (mm3) 134.99 ± 75.77 114.71 ± 41.86 0.928 124.41 ± 59.94
% frames with Isa 18.7 ± 17.7 7.2 ± 9.5 0.091 12.7 ± 14.9
max Isa area (mm²) 1.21 ± 1.41 0.47 ± 0.65 0.190 0.82 ± 1.12
Isa volume (mm3) 2.14 ± 1.89 0.70 ± 1.08 0.051 1.39 ± 1.66
Isa volume (%of stent vol) 2.24 ± 2.53 0.52 ± 0.77 0.118 1.34 ± 2.00
6 
m
on
th
s f
ol
lo
w
-u
p
mla (mm²) 4.94 ± 2.88 3.48 ± 2.41 0.270 4.21 ± 2.69
mean lumen area (mm²) 6.86 ± 2.91 5.14 ± 2.17 0.193 6.00 ± 2.65
lumen volume (mm3) 95.75 ± 57.32 90.68 ± 38.56 0.748 93.22 ± 47.74
% frames with Isa 4.06 ± 7.05 0.57 ± 1.88 0.270 2.31 ± 5.34
max Isa area (mm²) 0.43 ± 0.68 0.03 ± 0.09 0.243 0.23 ± 0.52
Isa volume (mm3) 0.56 ± 0.88 0.02 ± 0.08 0.243 0.29 ± 0.67
Isa volume (% of stent vol) 0.37 ± 0.75 0.02 ± 0.08 0.243 0.20 ± 0.55
max nIh area (mm²) 4.02 ± 1.77 2.93 ± 1.74 0.151 3.48 ± 1.80
nIh volume (mm3) 30.14 ± 23.71 27.35 ± 14.41 0.974 28.74 ± 19.20
% nIh vol obstruction 25.3 ± 15.9 24.9 ± 13.5 0.922 25.1 ± 20.8
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DIscussIon
To the best of our knowledge this is the first randomized trial testing the efficacy of a DCB with 
an OCT primary endpoint. The results suggest that the sequential application of DCB and not-
premounted BMS for the treatment of de novo coronary lesions is feasible and inhibits neointi-
mal hyperplasia efficiently. The overall in-stent NIH volume obstruction (primary endpoint) and 
the mean thickness of coverage (25.1% and 242μm, respectively) are comparable to the ones 
reported for paclitaxel-eluting stents (22.2 – 25.8%, 200 - 240μm)23,24, lower than in some DES 
and far from those in BMS (53.9%, 530μm)23. Also the proportion of uncovered struts (7%) is in 
the range of paclitaxel-eluting stents (5 – 7%), lower than in sirolimus eluting stents (8%), but 
higher than in BMS (1%)23,24. These OCT findings constitute an additional evidence of the bio-
logical effect exerted by DCB in the modulation of neointimal hyperplasia after stenting. Clinical 
and angiographic studies had already proven the concept consistently16-18, but this is the first 
time to quantify this effect with OCT, what will be interesting for the design of future studies.
table 5: Optical coherence tomography (OCT) areas and volumes: analysis of the stent edges.
post-implant Dcb before bms bms before Dcb p-val all
pr
ox
im
al
 e
dg
e
n 10 12 22
length (mm) 4.12 ± 1.54 4.94 ± 0.30 0.418 4.57 ± 1.11
mla (mm²) 7.03 ± 3.37 5.73 ± 2.50 0.314 6.32 ± 2.92
mean lumen area (mm²) 8.35 ± 3.44 6.79 ± 2.32 0.254 7.50 ± 2.92
lumen volume (mm3) 33.66 ± 13.96 33.29 ± 10.93 0.628 33.46 ± 12.09
% frames with dissection 15.00 ± 24.15 20.83 ± 36.32 0.974 18.18 ± 30.82
Di
st
al
 e
dg
e
n 9 11 20
length (mm) 4.47 ± 1.27 4.30 ± 1.29 0.941 4.37 ± 1.25
mla (mm²) 5.88 ± 1.79 4.54 ± 1.71 0.201 5.14 ± 1.83
mean lumen area (mm²) 6.97 ± 1.52 5.32 ± 1.79 0.056 6.06 ± 1.84
lumen volume (mm3) 30.44 ± 10.45 23.27 ± 10.77 0.201 26.50 ± 10.97
% frames with dissection 18.15 ± 29.68 16.67 ± 26.87 1.000 17.33 ± 27.41
6 months follow-up
pr
ox
im
al
 e
dg
e
n 10 11 21
length (mm) 4.64 ± 1.21 5.00 ± 0.00 1.000 4.83 ± 0.83
mla (mm²) 5.57 ± 2.11 4.88 ± 2.68 0.557 5.20 ± 2.39
mean lumen area (mm²) 7.87 ± 2.75 6.33 ± 2.98 0.314 7.06 ± 2.91
lumen volume (mm3) 37.24 ± 16.59 31.63 ± 14.89 0.512 34.30 ± 15.59
Di
st
al
 e
dg
e
n 9 11 20
length (mm) 5.00 ± 0.00 4.20 ± 1.40 0.175 4.56 ± 1.09
mla (mm²) 5.15 ± 1.97 3.83 ± 2.70 0.370 4.42 ± 2.43
mean lumen area (mm²) 6.05 ± 1.82 4.54 ± 3.14 0.261 5.22 ± 2.68
lumen volume (mm3) 30.25 ± 9.11 20.31 ± 16.03 0.175 24.79 ± 14.00
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table 6: Optical coherence tomography (OCT) analysis of apposition and coverage per strut: prespecified analysis and after correction by vessel 
size (mean stent area).
Dcb first bms first or (95% cI) p-val all
post-implant 10 patients
10 lesions
11 stents
1849 struts
12 patients
12 lesions
12 stents
2025 struts
22 patients
22 lesions
23 stents
3874 struts
apposition
Well-apposed 1644 (88.9%) 1902 (93.9%) 0.53 (0.24, 1.15)
0.54 (0.21, 1.42)*
0.106
0.213*
3546 (91.5%)
ISA 187 (10.1%) 110 (5.4%) 1.91 (0.81, 4.51)
1.82 (0.66, 5.04)*
0.139 
0.247*
297 (7.7%)
NASB 18 (1.0%) 13 (0.6%) 1.51 (0.45, 5.07)
1.81 (0.51, 6.39)*
0.507 
0.357*
31 (0.8%)
6 months follow-up 10 patients
10 lesions
11 stents
1580 struts
11 patients
11 lesions
11 stents
1785 struts
21 patients
21 lesions
22 stents
3365 struts
apposition
Well-apposed 1536 (97.2%) 1779 (99.7%) 0.10 (0.02, 0.55)
0.21 (0.03, 1.68)*
0.008 
0.143*
3315 (95.8%)
ISA 37 (2.3%) 2 (0.1%) 25.57 (5.58, 117.47)
12.56 (1.70, 93.10)*
<0.0001 
0.013*
39 (1.2%)
NASB 7 (0.4%) 4 (0.2%) 1.79 (0.21, 14.92)
0.63 (0.09, 4.26)*
0.592 
0.638*
11 (0.3%)
coverage
Covered struts 1437 (90.9%) 1690 (94.7%) 0.47 (0.14, 1.63)
0.89 (0.25, 3.11)*
0.237 
0.857*
3127 (92.9%)
Thickness of coverage (μm) 261 (238)* 225 (195)* 242 (217)
Corrected mean (μm)† 104 132 0.78 (0.32, 1.90)
1.15 (0.43, 3.08)*
0.575 
0.763*
Data reported as # (%), except for the thickness of coverage, reported as mean (SD).
*Estimation of the effect after correction by vessel size (mean stent area).
† Ln transformed. Estimate or the effect and confidence intervals represent group A/group B ratio.
table 7: Clinical and safety secondary endpoints at 30 days and 6 months.
30d 6m
Dcb before bms
n=13
bms before Dcb
n=13
p-value all
n=26
Dcb before bms
n=13
bms before Dcb
n=13
p-value all
n=26
Death 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0)
MI 0 (0.0) 1 (7.7) 0.232 1 (3.8) 0 (0.0) 2 (15.4) 0.166 2 (7.7)
TVR 1 (7.7) 0 (0.0) 0.232 1 (3.8) 3 (23.1) 2 (15.4) 0.628 5 (19.2)
TLR 0 (0.0) 0 (0.0) NA 0 (0.0) 2 (15.4) 2 (15.4) 0.987 4 (15.4)
Death, MI, TLR 0 (0.0) 1 (7.7) 0.232 1 (3.8) 2 (15.4) 4 (30.8) 0.432 6 (23.1)
Bleeding 0 (0.0) 2 (15.4) 0.086 2 (7.7) 0 (0.0) 2 (15.4) 0.149 2 (7.7)
Stent thrombosis 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0)
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Results: OCT
Stent area
Balloon area 
(nominal)
Stent length (mm) Stent length (mm)
NIH area
Axial mismatch NIH
10 mm2
4 mm2
Scale 5 mm2
0 mm2
Scale
figure 3:
Exploratory assessment of axial geographical miss post-implantation (left panel) and its eventual association with local neointimal hyperplasia 
(NIH, right panel) in the group B of the study (BMS before DCB).
The bars in the left panel represent the length of each implanted stent. The black and red lines represent the stent area and the nominal area of 
the inflated balloon, respectively, in each cross-section. Thus, in those regions where the stent area is higher than the nominal inflated balloon 
area (black above red), axial mismatch would be more likely to occur. The black line in the right panel represents the local NIH area at 6 months 
in the corresponding stents. At first glance, no clear relation between NIH and axial geographical miss can be concluded.
83
Chapter 3 : DCB in combination with BMS for treatment of de novo coronary lesions
The sequence “BMS first” translated into better apposition than “DCB first”, as reflected by 
significantly lower proportion of ISA struts and a non-significant trend to lower ISA areas and 
volumes. Although initially the sequence “BMS first” seemed to have also better coverage 
profile (higher proportion of covered struts at 6 months, with thinner tissue coverage), the log 
transform suggests that the neointimal coverage is actually comparatively thicker in this group, 
and the adjusted analysis suggests that these differences in coverage are mainly due to the 
smaller vessel size than to the allocation to treatment. Therefore both therapeutic strategies are 
comparable in terms of coverage at 6 months, but the sequence BMS first results in better ap-
position. Except from this advantage, there were no significant differences between treatment 
figure 4:
Spread-out-vessel charts showing the spatial distribution of uncovered struts at 6 months in both treatment groups. The graphic summarizes 
the clustering effect at the three levels: 1) allocation to treatment (right vs. left panel), 2) patient/lesion (bars are summaries per patient/
lesion), 3) stent. The regional clustering within the stented region is also represented.
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groups in the primary endpoint or in any of the remaining secondary endpoints. Thereafter the 
initial working hypothesis could not be confirmed. The results about the primary endpoint and 
struts coverage do not suggest that the application of DCB first actually results in better con-
tact with the vessel wall, better transfer of the paclitaxel and therefore more effective action. 
Likewise, the idea that the implantation of BMS first would reduce the incidence of longitudinal 
geographical miss and hence be more efficient in real-world practice in spite of an eventually 
suboptimal contact between the DCB and the vessel wall, was not either confirmed: although 
no single case of geographical miss was certainly observed in the group “BMS first”, this did not 
seem to have any impact in any of the efficacy endpoints.
The results of this exploratory study suggest that the deployment of BMS first might ease 
the recognition of the target region and reduce the longitudinal geographical miss. However, 
this strategy might also result in an incomplete contact between the DCB and the vessel wall 
at some points, when the former is inflated inside the stent (axial geographical miss). The 
documentation of axial mismatch is more challenging. In this study we introduce a graphic 
method to assess axial geographical miss, as already explained, and explore its potential 
association with regional NIH. The results, however, do not suggest any direct relation in 
this respect. Likewise, although axial mismatch is a common finding among the patients in 
BMS-first, this does not entail worse outcome in any of the tested endpoints. It seems that 
geographical miss, either longitudinal or axial, influences the results at a lesser extent than 
currently believed. A potential explanation for this finding might be the diffusion kinetics 
of paclitaxel. Posa et al. demonstrated in a coronary swine model that paclitaxel diffuses 
not only axially but also longitudinally into the vessel wall after DCB application25. Thus, a 
homogeneous inhibitory effect might be achieved, even though the contact with the vessel 
wall were suboptimal or the application were slightly distant from the target point. Further 
investigation to clarify these findings is warranted.
The spread-out vessel charts offer an intuitive graphic representation of the spatial dis-
tribution and clustering of struts uncoverage. For instance, the effect of stent overlap can 
be easily understood with this representation. The graphic also depicts the complexity of 
healing after stenting, still poorly understood, with large interindividual and regional vari-
ability within some patients. This marked clustering phenomenon highlights the importance 
of choosing an appropriate statistical method for the analysis of OCT data, in order to avoid 
misleading conclusions.
limitations
This was a pilot study with small sample size, conceived to explore the effect of a novel DCB 
on the treatment of de novo coronary lesions. The results of several efficacy variables were 
in the expected ranges of paclitaxel-eluting stents, what is a relevant finding, but careful 
extrapolation of these results must be warned, because this was not a proper comparative 
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study vs. a different device. Likewise, a bigger sample size might have contributed to under-
stand better the role played by the sequence of application.
Randomization resulted in a homogeneous distribution of all the control variables, except 
the vessel size. Although the primary endpoint was by definition corrected for vessel size, a 
statistical correction was required for the other efficacy endpoints. Sensitivity analysis includ-
ing mean stent area as covariate circumvented this limitation in the per strut analysis. Mean 
stent area resulted to be a significant confounding factor for apposition (only affecting the 
proportion of NASB struts: the bigger the vessel, the more NASB struts) and for coverage 
(the bigger the vessel, the more proportion of uncovered struts and the thinner the cover-
age). The results of this sensitivity analysis, in which the inclusion of vessel size in the model 
significantly modified the magnitude of some effects, and in some cases even reversed the 
sense of the association, are also hereby reported.
Angiographic late loss was slightly higher than initially expected in this trial (overall in-stent 
0.49mm), despite the relatively small size of the vessels. Other paclitaxel-coated balloons 
with hydrophilic carriers had reported in-stent late loss of 0.09 and 0.19mm for the treatment 
of in-stent restenosis16,18. Likewise, the rates of binary restenosis (overall in-segment 21.7%) at 
6 months are clearly higher than previously reported by other DCB in other clinical scenarios 
(in-segment 5-7%)16,18. These findings might be related to the reduced paclitaxel dose of the 
Moxy balloon or to a less efficient transfer of the drug by the carrier. Further investigation 
will be required to better understand the reasons why this technology yields optimal results, 
comparable to paclitaxel-eluting stents, in some cases, but cannot avoid restenosis in others.
conclusIon
Sequential application of a paclitaxel-coated balloon in combination with a not-premounted 
BMS for the treatment of de novo coronary lesions is feasible and results in efficient inhibi-
tion of neointimal hyperplasia. The sequence of application (balloon first vs. BMS first) does 
not seem to influence the outcome, except for a significantly better apposition if the BMS is 
deployed first.
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 “Il raziocinio è un lume che uno 
può accendere quando voule 
obbligar gli altri a vedere, e può 
soffiarci sopra quando non vuo più 
veder lui”.
 
(Reason is a light that one can turn 
on to compel the others to see, 
but one can also blow on it when 
oneself does not want to see any 
more)
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Covered stent in saphenous vein graft
‘‘Over-and-Under’’ pericardial covered stent with 
paclitaxel balloon in a saphenous vein graft.
Wykrzykowska JJ, Gutiérrez-Chico JL, van Geuns RJ.
Catheter Cardiovasc Interv 2010;75:964-966.
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abstract
Treatment of vein graft disease remains a challenge in interventional cardiology because of 
the risk of embolization and no-reflow phenomenon. Currently available distal protection 
devices have their limitations. The PTFE-covered stents may be well suited for venous graft 
lesion treatment, but those available commercially to date have poor crossing profiles, and 
deliverability and high rates of restenosis. We report the first use of over-and-under pericar-
dium-covered stent in combination with drug-eluting balloon to treat venous graft disease.
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case presentatIon
A 75-year-old man with past history of anterior myocardial infarction in 1981 and subsequent 
bypass surgery with venous graft to the LAD/D1 and venous graft to the RCA, subsequent 
RCA graft occlusion and LAD graft ostial stenting in 2007, now returned with symptoms of 
unstable angina. His risk factors included poorly controlled diabetes treated with insulin, 
hypercholesterolemia, hypertension and significant family history. Diagnostic angiography 
revealed severe three vessel disease with significant right coronary artery disease and ostial 
LAD graft in-stent restenosis.
We performed direct stenting with Xience V 3.0 X 28 mm (Xience V, Abbott, Santa Barbara, 
CA) of the RCA without complications. The attention was then turned to the graft. A 6 Fr JR4 
catheter provided good support and the lesion was crossed easily with a Pilot 50 hydrophilic 
wire (Pilot 50, Abbott, Santa Barbara, CA). Given the risk of embolization in this 28-year-old 
graft, we elected to use a covered “over-and-under” equine pericardial covered stent (ITGI 
Medical, Or Akiva, Israel) combined with an application of the paclitaxel drug eluting bal-
loon (Dior, EuroCor, Bonn, Germany). In addition to angiography (Figure 1A), intravascular 
ultrasound (IVUS) grey scale with a 20 MHz Eagle eye S5 Volcano catheter (Eagle Eye S5, 
Volcano Corp., San Diego, CA) was performed showing severe in stent restenosis (Figure 1B). 
The lesion was predilated with a non-compliant balloon given some degree of calcification 
seen on IVUS (Figure 1 B, C). A 3.5 x 20 mm Dior paclitaxel eluting balloon was applied at 6-8 
atms for 30 seconds twice. Optical Coherence Tomography (OCT) with C7 Lightlabs sytem 
(C7-XR, LightLab Imaging Inc, Westford, MA) was also performed after predilation to size the 
vessel. 3.5 x 23 mm “Over-and-under” pericardial stent delivered easily and was deployed at 
16 atms. Postdilation with a 3.5 x 15 mm non-compliant balloon was performed at 18 atms 
to achieve the most optimal result. OCT was repeated showing good stent apposition and 
presence of stent suture lines (Figure 2; arrows). Final angiography showed good result with 
figure 1:
A. Baseline angiography showing ostial graft in-stent restenosis. B. Initial IVUS assessment showing the MLD with complex plaque and 
calcifications. C. IVUS-VH.
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TIMI III flow (Figure 3). The patient tolerated the procedure well without biomarker evidence 
of periprocedural infarction.
The patient returned 6 months later with symptoms of unstable angina and both angi-
ography and OCT demonstrated in-segment (edge) restenosis. This was treated with an 
everolimus eluting Xience V stent with good result.
case DIscussIon
Interventions on venous grafts continue to present a challenge to an interventional car-
diologist. Particularly grafts older than 20 years, as in our case, tend to have high degree 
figure 2:
OCT after stenting showing good apposition and presence of suture lines (arrows).
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of friable atheromatous plaque, which is prone to embolization and may cause no-reflow 
phenomenon with periprocedural myocardial infarction and its consequent mortality.1 
Angiographic assessment of plaque burden does not predict with high accuracy the risk of 
periprocedural complications and which patients would benefit from devices such as distal 
protection devices.2 Distal protection devices have been shown to reduce complications, 
however, they suffer from certain limitations.3 Protruding friable plaque through the stent 
struts may continue to micro-embolize post-stent placement.
Covered stents would appear to be well suited for treatment of venous graft atheroma. PFTE 
covered devices such as Jomed stent were limited, however, by poor flexibility and deliver-
ability as well as in-stent restenosis.4 Our own group has circumvented the latter problem by 
placing a drug eluting stent within the covered stent.5 “Over-and-under” pericardial covered 
stent is a novel technology that may be more deliverable and have a better crossing profile.6 
It is more biocompatible than PTFE and therefore promises to have less in-stent restenosis. 
Unfortunately, in this case the patient returned with in-segment restenosis potentially due 
to the shorter length of the drug eluting balloon than the pericardium covered stent. This 
maybe also due to the fact that the first generation Dior balloon with lower concentration of 
paclitaxel was used and therefore less drug was delivered at the edges of the stent.
The manner of deployment is such that stent edges deploy before the middle of the stent, 
thereby effectively trapping the friable atheroma behind the pericardium and preventing 
embolization. Our patient had no biomarker evidence of microembolization and no peri-
procedural myocardial infarction. To further minimize the risk of in-stent restenosis, we pre-
treated the vessel with a paclitaxel drug-eluting balloon. This technology has been shown 
to be effective for treatment of in-stent restenosis and de novo disease.7-9 To our knowledge, 
figure 3: Final angiography with TIMI III flow.
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this is the first report of combined use of the drug eluting balloon with a pericardium covered 
“over-and-under” stent. A systematic registry or randomized study will be needed to further 
assess the safety and feasibility as well as efficacy of the combined use of the two devices. 
Careful assessment of the drug elution profile and how it is altered by the presence of the 
pericardium, as well as weather application directly on the vessel wall versus on the pericar-
dium post-stenting is preferable will be needed, to prevent edge restenosis as seen in this 
case. In addition as illustrated here, particular attention to ensuring drug elution at the edges 
of the stent is important for future restenosis risk.
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Self-expandable stents for vulnerable plaque 
treatment
Plaque sealing and passivation with a mechanical 
self-expanding low outward force nitinol vShield 
device for the treatment of IVUS and OCT-derived 
thin cap fibroatheromas (TCFAs) in native coronary 
arteries: report of the pilot study vShield Evaluated 
at Cardiac hospital in Rotterdam for Investigation 
and Treatment of TCFA (SECRITT).
Wykrzykowska JJ, Diletti R, Gutiérrez-Chico JL, van Geuns RJ, van 
der Giessen WJ, Ramcharitar S, Duckers HE, Schultz C, de Feyter P, 
van der Ent M, Regar E, de Jaegere P, Garcia-Garcia HM, Pawar R, 
Gonzalo N, Ligthart J, de Schepper J, van den Berg N, Milewski K, 
Granada JF, Serruys PW.
EuroIntervention 2012;8:945-954.
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abstract
aims: The aim of the pilot SECRITT trial was to evaluate the safety and feasibility of sealing 
the high risk IVUS and optical coherence tomography-derived thin cap fibroatheroma (TCFA), 
with a dedicated nitinol self-expanding vShield device.
methods and results: After screening with angiography, fractional flow reserve (FFR), intra-
vascular ultra sound virtual histology (IVUS-VH) and optical coherence tomography (OCT), 23 
patients met enrolment crite ria (presence of non-obstructive VH-derived TCFA lesion with 
thin cap on OCT) and were randomised to vShield (n=13) versus medical therapy (n=10). In 
the shielded group, baseline percent diameter stenosis was 33.2±13.5%, FFR was 0.93±0.06. 
At six-month follow-up in shielded patients percent diameter stenosis further decreased to 
18.7±16.9% and FFR remained the same 0.93±0.05. Average late loss was 0.24±0.13 mm. 
Average baseline fibrous cap thickness was 48±12 μm. After shield placement at six-month 
follow-up neo-cap formation was observed with average cap thickness of 201±168 μm. There 
were no dissections after shield placement and no plaque ruptures. In addition, mean stent 
area of 8.76±2.16 mm2 increased to 9.45±2.30 mm2, that is by 9% at six-month follow-up. The 
number of malapposed struts decreased from 10.7% to 7.6% and the number of uncovered 
struts at six months was 8.1%. There were no device-related major adverse cardiovascular 
events (MACE) events at six-month follow-up.
conclusion: High risk plaque passivation and sealing with a vShield self-expanding nitinol 
device appears feasible and safe. A long-term larger randomised study with streamlined 
screening criteria is needed to evalu ate the efficacy of this approach over medical therapy.
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abbrevIatIons
tcfa: thin cap fibroatheroma
csa: cross-sectional area
mI: myocardial infarction
arc: Academic Research Consortium
Isa: incomplete stent apposition
mace: major adverse cardiovascular events
Ivus: intravascular ultra-sound
Ivus-vh: intravascular ultrasound virtual histology
oct: optical coherence tomography
pcI: percutaneous coronary intervention
Qca: quantitative coronary angiography
ffr: fractional flow reserve
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IntroDuctIon
Our current understanding of the pathogenesis of acute coronary syndrome, the progression 
of coronary artery disease and sudden death is that 70% of the time patients with atheroscle-
rosis and fatal myocardial infarction incur plaque rupture of the so-called thin cap fibroather-
oma and in the rest of the cases pathology reveals plaque erosion or calcified nodule1-3. Many 
of these plaques have gone undetected by conventional coronary angiography because the 
underlying lesion was non-obstructive (<50% diameter stenosis) due to the so-called Glagov 
effect (positive remodelling at the site of large plaque burden). High-risk plaque is defined 
as a large lipid pool , thin cap (less than 65 μm) and macrophage dense inflamma tion, as 
well as positive remodeling2, 4-6. The majority of these plaques occur in the proximal portion 
of the three major epicardial coronary arteries7, 8. It is also becoming clear that obstructive 
plaques (with minimal luminal area < 4mm2) can also be high risk and identify a patient at 
risk of future events. In fact these plaques have been shown to result in the highest number 
of events in the PROSPECT trial9, the first prospective natural history study of atherosclerosis 
using multimodality imaging. Currently there are two strategies to manage patients with thin 
cap fibroatheromas: 1) Conservative medical therapy based on the premise that none of the 
imaging modalities to-date have been able to identify reliable features of the plaque that 
render it prone to major adverse cardiac events, and 2) focal treatment to seal and passiv-
ate the plaque. The latter approach has been recently demonstrated in the VELETI trial to 
prevent progression of disease in vein grafts with non-obstructive lesions10. The SECRITT trial 
is a randomised, controlled pilot study that evaluates the safety and feasibility of sealing the 
high risk IVUS and OCT-derived TCFA with a dedicated nitinol self-expanding vShield device. 
As such, it is the first trial of a dedicated device for treatment of “vulnerable plaque” in native 
coronary arteries.
methoDs
Device description
The vProtect™ luminal shield system (Prescient Medical, Inc., Doylestown, PA, USA) consists 
of the self-expanding (nitinol) vas cular shield (figure 1a) and a rapid exchange delivery 
system. The delivery system is compatible with 0.014” guidewires and 6 Fr guiding catheters. 
The delivery system consists of a distal outer sheath that houses the luminal shield and an 
inner body with radio paque markers at the distal and proximal ends of the shield. The luminal 
shield is constructed from a nickel-titanium alloy with an austenitic finish. The shield has a 
wall thickness that is less than 70 μm and has been designed with the objective to match the 
elastic properties of the TCFA. The shield is available in 3.5 mm, 4.0 mm and 4.5 mm diameter 
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with a length of 15 mm for all the diameters. This allows vessels of between 2.75 mm to 4.0 
mm to be treated. The distinctive feature of the shield is the hysteresis between the inward 
radial resistive force and the outward force exerted on the vessel wall. The latter is very low 
not exceeding 100 mm Hg (fig ure 1b) thereby minimising the trauma to the vessel wall and 
potential for plaque rupture during the deployment.
study design and patient population
SECRITT is a clinical prospective pilot, open, single centre ran domised study assessing the 
safety and feasibility of shielding the non-obstructive IVUS-derived TCFA, and the effects on 
the pre vention of plaque progression at six months follow-up. Patients over the age of 18 ad-
mitted with stable or unstable coronary syn dromes (including non-ST-elevation myocardial 
infarction) and an angiogram demonstrating the need for PCI in one or more lesion, and con-
comitant presence of angiographically and haemodynamically non-obstructive IVUS-derived 
TCFA were eligible for the study. After obtaining informed consent and successful treatment 
of the culprit lesion (figure 2) patients were randomised 1:1 to treatment with the shield 
figure 1:
A) Device design and structure highlighting the ultra-thin struts and tantalum markers to allow for positioning. B) Hysteresis curve between 
radial resistive force and chronic outward force (COF) exerted by the device on the vessel wall. In the case of the vShield, COF is around 100 
mmHg, minimising vessel trauma and allowing for gentle continued expansion over time (9% at six months).
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device or medical therapy. Exclusion criteria were as follows: acute myocardial infarction, 
prior coronary artery bypass graft (CABG), significant left main disease, cardiogenic shock, 
renal insufficiency (cr >1.5 mg/dL), resuscitation or intuba tion, cerebrovascular event within 
the last 30 days, major bleeding event within the last 30 days, severe hypertension refractory 
to medical therapy, history of significant trauma or surgery within the last six weeks, know 
nickel allergy, allergy to aspirin or clopidogrel that cannot be treated, pregnancy, coexisting 
condition with life expectancy <12 months and vessel diameter on angiography of <2.5 or 
>4.0 mm. All patients in the study were on aspirin therapy and received clopidogrel load-
ing dose (600 mg) or were on mainte nance clopidogrel dose. Anticoagulation during the 
procedure was achieved with heparin (with goal of ACT >300 msec). After the procedure 
all patients received aspirin and clopidogrel. All patients were treated with anti-cholesterol 
medications with the goal of low-density lipoprotein <70 mg/dL. The study protocol was 
approved by the institutional ethics committee and all patients provided signed informed 
consent.
Study lesion definition
Lesions qualified as study lesions if: 1) they were angiographically intermediate with 40-50% 
diameter stenosis, and 2) had an FFR of more than 0.75 (pathway B in the flow chart, figure 
2), and 3) ful filled the criteria for IVUS-derived TCFA. Cap thickness and pres ence of the lipid 
pool was also documented by OCT.
figure 2:
Flow chart.
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Quantitative angiography
The target coronary segment was filmed in two orthogonal planes that had been prescribed 
after viewing of the preceding angiogram. Quantitative coronary angiography (QCA) was 
performed follow ing administration of 100-200 micrograms of nitroglycerine to assess the 
proper length and diameter of the vessel. A final angiogram was made under the same rota-
tion and skew angles following intracoronary nitroglycerine administration. A QCA off-line 
using CMS-Medis quantitative angiography (Medis, Leiden, The Nether lands) was made to 
quantify the final result. The following meas ures were obtained for each lesion: minimal 
luminal diameter, reference vessel diameter and percent diameter stenosis. Late loss was 
figure 3:
Example of baseline imaging for one of the enrolled patients. A) In the upper left, palpogram showing stain value of 1.4% (ROC III-IV); B) In the 
upper right corresponding matched TCFA on IVUS VH analysis with plaque burden of 56% and necrotic core of 34% in three consecutive frames; 
C) In lower left corner, matched OCT frame showing cap thickness of 40 μm.
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calculated from the difference between minimal luminal diam eter immediately post shield-
ing and at six-month follow-up. Reste nosis was defined as the presence of in-lesion >50% 
diameter stenosis at follow-up.
fractional flow reserve assessment
Fractional flow reserve was measured with a sensor-tipped 0.014” angioplasty guidewire 
(WaveWire/WaveMap; Volcano Therapeu tics, Inc., Rancho Cordova, CA, USA; or PressureWire; 
Radi Medi cal Systems, Uppsala, Sweden). After crossing the target lesion with the wire, hy-
peraemia was induced with intravenous infusion of 140 μg/kg/min of adenosine (Adrecar; 
Sanofi, Munich, Germany) for a total of two minutes. The maximum pressure gradient used to 
calculate FFR was defined as the ratio of the mean post-stenotic pressure to the mean aortic 
pressure, measured by the guiding cath eter, during maximal hyperaemia. FFR of ≥0.75, was 
considered functionally not significant and constituted the enrolment criterion. Exact FFR 
measurement at baseline and at six-month follow-up was recorded.
Ivus-vh acquisition and analysis
Details regarding the validation of the technique, have previously been reported11, 12. Briefly, 
IVUS-VH uses spectral analysis of IVUS radiofrequency data to construct tissue maps that are 
correlated with a specific spectrum of the radiofrequency signal and assigned colour codes 
(fibrous [labelled green], fibrolipidic [labelled greenish-yel low], necrotic core [labelled red] 
and calcium [labelled white]).
IVUS-VH data was acquired using either the In-Vision Gold console (in the same pullback as 
palpography) or the S5 imaging system, and a 20 MHz Eagle Eye® Gold catheter (all: Volcano 
Therapeutics, Inc., Rancho Cordova, CA, USA). The IVUS-VH sampling rate during pullback is 
gated to peak R-wave and is there fore dependent on heart rate.  
IVUS B-mode images were reconstructed from the radio frequency (RF) data by customised 
software (IVUS Lab Version 4.4; Volcano Therapeutics INC., Rancho Cordova, CA, USA). Semi-
automated contour detection of both lumen and the media-adventitia interface was per-
formed and the RF data was normalised using a technique known as “blind deconvolution”, 
an iterative algorithm that deconvolves the catheter transfer function from the backscatter, 
thus accounting for catheter-to-catheter variability. Compositional data obtained for every 
slice was expressed as mean percent for each component.
Pullback of 40 mm was performed after administration of 100- 200 micrograms of intra-
coronary nitroglycerine and incorporated the segment at least 5 mm proximal and distal to 
the region of inter est. Pullback speed was 0.5 mm/sec.
Online analysis was performed to look for IVUS-defined thin-cap fibroatheroma (ID-TCFA) 
(enrolment criterion). The analysis was subsequently repeated off-line by two independent 
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observers blinded to patient clinical data and randomisation to verify the pres ence of ID-TCFA. 
After tracing the lumen and external elastic membrane diameters, plaque, lumen and total 
vessel area and vol umes were computed for the segment of interest. The three consec utive 
cross-sections with >40% plaque burden and >10% necrotic core in contact with the lumen 
were identified and their quantitative characteristics and measurements were recorded. In 
addition, mini mal luminal area (MLA) was measured.
Ivus-palpography acquisition and analysis
Intravascular ultrasound palpography is a technique that allows the assessment of local 
mechanical tissue properties. At a defined pressure difference, soft tissue (e.g., lipid-rich) 
components will deform more than hard tissue components (e.g., fibrous-calcified)13-15. In 
coronary arteries, the tissue of interest is the vessel wall, while the blood pressure with its 
physiologic changes during the heart cycle is used as the excita tion force. Radiofrequency 
data obtained at different pressure levels are compared to determine the local tissue defor-
mation.
Each palpogram represents the strain information for a certain cross-section over the 
full cardiac cycle. Palpograms will be acquired using a 20 MHz phased-array IVUS catheter 
(Eagle-Eye®; Volcano Therapeutics Inc. , Rancho Cordova, CA, USA). Cine runs, before and 
during contrast injection were performed to define the position of the IVUS catheter. Digital 
radiofrequency data was acquired using a custom-designed workstation.
During the recordings, data was continuously acquired at a pull back speed of 0.5 mm/
sec using an automated pullback device (Track Back II; Volcano Therapeutics Inc., Rancho 
Cordova, CA, USA) with simultaneous recording of the ECG and the aortic pressure. The data 
was stored on a DVD and sent to the imaging core lab for offline analysis (Cardialysis BV, 
Rotterdam, The Netherlands).
The local strain was then calculated from the gated radiofre quency traces using cross-
correlation analysis and displayed col our-coding, from blue (for 0% strain) via red through to 
yellow (for 2% strain). This colour-coded information was superimposed on the lumen vessel 
boundary of the cross-sectional IVUS image.
Using previously described methodology, plaque strain values were assigned a Rotterdam 
Classification (ROC) score ranging from one to four (ROC I: 0-0.5%; ROC II: 0.6-<0.9%; ROC III: 
0.9-1.2%; ROC IV: >1.2%). A cross-sectional area (CSA) was defined as a high strain when it had 
a high strain region (ROC III-IV) that spanned an arc of at least 12° at the surface of a plaque 
(identified on the IVUS recording) adjacent to low-strain regions (<0.5%). The highest value 
of strain in the cross-section is taken as the strain level of the CSA.
Highest strain value pre and post-shielding and was recorded and colocalisation with the 
IVUS-VH derived TCFA performed using timestamps.
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tD and ofDI-oct acquisition and analysis
The OCT M3 time domain optical coherence tomography (TD-OCT) and C7 optical frequency 
domain imaging optical coherence tomog raphy (OFDI-OCT) systems used in this study 
(LightLab Imaging Inc., Westford, MA, USA) have been described previously16-21. Briefly, 
the OCT catheter was advanced distal to the stented lesion over a conventional coronary 
guidewire in the case of the C7 system or, in the case of the M3 system, the OCT imaging 
wire (ImageWire™; Lightlab Imaging Inc., Westford, MA, USA) was directly advanced past 
the lesion. The OCT catheter was then withdrawn proximal to the stented segment and the 
lesion visualised using an automated pullback system at 20 mm/sec in the case of the C7 
system and 3.0 mm/sec in the case of the M3 system. During image acquisition, coronary 
blood flow was replaced by continuous flushing of contrast at 3.0-4.0 ml/sec using a power 
injector (Mark V ProVis; Medrad, Inc., Indianola, PA, USA) at 300 psi. Cross-sectional images 
were acquired at 100 frames/sec for the C7 and 20 frames/sec for the M3. During the baseline 
study documentary OCT was performed to meas ure and record the thickness of the fibrous 
cap overlying the lipid pool corresponding to the area of the ID-TCFA. A significant lipid pool 
was defined as a heterogeneous area of attenuated OCT signal, present in more than one 
quadrant of the vessel wall. The thinnest cap measurement was recorded. The assessment of 
the shield with OCT post implantation was used to assess procedure-related trauma to the 
vessel wall (plaque prolapse, presence of filling defects, proximal and distal edge dissection), 
and at six-months follow-up to assess shield strut apposition and tissue coverage and to 
measure the thick ness of neo-cap. The thickness of the cap was measured every 1 mm within 
the shielded segment (15 frames per shield) using 360 degree analysis off-line software. In 
addition, shield areas were measured immediately post-shielding and at six-months follow-
up to assess the degree of continued shield expansion with OCT.
A detailed per strut analysis was provided to illustrate the poten tial advantage of this 
device in treatment of these necrotic core rich non-obstructive lesions as compared to drug-
eluting balloon expandable stents.
Measurements were repeated off-line by two independent observers using Lightlabs 
imaging software.
follow-up and study endpoints
The primary endpoint of the study was the acute change in the lesion strain pattern im-
mediately after shielding and acute device and angiographic success. Secondary endpoints 
of the study included: 1) change in the fibrous cap thickness from baseline to six-months 
post-shielding, 2) change in the stent area, 3) percent diameter stenosis at baseline and at 
follow-up, late loss and binary restenosis rate, and 4) cumulative incidence of major adverse 
car diac events (death, MI and revascularisation) at six-month follow-up. Stent thrombosis oc-
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currence was defined and classified according to the Academic Research Consortium (ARC) 
criteria22.
sample size calculation and statistical analysis
The study population was statistically based on the change in study lesion strain patterns im-
mediately post-stenting, as noted in the ABSORB trial23. In this trial the mean of the maximal 
strain/cross-section/patient decreased from 0.44±0.25 to 0.00±0.01. Based on the assump-
tions for these, the sample size was calculated as detailed below.
Assumptions for the sample size calculation using a paired t-test:
 – mean difference between pre- and post-treatment equal to zero
 – alpha=0.05;
 – mean pre=0.4;
 – mean post=0.0;
 – SD of difference pre-post=0.3;
 – 90% power.
To assess the change in strain observed on palpography post-treatment, paired (pre-and 
post-) data of nine patients would have been needed. However, in order to account for the 
patients lost to follow-up, we aimed to enrol a total of 15 patients in each arm of the trial.
Discreet variables are presented as counts and percentages. Continuous variables are 
expressed as means + standard deviation.
results
patient enrollment
From June 2008 until February 2010 over 100 patients were approached for participation 
in the trial. Forty-eight signed informed consent, but only 23 patients met inclusion and 
enrolment criteria (including presence of ID-TCFA) and were enrolled in the trial. Thirteen 
patients were randomised to shield device and 10 randomised to medical therapy but with 
one patient crossing over to the shield arm. Baseline clinical characteristics of the patients 
enrolled are summarised in table 1. Notably 24% of the patients were diabetic and 65% had 
multivessel disease. Of the 13 shielded patients, 11 completed full angiographic and imag-
ing follow-up. Of the 10 control patients only five completed full angiographic and imaging 
follow-up.
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angiographic and ffr analysis
In 24% of the cases, proximal or mid left anterior descending (LAD) artery was the site of the 
TCFA , in 24% the left circumflex LCx coronary artery and in 52% cases the right coronary 
artery (RCA). In the shielded group, baseline percent diameter stenosis was 33.2±13.5% with 
minimum lumen diameter (MLD) of 2.01±0.39 mm (table 2). Baseline FFR was 0.93±0.06. 
Post-stent ing percent diameter stenosis decreased to 21.0±10.7 in the shielded patients and 
MLD increased to 2.43±0.44 mm. At six-month fol low-up in shielded patients, percent diam-
eter stenosis further decreased to 18.7±16.9% with MLD of 2.19±0.33 mm and FFR remained 
table 1. Baseline clinical characteristics for the overall population
Characteristic N=23
Age 67 (range 50-82)
Gender (male) 76%
Current smoking 18%
Hypertension 71%
Hypercholesterolemia 76%
Diabetes melitus 24%
Prior MI 41%
Prior PCI 58%
Angina type:
Stable 76%
Unstable 24%
Multivessel disease 65%
Non-culprit vessel (TCFA vessel)
LAD 24%
LCX 24%
RCA 52%
table 2: Serial angiographic and FFR assessment in shielded and control groups.
QCA
Baseline 6 months follow-up
Shielded group
Control group 
(n=5)
Shielded group 
(n=11)
Control group 
(n=5)Pre-stenting
(n=11)
Post-stenting
(n=11)
MLD (mm) 2.01+0.39 2.43+0.44 1.87+0.54 2.19+0.33 1.78+0.49
RVD (mm) 2.95+0.39 2.93+0.44 2.72+0.46 3.08+0.50
% diameter stenosis 33.2+13.5 21.0+10.7 35.4+16.3 18.7+16.9 39.0+19.3
Late loss (mm) 0.24+0.13 0.22+0.12
FFR 0.93+0.06 0.93+0.05 0.93+0.05 0.82+0.29
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the same (0.93±0.05). Average late loss was 0.24±0.13 mm. FFR in the control group at six 
months was 0.82±0.29 compared to 0.93±0.05 at baseline.
Ivus-vh analysis and palpography
At the site of the TCFA lesion baseline plaque burden was 60.6±8.8%, percent necrotic core 
in contact with the lumen was 34.7±6.3% averaged over three consecutive frames. Average 
MLA was 6.8±2.4 mm2 (table 3 and figure 3). At follow-up, the five control patients showed 
no increase in plaque burden or necrotic core observed over time and no MLA decrease.
Average strain before shield placement was 0.71%±0.53% (ROC score of II on average). This 
decreased acutely post-shield place ment to 0.1%±0.09% (ROC score of I).
oct analysis and data
As previously reported by our group24, deployment of the self-expanding shield resulted in 
minimal trauma to the vessel wall, particularly when compared to the balloon-expandable 
devices. There were no proximal or distal edge dissections and no filling defects. Length of 
intra-stent dissections was also minimal.
table 3: IVUS VH and palpography baseline and acute data summary
Parameter (n=23)
MLA mm2 6.8 + 2.4
% plaque burden 60.6 + 8.8
% necrotic core 34.7 + 6.3
% strain pre-shield 0.71+0.53
% strain post-shield 0.1+0.09
table 4: Optical coherence tomography at baseline, post-shield and at 6 month follow-up.
Shielded
(pre-shield/acute post-shield)
Shielded
6 months follow-up
Cap thickness / mean neointimal thickness (μm) 48 ± 12
(range 30-70)
201 ± 168
(range 50-608)
Presence of lipid pool 100%
Mean lumen area mm2 9.03 ± 2.29 8.36 ± 2.87
Mean stent area mm2 8.76 ± 2.16 9.45 ± 2.30
(9% increase)
Minimum lumen area mm2 7.23 ± 2.85 6.12 ± 2.75
Malapposed struts 185/1721 (10.7%) 159/2072 (7.6%)
Uncovered struts 167/2072 (8.1%)
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Average baseline fibrous cap thickness was 48±12 μm with a range of 30-70 μm. After 
shield placement at six-month follow-up neo-cap formation was observed with average cap 
thickness of 201±168 μm (range 50-608 μm) (table 4). The patient with 608 μm of neo-cap 
formation at baseline had adjacent calcifica tions that required high pressure (16 atms) post-
dilation of the shield with resultant barotrauma and more exuberant healing response.
In addition, mean stent area of 8.76±2.16 mm2 increased to 9.45±2.30 mm2, that is by 9% 
at six-month follow-up (table 4 and figure 4). The number of malapposed struts decreased 
from 10.7% to 7.6% and the number of uncovered struts at six months was 8.1%.
figure 4:
Example of per-strut OCT analysis and appearance of vShield at six-month follow-up with uniform strut coverage of around 200 μm and no 
malapposition.
115
Chapter 5 : Self-expandable stents for vulnerable plaque treatment
Detailed per strut analysis
A total of 11 stents were evaluated at baseline. In two patients there was a high degree of 
malaposition due to undersizing of the device. Mean incomplete stent apposition (ISA) area 
was 0.36±0.47 mm2. Mean prolapse area was 0.009±0.17 mm2. Of the 1,721 stent struts 
counted at baseline 1,521 were well apposed, 185 (10.7%) were malapposed and 15 were in 
front of side branches. There were no dissections seen. Mean thrombus area was 0.015 mm2.
At six-month follow-up 12 stents were evaluated with a total length of 142.95 mm. Mean 
lumen area was 8.36±2.87 mm2 (decreased by 7.4%). Mean stent area increased to 9.45±2.30 
mm2 (by 9%), implying continued stent expansion. Mean ISA area was 0.88±0.85 mm2. Of 
the total of 2,072 struts evaluated, 1,910 were well apposed, 159 were malapposed (7.6%; 
decrease from baseline), and three were in front of a side branch. Of all struts 8.1% were non-
covered. Of the well-apposed struts, 93.2% were covered, while of the malapposed struts 
78% were covered.
clinical events
There were no device-related MACE events (table 5). One of the control (non-shielded) patients 
returned within two weeks of the procedure with an unstable coronary syndrome and crossed 
figure 5:
MSCT image of vShield at six months. There is no beam-hardening artefact from nitinol struts (except for tantalum markers at the edges) 
allowing for good non-invasive evaluation of patency.
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over to the shield arm. There were no stent thrombosis events. Lastly, non-invasive assessment 
of shield patency with MSCT appears feasible owing to its thin nitinol struts (figure 5).
DIscussIon
In this first-in-man experience with shielding of vulnerable plaque (thin-cap fibroatheroma) 
using a self-expanding nitinol shield, we demonstrate the feasibility and preliminary efficacy 
of the approach. The device delivery was successful in all 13 patients who were ran domised 
to the shield and there were no MACE events related to the shield device treatment at six-
month follow-up. The treatment strategy employed in this protocol is based on the fact that 
most myo cardial infarctions (MI) result not from a critical blockage, but from lesions that are 
non-flow limiting25-30. In individuals who have under gone angiography in the months pre-
ceding myocardial infarction, the culprit lesions most often show <50% diameter stenosis27. 
Moreover, it has been shown on a previous angiogram that only approximately 15% of acute 
MI arise from lesions of <60% stenosis11. These lesions, however, have a substantial plaque 
volume/percent plaque burden. The coronary flow is not obstructed because of outward 
(positive) remodelling. Longer-term prognosis of a patient might depend on far more de-
tailed plaque assessment than angiography and on adequate treatment of plaques at risk of 
rupture.
The use of IVUS-VH to identify vulnerable plaques (ID-TFCA) is well documented and is 
comparative to what has been demon strated from documented plaque ruptures. ID-TCFA 
is currently defined as a lesion fulfilling the following criteria in at least three consecutive 
cross-sectional areas (CSA): 1) necrotic core ≥10% without evident overlying fibrous tissue, 
2) lumen obstruction ≥40%. In addition, the ID-TCFA must demonstrate positive remod elling 
by having a remodelling index (RI) >1.05. In a study popula tion of 21 patients Garcia-Garcia12 
found, in 13 patients, 42 ID-TCFA that fulfil the IVUS-VH criteria. This meant that on aver-
age there are approximately three ID-TCFA per patient. Documented plaque ruptures were 
reported by Rioufol31 in 2002 in 24 patients referred for PCI after a first acute coronary 
syndrome (ACS) with a troponin I elevation. He found that there were 50 plaque ruptures 
corresponding to 2.08 vulnerable plaques per patients presenting with an ACS, which is in 
table 5: Cummulative incidence of MACE rate at 6-month follow-up
Shield arm
(n=13)
Medical therapy arm
(n=10)
MACE 0 1
Death 0 0
MI 0 0
Clinically-driven revascularization 0 1 (cross-over to shield)
Revascularisation related to the target lesion/shielded vessel 0 0
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accordance with Garcia-Garcia’s IVUS-VH findings. Interestingly, plaque rupture on the culprit 
lesion was found only in nine patients (37%). In 19 patients (79%) at least one plaque rupture 
was found somewhere other than the cul prit lesion, in a different artery in 70% and in both 
other arteries in 12.5% of the patients. This reinforces the importance of identifying and treat-
ing vulnerable plaques and the fact that they can be remotely associated from the culprit 
lesion causing the presenting symptom. This also constitutes the rationale for the treatment 
of intermediate non-flow limiting lesions with signs of vulnerability. Accuracy of thin-cap 
atheroma detection can be further increased by combining IVUS-VH imaging with OCT 
imaging of the lesion, which due to its micron resolution can allow the measurement of the 
thickness of the fibrous cap. Sawada 32 has shown that out of 126 lesions examined with two 
modalities only 28 (22%) fulfill thin-cap fibroatheroma criteria by both IVUS-VH and OCT with 
thin cap defined as < 65 microns. For these reasons, we have chosen in this study to perform 
a very detailed multimodal ity examination of plaque before enrolling patients in the study. 
The examinations that each patient underwent were: 1) angiography, 2) FFR, 3) palpography 
(off-line), 4) IVUS-VH, and 5) OCT online at baseline. This was followed by post-shielding 
assessment with: 1) angiography, 2) palpography, and 3) OCT. At six-month follow-up the 
assessment included: 1) angiography, 2) FFR, 3) palpography/ IVUS, and 4) OCT. With such 
extensive examination and procedure times, which was challenging for patients, personnel 
and operators, enrolment in the study was rather slow (23 patients in under two years), and 
several patients (particularly in the control arm) were unwilling to participate in the follow-up 
catheterisation. The use of stringent criteria for enrolment was justified in this pilot study; the 
protocol may have been more successful had we used a simple combination of non-invasive 
coronary MSCT assessment (for posi tive remodelling, plaque burden, 3-D strain and flow) 
combined with intraprocedural OCT (to measure cap thickness and show presence of a lipid 
pool). In the future, angiography, FFR and IVUS/palpography assessment should be replaced 
by non-invasive methodologies such as MSCT or combined MSCT-FDG-PET examination33 
which after evaluation against invasive technologies could potentially provide equivalent 
information before the start of the invasive procedure34-36.
We have been able to demonstrate here that the self-expand ing device is ideally suited 
for treatment of thin-cap fibroathero mas. The self-expanding nature of the device causes 
minimal trauma to the vessel wall, minimising the risk of thin-cap rup ture and necrotic core 
embolisation. We had no periprocedural MI in this patient cohort. Furthermore, the device 
is well apposed and continues to expand gently by 9% over six months, minimis ing the risk 
of having malapposed and uncovered struts. While there is no drug coating and the device 
is bare metal, the combi nation of thin nitinol struts and lack of traumatic balloon expan sion 
result in minimal neointimal formation. Eight percent of the struts were still uncovered at 
six months with average neo-cap of 201 μm and late loss of 0.13 mm which is comparable 
to some of the state-of-the-art drug-eluting stents. There were no stent thrombosis events. 
The continued gentle expansion of the device is similar to that observed by Granada et al in 
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the first-in-man trial of the vShield device in moderate stable lesions, which was completed 
recently37 and also comparable to the results achieved with the Stentys stent (STENTYS Inc., 
Princeton, NJ, USA) in the Apposition study38.
The number of patients enrolled and lack of events made it impos sible to determine 
whether placement of the shield and plaque passi vation demonstrated by OCT offered an 
advantage over standard medical therapy with aspirin, clopidogrel and statins. The ability 
to prevent plaque growth and disease progression to a significant lesion was demonstrated 
recently in the VELETI trial of paclitaxel-eluting stent treatment versus medical therapy in 
graft disease10.
limitations
The present report is a pilot study and the number of patients is limited, and should therefore 
be considered exploratory and hypoth esis-generating, without formal statistical hypothesis.
The limited number of patients made any meaningful statistical analysis rather difficult and 
thus the data are presented for most part in a qualitative fashion.
Moreover, an important limitation was failure to complete the full projected study enrol-
ment and lack of angiographic/imaging follow-up in a large proportion of non-shielded con-
trol arm patients. In addition, since only 4.4% of the VH-derived TCFA lesions result in event 
rates at three years based on the finding of the PROSPECT study9 (in the absence of MLA<4 
mm2 or >70% plaque burden), despite our extensive use of imaging such as concomitant 
OCT we may have failed to identify truly high-risk plaques.
conclusIon
Passivation of the thin-cap fibroatheroma with a self-expanding nitinol vShield device ap-
pears to be safe and feasible. A larger cohort study with long-term follow-up will be needed 
to evaluate this device as a treatment for necrotic core rich lesions.
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abstract
aims: To compare the angiographic and clinical performance of a paclitaxel-eluting stent 
using reservoirs technology and a bioresorbable polymer, without surface coating (CoStar), 
vs. an equivalent bare metal stent (BMS) using identical metallic platform.
methods and results: 303 patients (335 lesions) with de novo coronary artery stenosis suit-
able for elective percutaneous treatment were randomized in an international multi-centre 
single-blind trial to receive the CoStar stent (n=152) or the equivalent BMS (n=151). At 8 
months, the primary endpoint of in-segment binary restenosis was significantly lower in the 
CoStar than in the BMS group (17.6 vs. 30.3%, p=0.029). In-stent late loss (0.41 vs. 0.81mm; 
p<0.0001) and all the other angiographic secondary endpoints also favoured CoStar. The 
composite of cardiac death, myocardial infarction related to the target vessel and target le-
sion revascularization was significantly lower at 8 months in the CoStar arm (19.7 vs. 29.1%; 
hazard ratio 0.54, 95% CI; 0.34 – 0.87; p=0.010), mainly due to lower incidence of target lesion 
revascularization (15.1 vs. 26.5%; hazard ratio 0.45, 95% CI: 0.27 – 0.76; p=0.002).
conclusions: As compared with a bare metal stent of identical design, the Paclitaxel elution 
from reservoirs results in significantly less binary restenosis, less late loss and lower revas-
cularization rates at 8 months. Therefore, based on these data, the CoStar Paclitaxel-eluting 
stent was found to be effective and safe.
key words: Angioplasty, transluminal percutaneous coronary; coronary stenosis; paclitaxel; 
stents; drug-eluting stents.
conDenseD abstract
303 patients with de novo coronary lesions were randomized to receive the paclitaxel-eluting 
CoStar stent with reservoirs technology (n=152) or an equivalent BMS using identical me-
tallic platform (n=151). At 8 months in-segment binary restenosis (primary endpoint) and 
in-stent late loss were significantly lower in the CoStar group (17.6 vs. 30.3%, p=0.029; 0.41 vs. 
0.81mm; p<0.0001, respectively). The composite of cardiac death, myocardial infarction and 
target lesion revascularization (TLR) was also significantly lower at 8 months in the CoStar 
arm (19.7 vs. 29.1%; hazard ratio 0.54, p=0.010), mainly due to lower incidence of TLR (15.1 vs. 
26.5%; hazard ratio 0.45, p=0.002).
127
Chapter 6 : Efficacy of drug elution from reservoirs
IntroDuctIon
Patients receiving bare metal stents (BMS) suffer from restenosis in 20.0 – 50.3% due to exces-
sive neointimal proliferation1. Due to their ability to inhibit cellular proliferation, drug-eluting 
stents (DES) have reduced the restenosis rates to 7.9 - 8.9 %2-5. However some reports have 
suggested an eventually higher incidence of late and very late stent thrombosis in DES6-10, 
with the common pathological finding of delayed neointimal healing and incomplete en-
dothelialization in fatal cases11-15. The mechanism for delayed neointimal healing and stent 
thrombosis seems to go beyond the antiproliferative potency of the drug and involve also 
other factors, like the thickness of the struts16, cracking of the polymer17, polymer-induced 
inflammatory reaction14,18-22 or inappropriate kinetics of drug release23,24. In some first gen-
eration DES a specific inflammatory reaction has been described, with presence of intense 
eosinophilic infiltrates in the vessel wall14 and in the thrombus harvested from patients 
suffering very late stent thrombosis19, that might be mediated by delayed type IVb hyper-
sensitivity, recruiting preferentially eosinophils. This hypersensitivity is likely triggered by the 
polymer rather than by other components of the device21, given the timing of onset (later 
than 90 days, when the drug is no longer detectable in the vessel wall) and the presence of 
polymer fragments surrounded by giant cells14,22. Also inadequate pharmacokinetics of the 
device are known to be potentially harmful: excessive drug release during the early phase of 
repair might cause not only delayed healing but also toxicity, leading to smooth muscle cells 
necrosis, positive remodelling and acquired malapposition23.
Intense research efforts are currently aimed to optimize DES design features, to improve its 
safety profile and to promote complete neointimal healing, in order to prevent stent throm-
bosis. Reservoir technology offers considerable advantages with respect to surface polymer 
coating: struts are honeycombed with laser-cut holes or wells that act as drug reservoirs. 
This design permits precise control of the spatial drug release (abluminal/ adluminal/ bidirec-
tional) and optimization of the temporal elution rate using inlaid stacked layers of drug and 
polymer25. The polymer layers can be bioresorbable and disappear after elution of the drug, 
thus circumventing the problem of delayed hypersensitivity and late inflammatory reactions 
associated to thrombotic phenomena. The lack of surface polymer coating avoids also the 
risk of cracking as previously described17, although stents with reservoirs require a specific 
design, with specifically engineered hinge points and bridges, to increase its flexibility and 
deliverability as well as preserve the structural and functional integrity of the reservoirs after 
the deployment stress25.
The CoStar stent (previously Conor MedSystems, Menlo Park, CA, USA, now Cordis Cor-
poration, Bridgewater, NJ) consists of a new cobalt-chromium platform (Unistar, Conor 
MedSystems, Menlo Park, CA, USA) with reservoirs containing a bioresorbable poly-(lactide-
co-glycolide) (PLGA) polymer and paclitaxel at a dose of 10μg/17mm of stent. The enhanced 
flexibility was achieved by a new stent design with bridge elements and ductile hinges 
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(figure 1). The elution of the drug is solely abluminal and prolonged to 30 days, coupled 
to the progressive degradation of the PLGA polymer by hydrolysis. This release formulation 
is the result of an evidence-based clinical selection process among other formulations, 
being the one with lowest incidence of major adverse cardiovascular events (MACE)26 and 
lowest angiographic late loss27. The thickness of the struts is 90μm. The CoStar stent failed 
to prove non-inferiority vs. a first-generation surface-coating paclitaxel-eluting stent (Taxus 
Express, Boston Scientific, Maple Grove, MN, USA) in the COSTAR-II trial28. Furthermore, the 
performance of the CoStar stent in this study was assumed not to be significantly different 
from the “imputed” i.e. theoretically constructed, virtual BMS27. These results questioned the 
efficacy of reservoirs DES as drug-delivery technology. Purpose of this study was to compare 
the performance of the CoStar reservoirs DES vs. a BMS of identical design but with empty 
reservoirs.
methoDs
The EUROSTAR-II trial was an international multi-centre , randomized, single-blind trial evalu-
ating the efficacy and safety of the CoStar paclitaxel-eluting stent with reservoir technology 
vs. a control of the identical BMS platform without drug or polymer (Unistar, Conor Med-
Systems, Menlo Park, CA, USA) for elective treatment of de novo lesions in native coronary 
arteries.
figure 1: Design of the CoStar DES.
The new cobalt-chromium platform has reservoirs containing a bioresorbable poly-(lactide-co-glycolide) (PLGA) polymer and paclitaxel at a 
dose of 10μg/17mm of stent. Its enhanced flexibility was achieved by a new stent design with bridge elements and ductile hinges.
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study endpoints
Primary endpoint for the study was in-segment binary restenosis rate at 8 months by quanti-
tative coronary angiography (QCA). Angiographic secondary endpoints at 8 months were: 1) 
In-stent and In-segment late lumen loss, 2) In-stent and In-segment minimal lumen diameter 
(MLD). Clinical secondary endpoints were 1) MACE at 30 days and 8 months, defined as an 
adjudicated composite of death that cannot be clearly attributed to a non-cardiac cause or 
non-intervention vessel, new myocardial infarction (MI, Q- or non-Q-Wave) that cannot be 
clearly attributed to a non-intervention vessel, according to World Health Organization crite-
ria29 and target vessel revascularization (TVR); 2) clinically-driven TVR and 3) clinically-driven 
TLR. Combined secondary endpoints were: 1) Device success, defined as attainment of <50% 
in-stent residual stenosis by QCA as final result of the intervention, in absence of device mal-
function, and 2) Procedural success, defined as attainment of <50% in-stent residual stenosis 
by QCA as final result of the intervention, in absence of in-hospital MACE.
sample size calculation
This trial was designed as a superiority one-sided trial of the DES vs. the control arm using 
the BMS of identical design. Based on prior studies, the estimated incidence of the primary 
endpoint was estimated in 5% for the CoStar DES intervention arm27 and in 15% for the 
UniStar BMS active control arm26. On these assumptions and for a one-sided α error of 0.05, 
a minimum sample size of 131 patients per treatment arm was calculated to yield a greater 
than 80% power of finding a significant difference, using the normal method with Fleiss’ cor-
rection. Accounting for up to 10% patients lost to follow-up, the final sample size calculation 
resulted in 146 patients per group.
study population
Patients between 18-80 years of age, with stable or unstable angina pectoris or with a posi-
tive functional test for ischemia and up to two discrete de novo lesions in native coronary 
arteries, amenable to treatment with percutaneous coronary intervention (PCI) using the 
study stents were enrolled into the trial. Eligible lesions had to be between 50% and 99% 
diameter stenosis, reference vessel diameter (RVD) 2.5-3.5mm and length ≤25mm by visual 
estimation that could be treated with a single study stent. TIMI flow pre-intervention had to 
be ≥ I. Study lesions should not have undergone any previous interventional procedure of 
any kind, and no additional treatment should be planned for the patient in the following 30 
days. Exclusion criteria were: cerebrovascular event or transient ischemic attack within the 
prior 6 months, percutaneous or surgical coronary revascularization within the prior 30 days, 
acute myocardial infarction within the prior 72 hours, cardiogenic shock, unstable ventricular 
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arrhythmias, left ventricular ejection fraction <30%, serum creatinine >2.5 mg/dL, known 
hypersensitivity to any of the components of the study devices or to the procedure medica-
tion, episode of gastrointestinal bleeding in the preceding 3 months, contraindication for 
dual antiplatelet therapy, any other clinical condition conferring the patient a life expectancy 
<2 years, presence of >2 lesions (or >1 lesion in the same coronary artery) requiring treat-
ment, target lesion involving a bifurcation with a side branch >2mm in diameter, detection of 
intraluminal thrombus visible in the angiography and planned used of adjunctive coronary 
devices (e.g. cutting-balloon or atherectomy).
All patients in the trial provided written informed consent before enrolment, and were 
randomly allocated on a 1:1 basis to receive the CoStar paclitaxel-eluting stent with reservoir 
technology or the UniStar BMS with identical, but empty reservoirs. Allocation to treatment 
used a random computer-generated sequence of numbers, and sequentially numbered 
sealed envelopes available at each study site. The patient, but not the operator, was kept 
blinded to the allocation. The study was conducted in accordance with Good Clinical Prac-
tice, Declaration of Helsinki and local regulations, and protocol was approved by the Ethical 
Committees of the centres involved in the trial.
Description of the intervention and follow-up
All patients received 100 mg of aspirin at least one hour before the intervention and a mini-
mum loading dose of 300mg of clopidogrel prior or immediately following the procedure. 
Use of glycoprotein IIb/IIIa inhibitors was left at the operator’s discretion. Intravenous heparin 
was administered during the procedure to keep an activated clotting time ≥250 seconds, or 
200-250 if a glycoprotein IIb/IIIa receptor blocker was administered.
The interventions were performed with a ≥6F guiding catheter. Direct stenting or predilata-
tion with a balloon shorter and at least 0.5mm smaller in diameter than the study stent were 
both allowed. The study stents (as described above) were available at 2.5, 3.0 and 3.5mm 
diameter, and at 10, 16, 22, 28 and 33mm length. The implanted stent had to cover the whole 
target lesion length and the entire ballooned segment in case of predilatation, extending at 
least 2mm beyond on each side. Use of additional stents had to be avoided, except in the 
cases of insufficient lesion coverage or bailout procedure. If the patient required additional 
bailout stents, these had to be identical to
the initial study stents implanted. The stent was deployed at an inflation pressure between 
nominal and rated burst pressure to achieve full expansion, complete apposition and a final 
diameter stenosis <10%. If necessary the stent could be postdilated with a balloon shorter 
than the stent length at the operator’s discretion. IVUS guidance was allowed but not manda-
tory. Systematic monitoring of ECG and cardiac serum markers was performed in all patients 
after the procedure and before discharge.
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After the intervention, patients were kept on dual antiplatelet therapy with 100mg of 
aspirin and 75mg of clopidogrel daily for a minimum of 6 months, followed by daily aspirin 
indefinitely. Clinical follow-up visits were scheduled 30 days and 8 months post-procedure, 
and angiographic follow-up at 8 months.
Quantitative coronary angiography (Qca) analysis
Coronary angiography was performed according to standard procedures30. QCA analysis 
was performed with the CAAS II system31 (Pie Medical BV, Maastricht, The Netherlands) in 
a core-lab setting (Bio-Imaging Technologies, Leiden, NL) by analysts blinded to patients’ 
characteristics and to the allocation to treatment. The analysis results were reported for the 
stented segment (in-stent) and for the segment comprising 5mm proximal and distal to the 
stent edges (in-segment). MLD was automatically detected by the software. RVD at the point 
of MLD was calculated by the software by interpolation. % diameter stenosis was calculated 
as: (1-[MLD/RVD])*100. Binary restenosis was defined as % diameter stenosis ≥50%. In-Stent 
and In-Segment late lumen loss was defined as the difference between MLD at 8 months 
follow-up and the respective post-procedure MLD.
statistical analysis
Results are reported as mean±standard deviation for continuous variables, and as count 
(percent) for nominal variables. Continuous variables were compared with Fisher’s t-test 
for independent samples. Nominal variables were compared with Pearson’s chi-square, or 
Fisher’s exact test if the expected frequency was <5 in any cell.
Clinical and safety endpoints followed a hierarchical events model. Incidences of the dif-
ferent endpoints at 30 days were calculated and compared as risk ratios. Results at 8 months 
were analyzed as events-free survival using Cox proportional hazards regression and log rank 
tests.
All statistical analyses were performed according to the intention-to-treat principle, using 
the PASW 17.0.2 statistical package (SPSS Inc., Chicago, IL, USA).
results
303 patients (335 lesions) were enrolled in the EUROSTAR-II trial at 18 different European 
sites: 152 in the CoStar DES group, and 151 in the Unistar BMS group (figure 2). Tables 1 and 2 
show the baseline characteristics of patients and lesions, respectively, with no significant dif-
ference in any of the variables tested, except for a larger proportion of prior coronary artery 
bypass graft in the UniStar group (p=0.010). QCA analysis did not show significant differences 
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in the pre-procedural analysis of the lesions (table 3). Both groups were also comparable with 
respect to QCA results post-stenting, except for a slightly higher residual diameter stenosis in 
the CoStar than in the UniStar subgroup (21.2 vs. 18.62%, respectively; p=0.030).
42 patients (13.9%) were lost for angiographic follow-up: 21 (13.8%) and 21 (13.9%) in the 
CoStar and UniStar groups, respectively. Clinical follow-up was completed in all patients at 
8 months. Median FU time was 243 days, inter-quartile range (217 – 250 days). The primary 
endpoint (in-segment % binary restenosis) was significantly reduced in the Costar arm: 17.6 
vs. 30.3%, p=0.029; (table 3, figure 3). Significant differences in favour of CoStar were also 
found in all the angiographic secondary endpoints (table 3, figures 3-5).
Regarding the clinical and safety endpoints, no significant difference was found between 
groups at 30 days (table 4). However, the incidence of MACE was significantly reduced at 8 
months in the CoStar arm (19.7 vs. 29.1%; hazard ratio 0.54, 95% CI; 0.34 – 0.87; p=0.010). 
Similar death, and MI rates were found at 8 months in both treatment groups, but the inci-
dence of TLR was significantly lower in CoStar (15.1 vs. 26.5%; hazard ratio 0.45, 95% CI: 0.27 
– 0.76; p=0.002). A single case of stent thrombosis was registered in the UniStar group seven 
days after the intervention (subacute), and classified as definite according to ARC criteria32.
DIscussIon
The results of this EUROSTAR-II trial prove the efficacy of reservoirs technology for inhibi-
tion of neointimal hyperplasia and clinically relevant prevention of restenosis, compared 
303 patients (335 lesions) randomized
CoStar DES
152 patients (172 lesions)
UniStar BMS
151 patients (163 lesions)
131 patients (148 lesions) 130 patients (142 lesions)
21 pt (24 lesions) lost at FU
145 lesions QCA pre 128 lesions
167 lesions QCA post     153 lesions
21 pt (21 lesions) lost at FU
132 lesions QCA FU 103 lesions
8 months FU
figure 2: Flow chart of the study.
FU: Follow-up; QCA: Quantitative coronary angiography suitable for analysis.
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to an identical BMS platform. The primary endpoint (in-segment % binary restenosis) was 
significantly lower in the group treated with a CoStar DES than in the group treated with the 
UniStar BMS. Other secondary endpoints addressing the inhibition of neointimal hyperplasia 
and prevention of restenosis, like late loss, or incidence of TVR and TLR, were also significantly 
in favour of the reservoirs DES. The reservoirs DES also proved to be superior in secondary 
clinical endpoints, like the incidence of the composite of death, MI and TLR, although this 
clinical superiority was mainly due to the reduction of TLR, showing similar rates of death 
and MI. This finding is consistent with the angiographic findings, and can be interpreted as 
efficient and clinically relevant prevention of restenosis, without clinical safety concerns.
The results of the COSTAR-II study had questioned the efficacy of reservoirs DES28: the 
reservoir paclitaxel-eluting CoStar stent failed to prove non-inferiority vs. a first-generation 
surface-coating paclitaxel-eluting stent (Taxus Express, Boston Scientific, Maple Grove, MN, 
table 1: Baseline characteristics of the patients.
costar Des
(n=152)
unistar bms (n=151) p-value
Male 113 (74.3%) 104 (68.9%) 0.291
Age (years) 64.9 ± 9.2 66.2 ± 9.4 0.228
Weight (kg) 82.8 ± 13.3 81.5 ± 12.5 0.417
Height (cm) 171.1 ± 8.0 171.1 ± 8.9 0.985
BMI (kg/m2) 28.2 ± 4.0 27.8 ± 3.6 0.361
risk factors
Hypertension 102 (67.1%) 113 (74.8%) 0.138
Hypercholesterolemia 92 (60.5%) 94 (62.3%) 0.758
Diabetes mellitus 40 (26.3%) 34 (22.5%) 0.442
Insulin therapy 15 (9.9%) 14 (9.3%) 0.860
Smoking 71 (46.7%) 64 (42.4%) 0.449
Current smoker 30 (19.7%) 28 (18.5%) 0.792
Peripheral vascular disease 12 (7.9%) 4 (9.3%) 0.669
Stroke / TIA 7 (4.6%) 4 (2.6%) 0.363
Renal insufficiency 13 (8.6%) 10 (6.6%) 0.526
CHF 6 (3.9%) 5 (3.3%) 0.767
Chronic respiratory disease 7 (4.6%) 8 (5.3%) 0.781
Prior MI 41 (27.0%) 41 (27.2%) 0.972
Prior PCI 56 (36.8%) 47 (31.1%) 0.294
Pior CABG 3 (2.0%) 13 (8.6%) 0.010
LVEF (%) 62.2 ± 13.0 61.1 ± 12.9 0.464
clinical indication 0.390
Stable angina 101 (66.4%) 101 (66.9%) 0.935
Unstable angina 29 (19.1%) 35 (23.2%) 0.382
Silent ischemia 22 (14.5%) 15 (9.9%) 0.228
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table 2: Baseline characteristics of the lesions and procedural results.
costar Des
(n=172)
unistar bms (n=163) p-value
Target coronary vessel
LM 1 (0.6) 1 (0.6) 1.000
LAD 67 (39.0) 66 (40.5) 0.774
LCX 41 (23.8) 44 (27.0) 0.507
RCA 62 (36.0) 51 (31.3) 0.357
Lesion length 0.855
Discrete (<10mm) 82 (48.2) 86 (53.1)
Tubular (≥10; ≤20mm) 80 (47.1) 70 (43.2)
Diffuse (>20mm) 8 (4.7) 6 (3.7)
Ostial lesion 9 (5.2) 6 (3.7) 0.500
Bifurcation requiring double wiring 8 (4.7) 7 (4.3) 0.875
Eccentric 111 (66.5) 107 (66.0) 0.936
Irregular contour 25 (15.0) 29 (17.9) 0.473
Angulation 0.561
Mild 151 (87.8) 144 (88.3)
Moderate 21 (12.2) 18 (11.0)
Severe 0 (0.0) 1 (0.6)
Moderate/severe tortuousity 21 (12.2) 20 (12.3) 0.986
Moderate/severe calcification 5 (2.9) 4 (2.5) 1.000
TIMI flow pre-procedure 0.287
0 0 (0.0) 0 (0.0)
I 4 (2.4) 1 (0.6)
II 11 (6.5) 15 (9.3)
III 154 (91.1) 145 (90.1)
procedural results
Direct stenting 111 (63.8%) 99 (60.0%) 0.472
Need for bailout 2nd stent 15 (8.6%) 14 (8.5%) 0.964
Reason for bailout 2nd stent
Residual stenosis >50% 1 (6.7%) 1 (7.1%) 1.000
Coronary dissection 5 (33.3%) 12 (85.7%) 0.008
Lesion incompletely covered 9 (60.0%) 1 (7.1%) 0.005
Post-dilatation 18 (10.3%) 19 (11.5%) 0.730
TIMI flow post-procedure III 170 (100.0) 162 (100.0) NA
Residual dissection 2 (1.2) 1 (0.6) 1.000
Device success 170 (98.8) 162 (99.4) 1.000
Results expressed as n(%).
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table 3: QCA analysis per lesion.
QCA results
costar Des
(n=167)
unistar bms (n=153) p-value
Mean SD Mean SD
lesion pre-stenting n=145 n=128
Length (mm) 15.12 7.58 15.16 7.69 0.971
RVD (mm) 2.74 0.51 2.73 0.48 0.860
MLD (mm) 1.12 0.37 1.05 0.30 0.129
% diameter stenosis 59.41 10.64 60.93 10.45 0.236
results post-stenting
In-stent n=167 n=153
Stent length (mm) 16.98 6.74 17.01 8.29 0.975
RVD (mm) 2.88 0.49 2.84 0.43 0.471
MLD 2.55 0.46 2.55 0.38 0.977
% diameter stenosis 11.21 8.32 10.30 8.24 0.322
In-segment n=160 n=143
Segment length (mm) 25.51 6.98 25.26 8.11 0.776
RVD (mm) 2.83 0.50 2.80 0.45 0.554
MLD 2.25 0.55 2.27 0.44 0.636
% diameter stenosis 21.15 10.53 18.62 9.65 0.030
results at 8 months fu
In-stent n=132 n=103
Stent length (mm) 17.08 7.07 16.57 8.69 0.639
RVD (mm) 2.82 0.52 2.80 0.46 0.735
MLD 2.16 0.65 1.77 0.57 <0.0001
% diameter stenosis 23.79 16.33 36.95 16.93 <0.0001
Late loss 0.41 0.48 0.81 0.49 <0.0001
Binary restenosis* 12 (9.1%) 29 (28.2%) <0.0001
In-segment n=125 n=89
Segment length (mm) 25.63 7.36 24.85 8.60 0.479
RVD (mm) 2.81 0.50 2.79 0.45 0.720
MLD 1.99 0.66 1.69 0.52 <0.0001
% diameter stenosis 30.18 17.39 39.56 15.04 <0.0001
Late loss 0.29 0.50 0.64 0.49 <0.0001
Binary restenosis* 22 (17.6%) 27 (30.3%) 0.029
*Results expressed as n(%)
136
USA). Furthermore, in the COSTAR-II study, the performance of the CoStar reservoirs DES was 
assumed not to be significantly different from the “imputed” i.e. theoretically constructed, 
virtual BMS27. The hereby reported EUROSTAR-II trial was run simultaneously to the COSTAR-II 
trial. In contrast to COSTAR-II, EUROSTAR-II is the only randomized trial directly comparing 
the performance of the same reservoirs DES vs. an equivalent BMS platform of identical de-
sign. The EUROSTAR-II results definitely answer the question about the efficacy of reservoirs 
DES vs. BMS, at a higher level of evidence than indirect hypothetical placebo imputations of 
COSTAR-II. Our results are also more consistent with preceding evidence about the CoStar 
stent25-27 and other reservoirs DES33. The hereby reported angiographic results for the CoStar 
DES (in-stent binary restenosis 9.1%, in-stent late loss 0.41mm) are in between the ones 
obtained in the CoStar-II trial (17.9%, 0.64mm, respectively)28 and the values from preced-
ing studies with the same device (0-5.7%, 0.28-0.38mm)26,27; being similar to Taxus Express 
In-stent In-segment
p<0,0001 p=0,029
figure 3: In-stent and in-segment binary restenosis (primary endpoint) of the CoStar DES and the UniStar BMS at 8 months follow-up.
p<0,0001 p<0,0001
figure 4: In-stent and in-segment absolute late lumen loss of the CoStar DES and the UniStar BMS at 8 months follow-up.
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table 4: Clinical follow-up results at 30 days and 8 months.
30 days FU costar Des
(n=152)
unistar bms 
(n=151)
risk ratio p-value
Estimate 95% CI
Low Up
Death 0 (0.0) 0 (0.0) NA NA NA NA
Cardiac 0 (0.0) 0 (0.0) NA NA NA NA
Non cardiac 0 (0.0) 0 (0.0) NA NA NA NA
MI 1 (0.7) 2 (1.3) 0.50 0.05 5.42 0.995
Q-wave 0 (0.0) 1 (0.7) NA NA NA 0.997
TVR 0 (0.0) 1 (0.7) NA NA NA 0.997
TLR 0 (0.0) 1 (0.7) NA NA NA 0.997
Stent thrombosis 0 (0.0) 1 (0.7) NA NA NA 0.997
MACE (Cardiac death, MI, TLR) 1 (0.7) 3 (2.0) 0.33 0.03 3.15 0.611
Procedural success 148 (99.3) 140 (98.6) 1.01 0.98 1.03 0.967
8 months FU hazard ratio p-value
Estimate 95% CI
Low Up
Death 0 (0.0) 2 (1.3) 0.01 0.00 >1000 0.111
Cardiac 0 (0.0) 1 (0.7) 0.01 0.00 >1000 0.301
Non cardiac 0 (0.0) 1 (0.7) 0.01 0.00 >1000 0.223
MI 5 (3.3) 3 (2.0) 1.53 0.37 6.41 0.558
Q-wave 1 (0.7) 1 (0.7) 0.96 0.06 15.37 0.978
TVR 27 (17.8) 42 (27.8) 0.49 0.30 0.80 0.003
TLR 23 (15.1) 40 (26.5) 0.45 0.27 0.76 0.002
Stent thrombosis 0 (0.0) 1 (0.7) 0.02 0.00 >1000 0.312
MACE (Cardiac death, MI, TLR) 30 (19.7) 44 (29.1) 0.54 0.34 0.87 0.010
figure 5: In-stent and in-segment late lumen loss cumulative curves of the CoStar DES and the UniStar BMS at 8 months follow-up.
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figure 6: Event-free survival plots for the composite endpoint of major adverse cardiovascular events (MACE) at 8 months, comprising cardiac 
death (only 1 event, not represented in the charts), myocardial infarction (MI) and clinically-driven target lesion revascularization (TLR).
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in its pivotal trial (5.5%, 0.39mm)5. The angiographic results for the UniStar BMS are also 
comparable to those reported for the BMS in TAXUS IV5. Putting into perspective the results 
of EUROSTAR-II with the preceding results, it seems that the first studies about the reservoirs 
CoStar DES overestimated its efficacy26,27, but the present study proves that the reservoirs 
paclitaxel-eluting CoStar DES prevents restenosis compared to an equivalent BMS.
The incidence of MACE in this trial is however much higher than in any preceding study5,26-28, 
so for the CoStar DES group as for the BMS control group. This excess of MACE is exclusively due 
to a much higher incidence of revascularization: TVR for the CoStar DES was 17.8%, whereas 
it was 8.1% in the COSTAR-II28; 2.8% in EUROSTAR-I27 and 2.6% in PISCES26. Revascularization 
in the BMS group was also higher than in prior studies: TVR for the UniStar BMS was 27.8%, 
whilst it was 12.0% in the BMS arm of the TAXUS IV trial5. The reason explaining this excess 
of revascularization and consequently of MACE can be the coincidence in time of the clinical 
and angiographic follow-up at 8 months, resulting in some “oculostenotic” revascularizations 
performed during routine angiographic follow-up and accounted as clinically-driven. In fact 
the curves in figure 6 show a steep increase in both TLR and composite MACE around 244 
days (8 months). In contrast, in COSTAR-II the primary clinical endpoint could not have been 
affected by the “oculostenotic” revascularization because it was defined at 8months with 
angiographic follow-up at 9 months. However the coincidence in time of the angiographic 
and clinical follow-up explains only partially these results: as compared with the TAXUS IV 
trial, binary restenosis was twice bigger in the CoStar than in the paclitaxel-surface coated 
Taxus Express stent, even though their late loss was similar and the restenosis rate in the BMS 
control arms was comparable5. Thus, the CoStar stent might be less efficient than Taxus for 
inhibition of neointimal hyperplasia, as suggested by COSTAR-II28. An optimized design of the 
honeycombed stent platform, and the different anti-proliferative drugs, with different dos-
age and kinetics of release, could have contributed to improve the clinical and angiographic 
outcomes of DES reservoir technology, as recently reported33.
limitations
This trial was performed on a selected population, with respect to clinical and angiographic 
features. This must be taken into account in the interpretation and generalization of the 
results.
Although the randomization process worked well in general, it resulted in the imbalanced 
distribution of the variable “prior coronary artery bypass graft surgery” between treatment 
groups. This imbalance might have biased the results at some extent, but the magnitude 
of this bias was deemed minor and therefore an eventual modification of the pre-specified 
statistical analysis was not considered to be justified.
Loss at angiographic follow-up was approx. 14%, therefore it remained in the range consid-
ered acceptable for the validity of studies with a primary angiographic endpoint. The attrition 
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at follow-up did not seem to affect selectively to any of the treatment groups. Nonetheless, 
some angiographic studies were discarded for QCA analysis due to insufficient quality. This 
might have introduced some selection bias in the results, although it affected both groups 
alike. In spite of this limitation, the QCA results are consistent with the clinical efficacy vari-
ables, less affected by loss or selection.
Although the absence of thrombotic events in the CoStar DES group is compatible with 
the hypothesis that a bioresorbable polymer might avoid delayed hypersensitivity reactions 
triggering very late thrombosis, this study, like all other DES randomized trials published so 
far, is underpowered for testing stent thrombosis and no valid conclusion can be stated in 
this regard.
conclusIon
As compared with an equivalent bare metal stent, paclitaxel elution from reservoirs resulted 
in significantly less binary restenosis, less late loss and lower revascularization rates at 8 
months.. No safety concerns were observed.
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Hydrophilic vs. hydrophobic polymers
Tissue coverage of a hydrophilic polymer-coated 
zotarolimus-eluting stent vs. a fluoropolymer-
coated everolimus-eluting stent at 13 months 
follow-up: an optical coherence tomography 
substudy from the RESOLUTE All Comers trial.
Gutiérrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, 
Kelbæk H, Saunamäki K, Escaned J, Gonzalo N, di Mario C, Borgia F, 
Nüesch E, García-García HM, Silber S, Windecker S, Serruys PW.
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structureD abstract
aims: To compare the tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting 
stent (ZES) vs. a fluoropolymer-coated everolimus-eluting stent (EES) at 13 months, using 
optical coherence tomography (OCT) in an “all-comers” population of patients, in order to 
clarify the mechanism of eventual differences in the biocompatibility and thrombogenicity 
of the devices.
methods and results: Patients randomized to angiographic follow-up in the RESOLUTE 
All Comers trial (NCT00617084) at pre-specified OCT sites underwent OCT follow-up at 13 
months. Tissue coverage and apposition were assessed strut by strut, and the results in both 
treatment groups were compared using multilevel logistic or linear regression, as appropri-
ate, with clustering at three different levels: patient, lesion and stent. 58 patients (30 ZES, 28 
EES), 72 lesions, 107 stents and 23197 struts were analyzed. 887 and 654 uncovered struts 
(7.4% and 5.8%, p=0.378); 216 and 161 malapposed struts (1.8% and 1.4%, p=0.569) were 
found in the ZES and EES groups, respectively. Mean thickness of coverage was 116±99μm in 
ZES and 142±113μm in EES (p=0.466). No differences in percent neointimal volume obstruc-
tion (12.5±7.9 vs. 15.0±10.7%) or other areas-volumetric parameters were found between 
ZES and EES, respectively.
conclusions: No significant differences in tissue coverage, malapposition or lumen/stent 
areas and volumes were detected by OCT between the hydrophilic-polymer coated ZES and 
the fluoropolymer-coated EES at 13 months follow-up.
key words: Tomography, optical coherence; polymers; poly(vinylidene fluoride-co-hexaflu-
oro propylene); zotarolimus; everolimus; drug-eluting stents; coronary vessels; Angioplasty, 
transluminal, percutaneous coronary.
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abbrevIatIons
bms: bare-metal stent
Des: drug-eluting stent.
ees: Everolimus-eluting stent
Isa: incomplete stent apposition.
Ivus: intravascular ultrasound.
mla: minimal lumen area.
nasb: non-apposed side branch.
nIh: neointimal hyperplasia.
oct: optical coherence tomography.
pcI: percutaneous coronary intervention.
Qca: quantitative coronary angiography
Zes: Zotarolimus-eluting stent
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IntroDuctIon
The neointimal healing response after stenting strongly determines the long-term outcome. 
In the era of bare-metal stents (BMS) the concern was focused on an exaggerated neointimal 
proliferation, often leading to restenosis, that accounted for 20.0 – 50.3% of the cases1. Drug-
eluting stents (DES) have reduced the restenosis rates to 7.9 - 8.9 %1, due to their ability to 
inhibit cellular proliferation. However, since some reports suggested an eventually higher 
incidence of late and very late stent thrombosis in DES2-5, the concern shifted to the oppo-
site pole: avoiding an incomplete neointimal coverage of the metallic scaffold that might 
eventually pose a risk for stent thrombosis6-10. Intense research is currently aimed to promote 
optimal neointimal healing11.
The neointimal healing response can be quantified in vivo by invasive imaging techniques. 
Intravascular ultrasound (IVUS) can quantify neointimal hyperplasia and discern whether it is 
exaggerated, but it cannot assess the completeness of healing, because the thin neointimal 
layer covering the DES struts is often below IVUS axial resolution (100 μm). Optical coherence 
tomography (OCT) provides an axial resolution of 10-15 μm, thus enabling accurate evalua-
tion of tissue coverage after stenting. OCT coverage correlates well with histological neointi-
mal healing and endothelialization after stenting in animal models12-15, thus constituting an 
in-vivo surrogate to estimate the completeness of neointimal healing14,15. OCT has become an 
exploratory tool for the evaluation of healing in studies comparing different types of DES16-18.
The polymers releasing the drug play a role in the modulation of the neointimal response 
after stenting. In first-generation DES some polymers were believed to induce allergic 
reactions and inflammation, resulting in incomplete neointimal healing and ultimately 
stent thrombosis10,19. The second generation of polymer coatings is designed to enhance 
biocompatibility and minimize the inflammatory reaction through different approaches16,20. 
The BioLinx polymer (Medtronic Inc., Santa Rosa, California, USA) comprises 3 different 
polymers: 1) the hydrophobic C10 acts as drug reservoir for a slow and sustained release, 2) 
the hydrophilic polyvinyl-pyrrolidinone improves biocompatibility, and 3) C19 contains both 
hydrophobic and hydrophilic polyvinyl pirrolidinone groups playing a role in the control 
of drug release and in the biocompatibility, respectively. The blend acts as an amphiphilic 
molecule, with topographic orientation of its hydrophilic components towards the surface 
in contact with the cells21,22, thus improving the biocompatibility, since hydrophilic polymers 
do not induce activated monocyte adhesion23, which is associated with local inflammation 
and vascular cells proliferation24. The BioLinx polymer also enables a finer and more sustained 
drug elution. In the porcine model 85% of the drug content is eluted into tissue during the 
first 60 days, and the remainder is completely eluted by 180 days25. Another contemporary 
biocompatible polymer is the fluoropolymer, poly(vinylidene fluoride-co-hexafluoropropyl-
ene). The fluoropolymer surface is hydrophobic, but elicits a biological response known as 
“fluoropassivation” which consists of minimizing the fibrin deposition and thrombogenicity, 
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reducing the inflammatory reaction and enhancing a faster neointimal healing26,27. Prefer-
ential affinity of fluorinated surfaces for albumin, with respect to fibrin, and the inhibitory 
effect of fluorination on platelets adhesion/activation or leucocytes recruitment have been 
postulated as mechanisms to explain this phenomenon.
The BioLinx polymer is a component of the Resolute stent (Medtronic, Santa Rosa, California, 
USA), together with the Driver BMS (Medtronic) and the antiproliferative agent zotarolimus, 
at a dose of 160μg/cm2 21. The stent has proven excellent clinical and angiographic results 
in selected groups28-30. The RESOLUTE-All Comers trial (NCT00617084) compared for the first 
time the Resolute zotarolimus-eluting stent (ZES) vs. another DES (XIENCE V, Abbott Vascular 
, Santa Clara, California, USA) in an “all-comers” patient population, with a non-inferiority de-
sign31. XIENCE V is an everolimus-eluting stent (EES) at a dose of 100μg/cm2 of stent surface, 
coated with a fluoropolymer, designed to release 80% of the everolimus in the first 30 days 
after deployment32. ZES proved to be non-inferior to EES for target-lesion failure, a composite 
of cardiac death, myocardial infarction and clinically indicated target-lesion revasculariza-
tion31. Nevertheless, the interpretation of the stent thrombosis rates is still a matter of dispute: 
definite stent thrombosis was significantly higher in ZES than in EES (1,2% vs. 0.3%) at 1 year, 
but there were no significant differences in definite/probable stent thrombosis31. In order to 
better understand these clinical results, this OCT substudy of the RESOLUTE-All Comers trial 
compares the neointimal coverage of both devices 13 months after implantation.
methoDs
The design and main results from the RESOLUTE All Comers have been published elsewhere31. 
It was an international, multi-centre, prospective, randomized, open-label non-inferiority trial 
comparing the Resolute ZES, with BioLinx polymer vs. the XIENCE V EES, with fluoropolymer 
coating. Patient eligibility followed a real-world all-comers design, including patients with 
symptomatic coronary heart disease with every possible presentation or with silent isch-
aemia, with one or more coronary artery stenoses >50% in 2.25-4.00mm diameter vessels, 
susceptible to be treated with either of the two devices. There were no limitations regarding 
the number of lesions or vessels treated, or lesion length. Exclusion criteria comprised known 
allergy to anti-platelet /anti-thrombotic regimes, or to any of the components of the two 
stents of the study. Planned surgery in the following 6 months after PCI was also an exclu-
sion criterion. The primary endpoint was target lesion failure, a composite of cardiac death, 
myocardial infarction (not clearly attributable to a non-target vessel) and clinically indicated 
target lesion revascularisation at 1 year follow-up.
Twenty percent of the patients were randomly selected for an angiographic sub-study, 
thus undergoing quantitative coronary angiography (QCA) at baseline and repeat angiogra-
phy at 13 months follow-up. OCT was performed in patients in the angiographic sub-study 
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from selected sites in which OCT was available. The sample size was calculated for the angio-
graphic substudy31, but no formal sample size calculation based on an endpoint hypothesis 
was performed for the OCT substudy, because no evidence about the expected magnitude 
of the effect was available when the trial was designed. Based on unpublished data and on 
the expertise of the investigators with other ongoing OCT trials, a minimum number of 50 
patients was considered necessary to provide reliable and non-trivial results.
Several clinical, angiographic and OCT variables were identified as secondary endpoints 
in the main RESOLUTE All Comers trial. The principal OCT endpoint was tissue coverage, 
evaluated as completeness of coverage (proportion of uncovered struts per stent) and as 
mean thickness of coverage. Additional OCT endpoints included apposition and standard 
areas and volumes.
oct analysis
OCT pullbacks were obtained at 13 months follow-up with M2, M3 or C7 systems (Lightlab 
Imaging, Westford, Massachusetts, USA), depending on the site, using occlusive or non-
occlusive technique, as appropriate33 (Table 1).
OCT pullbacks were analysed offline in a core-laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) by independent analysts blinded to stent-type allocation and clinical and 
procedural characteristics of the patients, using proprietary software (Lightlab Imaging). 
Cross-sections at 1mm intervals within the stented segment and 5mm proximal and distal 
to the stent edges were analyzed. Lumen and stent areas were drawn in each analysed 
cross-section, and the derived incomplete stent apposition (ISA) or neointimal hyperplasia 
(NIH) areas were calculated as appropriate. A metallic strut typically appears as a bright 
signal-intense structure with dorsal shadowing. Apposition was assessed strut by strut by 
table 1: Characteristics of the different OCT systems* in the study.
M2 M3 C7
technique Occlusive Non-occlusive Non-occlusive
Domain Time Time Fourier
catheter ImageWire ImageWire Dragonfly
rotation speed (frames/s) 15.6 20 100
pullback speed (mm/s) 2 3 20
patients with Zes 1 9 20
patients with ees 2 9 17
total 3 18 37
*All systems and catheters from Lightlab Imaging, Westford, Massachusetts, USA.
ZES: zotarolimus-eluting stent; EES: everolimus-eluting stent.
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measuring the distance between the strut marker and the lumen contour. The marker of each 
strut was placed at the endoluminal leading edge, in the mid-point of its long-axis, and the 
distance was measured following a straight line connecting this marker with the centre of 
gravity of the vessel34 (Figure 1). Struts with distance to lumen contour larger than the sum 
of strut + polymer thickness were considered malapposed. This resulted in ISA thresholds 
of >97μm for ZES and >89μm for EES. Struts located at the ostium of side branches, with no 
vessel wall behind, were labelled as non-apposed side-branch (NASB) struts and excluded 
from the analysis of apposition (Figure 1).
≥100 µm
NASB
NASB
figure 1:
Categories of apposition.
OCT cross-sections showing examples of struts in the 3 different categories of apposition: Well-apposed (white arrows), ISA (orange arrows) and 
NASB.
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Struts were classified as uncovered if any part of the strut was visibly exposed to the lumen, 
or covered if a layer of tissue was visible over all the reflecting surfaces. In covered struts, 
thickness of coverage was measured from the strut marker to the endoluminal edge of the 
tissue coverage, following a straight line connecting the strut marker with the centre of grav-
ity of the vessel (Figure 2).
To summarize the spatial distribution of the uncovered struts along the stents, “spread-out 
vessel graphics” were created by correlating the longitudinal distance from the distal edge of 
the stent to the strut (abscises) with the angle where the struts were located in the circular 
cross-section section respect to the centre of gravity of the vessel (ordinates). The resultant 
graphic represented the stented vessel, as if it had been cut longitudinally along the refer-
ence angle 0º and spread out on a flat surface (Figure 3).
statistical analysis
Results are reported as mean±standard deviation for continuous variables, and as count (per-
cent) for nominal variables. Continuous variables with normal distribution were compared 
with Student’s t-test for independent samples, or with U-Mann-Whittney in the case that 
normal distribution could not be assumed. Nominal variables were compared with Fisher’s 
exact test.
In the per strut analysis, apposition was estimated through a categorical variable, compris-
ing three possible excluding categories (well-apposed, ISA or NASB). Tissue coverage was 
figure 2:
Coverage.
OCT cross-sections showing examples of covered (white arrows) and non-covered struts (red arrows).
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estimated through the proportion of uncovered struts (dichotomous variable) and through 
the mean thickness of coverage (continuous). Dichotomous or categorical variables were 
analyzed using multi-level logistic regression models with random effects at 4 different 
levels: 1) treatment arm, 2) patient, 3) lesion, 4) stent. Likewise, continuous variables were 
analyzed using multi-level linear regression models with random effects at the same 4 levels. 
Overlapping stents and stents separated by a gap <5mm length within the same coronary 
segment were assigned to the same coronary lesion. Overlap segments were considered 
separate units of clustering at the stent level for the per strut multilevel analysis.
All statistical analyses were performed according to the intention-to-treat as specified in 
the protocol, using the SAS v8.2 package (SAS Institute Inc., Cary, North Carolina, USA). All 
tests were two-sided and p-value <0.05 was considered statistically significant.
figure 3:
Spread-out-vessel graphs.
The X-axis represents the distance from the distal edge of the stent to the strut; the Y-axis represents the angle where the strut is located in the 
circular cross section respect to the centre of gravity of the vessel. The result is a graphic representing the spatial distribution of the non-covered 
stents (red spots) along the stent, as if it had been cut along the reference angle (0º) and spread out on a flat surface.
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table 2: Baseline patient characteristics.
Zes (n=30) ees (n=28) p-val
Age (years) 60.9 (12.5) 62.6 (8.9) 0.547
Males 23 (76.7%) 23 (82.1%) 0.749
BMI (kg/m2) 83.7 (18.4) 28.8 (4.8) 0.476
cardiovascular risk factors
18 (60.0%) 15 (53.6%) 0.791
7 (23.3%) 7 (25%) 1.000
Insulin-requiring 0 (0.0%) 2 (7.1%) 0.229
Hypercholesterolemia 21 (70.0%) 20 (71.4%) 1.000
Smoking 18 (60.0%) 16 (57.1%) 1.000
Current smoker (<30d) 11 (36.7%) 9 (32.1%) 0.787
Family history of CHD 7 (35.0%) 11 (50.0%) 0.366
antecedents
7 (25.0%) 9 (32.1%) 0.768
8 (26.7%) 4 (14.3%) 0.336
With BMS 1 (3.3%) 3 (10.7%) 0.344
With DES 5 (16.7%) 1 (3.6%) 0.195
Previous CABG 2 (6.7%) 3 (10.7%) 0.665
clinical presentation
Stable angina 16 (53.3%) 11 (39.3%) 0.306
Unstable angina 3 (10.0%) 5 (17.9%) 0.464
Myocardial infarction 9 (30%) 10 (35.7%) 0.781
STEMI 6 (20.0%) 7 (25.0%) 0.757
Silent ischaemia 2 (6.7%) 2 (7.1%) 1.000
Serum creatinine (μmol/L) 76.2 (18.1) 87.4 (23.6) 0.048*
Ejection fraction (%) 65 (10) 55 (11) 0.041*
angiographic characteristics
Nr of diseased major vessels
One 22 (73.3%) 22 (78.6%) 0.762
Two 7 (23.3%) 6 (21.4%) 1.000
Three 1 (3.3%) 0 (0.0%) 1.000
LM + 3 vessels 0 (0.0%) 0 (0.0%) NA
Syntax score 14.13 (12.19) 14.19 (9.10) 0.984
* p≤0,05
Data presented as # of events(%) or mean(SD), as appropriate.
BMI: Body Mass Index; BMS: Bare Metal Stent; CABG: Coronary Artery By-pass Graft; CHD: Coronary Heart Disease; DES: Drug-eluting stent; 
DM: Diabetes Mellitus; EES: everolimus-eluting stent; LM: Left Main Stem; MI: Myocardial Infarction; PCI: Percutaneous Coronary Intervention; 
STEMI: ST elevation myocardial infarction; ZES: Zotarolimus-eluting stent.
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results
2292 patients were enrolled in the RESOLUTE All Comers trial. 58 patients (30 ZES, 28 EES) with 
107 stents in 72 lesions underwent OCT at 13 months. 9 out of 2718 (0.33%) cross-sections 
were deemed of insufficient quality for the quantitative analysis. In total 23197 struts were 
analyzed. Tables 2-4 show the baseline characteristics of patients, procedures and lesions, 
respectively, in both treatment arms. The randomization produced comparable groups, ex-
cept patients who received EES had significantly higher serum levels of creatinine and lower 
left ventricular ejection fraction than the patients who received ZES. No clinical events were 
observed in the patients in the OCT substudy, except for a non-Q wave myocardial infarction 
in the EES group. No patient was excluded from the study on the basis of clinical outcomes.
Tables 5-6 show mean in-stent areas and volumes in non-overlapping and overlapping 
segments, respectively, without significant differences between both stent types. Table 7 
shows the comparative results of the variables estimating apposition and tissue coverage. 
table 3: Procedural characteristics (per patient).
Zes (n=30) ees(n=28) p-val
Contrast (ml) 264.0 (148.6) 265.8 (125.4) 0.962
Procedure duration (min) 59.1 (40.3) 56.7 (41.8) 0.826
Nr vessels treated 1.30 (0.54) 1.21 (0.42) 0.501
LAD 15 (50.0%) 13 (46.4%) 0.799
LCX 8 (26.7%) 9 (32.1%) 0.775
RCA 15 (50.0%) 11 (39.3%) 0.441
LM 1 (3.3%) 1 (3.6%) 1.000
Nr of lesions treated 1.4 (0.7) 1.5 (0.6) 0.711
Nr of stents implanted 2.0 (1.8) 2.4 (1.2) 0.381
Total stented length (mm) 40.1 (42.6) 47.9 (29.7) 0.428
Cross-over 0 (0.0%) 0 (0.0%) NA
On-label use 13 (43.3%) 10 (35.7%) 0.600
Long lesion (>27mm)* 3 (12.0%) 3 (13.6%) 1.000
Small vessel (<2.5mm diameter)* 12 (48.0%) 15 (68.2%) 0.238
antiplatelet therapy
Dual at 6 months 28 (93.3%) 27 (96.4%) 1.000
Dual at 12 months 27 (90.0%) 26 (92.9%) 1.000
Aspirin at 12 months 28 (93.3%) 27 (96.4%) 1.000
Clopidogrel at 12 months 29 (96.7%) 27 (96.4%) 1.000
Data presented as # of events(%) or mean(SD), as appropriate.
EES: everolimus-eluting stent; LAD: Left anterior descending; LCX: Left Circumflex; LIMA: Left internal mammary artery; LM: Left Main Stem; 
RCA: Right coronary artery; SVG: Saphenous vein graft; ZES: Zotarolimus-eluting stent.
*Derived from QCA data.
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table 4: Lesions characteristics.
Zes (n=36) ees (n=36) p-val
target vessel
LM 0 (0.0%) 1 (2.8%) 1.000
LAD 14 (38.9%) 15 (41.7%) 1.000
LCX 5 (13.9%) 6 (16.7%) 1.000
RCA 17 (47.2%) 14 (38.9%) 0.634
pre-procedural tImI flow
0 6 (16.7%) 6 (16.7%) 1.000
I 1 (2.8%) 2 (5.6%) 1.000
II 3 (8.3%) 2 (5.6%) 1.000
III 26 (72.2%) 26 (72.2%) 1.000
post-procedural tImI flow
II 1 (2.8%) 0 (0.0%) 1.000
III 35 (97.2%) 36 (100.0%) 1.000
to 6 (16.7%) 6 (16.7%) 1.000
ostial lesion 1 (2.8%) 1 (2.8%) 1.000
bifurcation 8 (22.2%) 12 (33.3%) 0.430
moderate or severe calcification 8 (22.2%) 5 (13.9%) 0.541
angiographic edge dissections 1 (2.8%) 0 (0.0%) 1.000
complications 0 (0.0%) 0 (0.0%) NA
Qca characteristics
Lesion length (mm) 16.6 (9.9) 13.8 (10.0) 0.297
Pre-stenting
RVD (mm) 2.84 (0.56) 2.59 (0.54) 0.089
MLD (mm) 0.88 (0.58) 0.78 (0.51) 0.438
% diam stenosis 69(19) 70 (19) 0.942
Post-stenting
In-stent
RVD (mm) 2.91 (0.49) 2.82 (0.45) 0.401
MLD (mm) 2.44 (0.51) 2.40 (0.48) 0.717
% diam stenosis 16 (8) 15 (7) 0.476
In-segment
RVD (mm) 2.83 (0.47) 2.66 (0.46) 0.116
MLD (mm) 2.15 (0.44) 2.01 (0.39) 0.161
% diam stenosis 24 (9) 24 (9) 0.923
* p≤0,05
Data presented as # of events(%) or mean(SD), as appropriate.
EES: everolimus-eluting stent; LAD: Left anterior descending; LCX: Left Circumflex; LIMA: Left internal mammary artery; LM: Left Main Stem; 
MLD: Minimal Lumen Diameter; QCA: Quantitative Coronary Angiography; RCA: Right coronary artery; RVD: Reference vessel diameter; TO: Total 
occlusion; ZES: Zotarolimus-eluting stent.
Lesion length and RVD were not available for 17 lesions due to initial TIMI flow 0/I; for one lesion in the ZES group the pre-stenting lesion 
length, RVD, MLD and % diameter stenosis could not be determined due to overlapping vessels.
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figure 4:
Spread-out-vessel graphics showing non-covered struts of the 109 stents and corresponding overlaps analyzed at 13 months. The graphic 
summarizes the spatial distribution of non-coverage and its clustering of at the four considered levels (allocation to treatment, patient, lesion, 
stent).
